


**CUMULATIVE
SUPPLEMENT 4
APRIL 2019**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2019

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**Cumulative Supplement 4
April 2019**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	x
1.7 Cumulative Supplement Legend.....	xi
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**CUMULATIVE SUPPLEMENT 4
APRIL 2019**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 39th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the

"@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in

G AND W LABORATORIES INC
(G AND W LABS INC)

ACP NIMBLE BUYER INC
(ACP NIMBLE)

SUN PHARMA GLOBAL FZE
(SUN PHARMA GLOBAL)

SUN PHARMACEUTICIAL
INDUSTRIES LTD
(SUN PHARM)

SUN PHARMA GLOBAL INC
(SUN PHARMA GLOBAL)

SUN PHARMACEUTICIAL
INDUSTRIES LTD
(SUN PHARM)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF	0.025MG	AB1	021342	001

	INC				
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB2	209713	001
EUTHYROX	PROVELL PHARMS	0.025MG	AB2	021292	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2018</u>	<u>MAR 2019</u>	<u>JUN 2019</u>	<u>SEP 2019</u>	<u>DEC 2019</u>
DRUG PRODUCTS	20295	20580			
LISTED SINGLE SOURCE	2724 (13.4%)	2713 (13.2%)			
MULTISOURCE	17571 (86.6%)	17867 (86.8%)			

THERAPEUTICALLY EQUIVALENT	17483 (86.1%)	17777 (86.4%)
NOT THERAPEUTICALLY EQUIVALENT	88 (0.4%)	90 (0.4%)
EXCEPTIONS ¹	58 (0.3%)	58 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	25	3
NUMBER OF APPLICANTS	1133	1129

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
NFTG	New first time generic approval.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.

CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

@ ZYDUS PHARMS EQ 600MG BASE;300MG A208990 001 Nov 15, 2018 Mar DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB WOCKHARDT BIO AG 250MG A208380 001 Feb 27, 2019 Feb NEWA

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL

APADAZ

+ KEMPHARM 325MG;EQ 4.08MG BASE N208653 002 Jan 04, 2019 Jan NEWA
 + 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Jan NEWA
 + KVK TECH INC 325MG;EQ 4.08MG BASE N208653 002 Jan 04, 2019 Feb CAHN
 + 325MG;EQ 6.12MG BASE N208653 001 Feb 23, 2018 Feb CAHN
 + 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Feb CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ LANNETT CO INC 120MG/5ML;12MG/5ML A091238 001 Nov 10, 2011 Jan DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA WES PHARMA INC 325MG/15ML;7.5MG/15ML A211023 001 Mar 08, 2019 Feb NEWA

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D> AA ALVOGEN PINE BROOK 300MG;5MG A208540 001 Nov 08, 2018 Apr DISC
 >A> @ 300MG;5MG A208540 001 Nov 08, 2018 Apr DISC
 >D> AA 300MG;7.5MG A208540 002 Nov 08, 2018 Apr DISC
 >A> @ 300MG;7.5MG A208540 002 Nov 08, 2018 Apr DISC
 >D> AA 300MG;10MG A208540 003 Nov 08, 2018 Apr DISC
 >A> @ 300MG;10MG A208540 003 Nov 08, 2018 Apr DISC
 >D> AA 325MG;2.5MG A209958 001 Oct 24, 2018 Apr DISC
 >A> @ 325MG;2.5MG A209958 001 Oct 24, 2018 Apr DISC
 >D> AA 325MG;5MG A209958 002 Oct 24, 2018 Apr DISC
 >A> @ 325MG;5MG A209958 002 Oct 24, 2018 Apr DISC
 >D> AA 325MG;7.5MG A209958 003 Oct 24, 2018 Apr DISC
 >A> @ 325MG;7.5MG A209958 003 Oct 24, 2018 Apr DISC
 >D> AA 325MG;10MG A209958 004 Oct 24, 2018 Apr DISC
 >A> @ 325MG;10MG A209958 004 Oct 24, 2018 Apr DISC
 @ UPSHER SMITH LABS 325MG;5MG A206484 001 Mar 24, 2017 Jan DISC
 @ 325MG;7.5MG A206484 002 Mar 24, 2017 Jan DISC
 @ 325MG;10MG A206484 003 Mar 24, 2017 Jan DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

>D> AB ACCORD HLTHCARE 500MG A207659 001 Oct 18, 2018 Apr DISC
 >A> @ 500MG A207659 001 Oct 18, 2018 Apr DISC
 AB ALEMBIC PHARMS LTD 500MG A210423 001 Feb 19, 2019 Feb NEWA
 AB CADILA 500MG A205301 001 Jan 16, 2019 Mar CAHN

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

>A> AP ZYDUS PHARMS EQ 500MG BASE/VIAL A206533 001 Apr 15, 2019 Apr NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

>D> AP PAR STERILE PRODUCTS EQ 500MG BASE/VIAL A205358 001 Jun 20, 2017 Apr DISC
 >A> @ EQ 500MG BASE/VIAL A205358 001 Jun 20, 2017 Apr DISC

ACETYLCHOLINE CHLORIDE

	FOR SOLUTION;OPHTHALMIC						
	MIOCHOL						
>D>	@ NOVARTIS	20MG/VIAL	N016211	001		Apr	CRLD
>A>	+ @	20MG/VIAL	N016211	001		Apr	CRLD

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

@ MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML)

A203624 001 Jun 19, 2015 Mar DISC

TABLET, EFFERVESCENT;ORAL

CETYLEV

+ @ ARBOR PHARMS LLC 500MG

N207916 001 Jan 29, 2016 Mar DISC

+ @ 2.5GM

N207916 002 Jan 29, 2016 Mar DISC

ACITRETIN

CAPSULE;ORAL

SORIATANE

+ @ STIEFEL LABS INC 17.5MG

N019821 003 Aug 06, 2009 Jan DISC

+ @ 22.5MG

N019821 004 Aug 06, 2009 Jan DISC

ACOLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

>D> ASTRAZENECA PHARMS 0.4MG/INH;0.012MG/INH

N210595 001 Mar 29, 2019 Apr CAHN

0.4MG/INH;0.012MG/INH

N210595 001 Mar 29, 2019 Mar NEWA

>A> CIRCASSIA 0.4MG/INH;0.012MG/INH

N210595 001 Mar 29, 2019 Apr CAHN

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB KENTON 200MG

A075090 001 Jan 26, 1999 Mar CAHN

CREAM;TOPICAL

ACYCLOVIR

AB PERRIGO UK FINCO 5%

A208702 001 Feb 04, 2019 Jan NFTG

ZOVIRAX

AB +! BAUSCH 5%

N021478 001 Dec 30, 2002 Feb CAHN

AB +! VIB 5%

N021478 001 Dec 30, 2002 Jan CFTG

OINTMENT;OPHTHALMIC

AVACLYR

+! FERA PHARMS LLC 3%

N202408 001 Mar 29, 2019 Mar NEWA

OINTMENT;TOPICAL

ACYCLOVIR

AB CIPLA 5%

A211794 001 Jan 18, 2019 Jan NEWA

AB PERRIGO UK FINCO 5%

A205659 001 Feb 20, 2019 Feb NEWA

AB ZYDUS PHARMS 5%

A205974 001 Mar 15, 2019 Mar NEWA

ZOVIRAX

AB +! BAUSCH 5%

N018604 001 Mar 29, 1982 Feb CAHN

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

! ZYDUS PHARMS EQ 500MG BASE/VIAL

A206535 001 Aug 31, 2018 Jan CHRS

! EQ 1GM BASE/VIAL

A206535 002 Aug 31, 2018 Jan CHRS

ACYCLOVIR; HYDROCORTISONE

CREAM;TOPICAL

XERESE

+! BAUSCH 5%;1%

N022436 001 Jul 31, 2009 Feb CAHN

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

@ LUITPOLD 3MG/ML

A090010 001 Apr 28, 2009 Mar DISC

ALBENDAZOLE

TABLET;ORAL

ALBENDAZOLE

>A>	AB	EDENBRIDGE PHARMS	200MG	A211117	001	May 14, 2019	Apr	NEWA
-----	----	-------------------	-------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE

POWDER, METERED; INHALATION

PROAIR DIGIHALER

	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Jan	NEWA
--	---	--------------------	--------------------	---------	-----	--------------	-----	------

PROAIR RESPICLICK

	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Jan	CPOT
--	---	--------------------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL

ALBUTEROL SULFATE

AB		AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Mar	NEWA
----	--	--------	-------------	---------	-----	--------------	-----	------

AB			EQ 4MG BASE	A210948	002	Mar 15, 2019	Mar	NEWA
----	--	--	-------------	---------	-----	--------------	-----	------

AB		APPCO PHARMA LLC	EQ 2MG BASE	A207046	001	Jun 29, 2018	Feb	CAHN
----	--	------------------	-------------	---------	-----	--------------	-----	------

AB			EQ 4MG BASE	A207046	002	Jun 29, 2018	Feb	CAHN
----	--	--	-------------	---------	-----	--------------	-----	------

ALISKIREN HEMIFUMARATE

TABLET;ORAL

ALISKIREN HEMIFUMARATE

AB		ANCHEN PHARMS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Mar	NFTG
----	--	---------------	---------------	---------	-----	--------------	-----	------

AB			EQ 300MG BASE	A206665	002	Mar 22, 2019	Mar	NFTG
----	--	--	---------------	---------	-----	--------------	-----	------

TEKTURNA

AB	+	NODEN PHARMA	EQ 150MG BASE	N021985	001	Mar 05, 2007	Mar	CFTG
----	---	--------------	---------------	---------	-----	--------------	-----	------

AB	+	!	EQ 300MG BASE	N021985	002	Mar 05, 2007	Mar	CFTG
----	---	---	---------------	---------	-----	--------------	-----	------

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB		UNICHEM LABS LTD	100MG	A211820	001	Mar 12, 2019	Feb	NEWA
----	--	------------------	-------	---------	-----	--------------	-----	------

AB			300MG	A211820	002	Mar 12, 2019	Feb	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

>D> ALLOPURINOL; LESINURAD

>D> TABLET;ORAL

>D> DUZALLO

>D>	+	IRONWOOD PHARMS INC	200MG;200MG	N209203	001	Aug 18, 2017	Apr	DISC
-----	---	---------------------	-------------	---------	-----	--------------	-----	------

>A>	+	@	200MG;200MG	N209203	001	Aug 18, 2017	Apr	DISC
-----	---	---	-------------	---------	-----	--------------	-----	------

>D>	+	!	300MG;200MG	N209203	002	Aug 18, 2017	Apr	DISC
-----	---	---	-------------	---------	-----	--------------	-----	------

>A>	+	@	300MG;200MG	N209203	002	Aug 18, 2017	Apr	DISC
-----	---	---	-------------	---------	-----	--------------	-----	------

ALTRETAMINE

CAPSULE;ORAL

HEXALEN

	+	@	EISAI INC	50MG	N019926	001	Dec 26, 1990	Feb	DISC
--	---	---	-----------	------	---------	-----	--------------	-----	------

AMBRISANTAN

TABLET;ORAL

AMBRISANTAN

>A>	AB	CIPLA	5MG	A210715	001	Apr 26, 2019	Apr	NEWA
-----	----	-------	-----	---------	-----	--------------	-----	------

>A>	AB		10MG	A210715	002	Apr 26, 2019	Apr	NEWA
-----	----	--	------	---------	-----	--------------	-----	------

AB		MYLAN	5MG	A208441	001	Mar 28, 2019	Mar	NFTG
----	--	-------	-----	---------	-----	--------------	-----	------

AB			10MG	A208441	002	Mar 28, 2019	Mar	NFTG
----	--	--	------	---------	-----	--------------	-----	------

AB		PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Mar	NEWA
----	--	---------------	-----	---------	-----	--------------	-----	------

AB			10MG	A209509	002	Apr 10, 2019	Mar	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB		SIGMAPHARM LABS LLC	5MG	A208354	001	Apr 10, 2019	Mar	NEWA
----	--	---------------------	-----	---------	-----	--------------	-----	------

AB			10MG	A208354	002	Apr 10, 2019	Mar	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB		SUN PHARM	5MG	A210784	001	Mar 28, 2019	Mar	NFTG
----	--	-----------	-----	---------	-----	--------------	-----	------

AB			10MG	A210784	002	Mar 28, 2019	Mar	NFTG
----	--	--	------	---------	-----	--------------	-----	------

AB		WATSON LABS INC	5MG	A208252	001	Mar 28, 2019	Mar	NFTG
----	--	-----------------	-----	---------	-----	--------------	-----	------

AB			10MG	A208252	002	Mar 28, 2019	Mar	NFTG
----	--	--	------	---------	-----	--------------	-----	------

AB		ZYDUS PHARMS	5MG	A210058	001	Mar 28, 2019	Mar	NFTG
----	--	--------------	-----	---------	-----	--------------	-----	------

AB			10MG	A210058	002	Mar 28, 2019	Mar	NFTG
----	--	--	------	---------	-----	--------------	-----	------

LETAIRIS

AB	+	GILEAD	5MG	N022081	001	Jun 15, 2007	Mar	CFTG
----	---	--------	-----	---------	-----	--------------	-----	------

AB	+	!	10MG	N022081	002	Jun 15, 2007	Mar	CFTG
----	---	---	------	---------	-----	--------------	-----	------

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

	AMILORIDE HYDROCHLORIDE								
AB	WINDLAS HLTHCARE	5MG		A204180	001	Aug 07, 2015	Feb	CAHN	

AMINOCAPROIC ACID

TABLET; ORAL

	AMICAR								
AB	+ CLOVER PHARMS	1GM		N015197	002	Jun 24, 2004	Feb	CHRS	
	AMINOCAPROIC ACID								
AB	! SUNNY PHARMTECH INC	1GM		A209060	002	Nov 27, 2018	Feb	CHRS	

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

!	HOSPIRA	25MG/ML		A087242	001	Oct 26, 1983	Feb	CTEC	
@	LUITPOLD	25MG/ML		A087600	001		Feb	DISC	

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	AB	STRIDES PHARMA	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr	CAHN	
>A>	AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr	CAHN	
>A>	AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr	CAHN	
>D>	AB	STRIDES VIVIMED	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr	CAHN	
>D>	AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr	CAHN	
>D>	AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr	CAHN	

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	MYLAN	EQ 2.5MG BASE;10MG		A077375	001	May 21, 2010	Feb	DISC	
@		EQ 5MG BASE;10MG		A077375	002	May 21, 2010	Feb	DISC	
@		EQ 5MG BASE;20MG		A077375	003	May 21, 2010	Feb	DISC	
@		EQ 5MG BASE;40MG		A079047	001	Jul 05, 2011	Feb	DISC	
@		EQ 10MG BASE;20MG		A077375	004	May 21, 2010	Feb	DISC	
@		EQ 10MG BASE;40MG		A079047	002	Jul 05, 2011	Feb	DISC	

AMLODIPINE BESYLATE; CELECOXIB

TABLET; ORAL

CONSENSI

+	COEPTIS	EQ 2.5MG BASE;200MG		N210045	001	May 31, 2018	Mar	CAHN	
+		EQ 5MG BASE;200MG		N210045	002	May 31, 2018	Mar	CAHN	
+	!	EQ 10MG BASE;200MG		N210045	003	May 31, 2018	Mar	CAHN	

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

@	ACCORD HLTHCARE INC	EQ 5MG BASE;20MG		A209600	001	Aug 30, 2018	Mar	DISC	
@		EQ 5MG BASE;40MG		A209600	003	Aug 30, 2018	Mar	DISC	
@		EQ 10MG BASE;20MG		A209600	002	Aug 30, 2018	Mar	DISC	
@		EQ 10MG BASE;40MG		A209600	004	Aug 30, 2018	Mar	DISC	

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

>A>	+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Apr	CAHN	
>A>	+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Apr	CAHN	
>A>	+	!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Apr	CAHN	
>D>	+	MARINA BIOTECH	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Apr	CAHN	
>D>	+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Apr	CAHN	
>D>	+	!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Apr	CAHN	

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>A>	AP	DECATUR	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Apr	CAHN	
>D>	AP	GLOBAL ISOTOPES LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Apr	CAHN	

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>	AB	AUROBINDO PHARMA LTD	125MG/5ML;EQ 31.25MG BASE/5ML	A209371	001	Apr 19, 2019	Apr	NFTG
>A>	AB		250MG/5ML;EQ 62.5MG BASE/5ML	A209371	002	Apr 19, 2019	Apr	NEWA
		AUGMENTIN '125'						
>D>	+	NEOPHARMA	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Apr	CFTG
>A>	AB	+	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Apr	CFTG
		TABLET;ORAL						
		AUGMENTIN '875'						
AB	+	NEOPHARMA	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Feb	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		AMERIGEN PHARMS LTD	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan	NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan	NEWA
AB			3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan	NEWA
AB			5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan	NEWA
AB			6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan	NEWA
AB			7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan	NEWA
>A>	AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019	Apr	NEWA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019	Apr	NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019	Apr	NEWA
>A>	AB		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019	Apr	NEWA
>A>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019	Apr	NEWA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019	Apr	NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

>A>	AA	AUROLIFE PHARMA LLC	5MG	A211639	001	Apr 17, 2019	Apr	NEWA
>A>	AA		10MG	A211639	002	Apr 17, 2019	Apr	NEWA
		TABLET, ORALLY DISINTEGRATING;ORAL						
		EVEKEO ODT						
	+	ARBOR PHARMS LLC	5MG	N209905	001	Jan 30, 2019	Jan	NEWA
	+		10MG	N209905	002	Jan 30, 2019	Jan	NEWA
	+		15MG	N209905	003	Jan 30, 2019	Jan	NEWA
	+		20MG	N209905	004	Jan 30, 2019	Jan	NEWA

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

AB		FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010	Feb	CAHN
AB		KENTON	1MG	A078944	001	Jun 28, 2010	Mar	CAHN

ARIPIPIRAZOLE

SOLUTION;ORAL

ARIPIPIRAZOLE

AA		AUROBINDO PHARMA LTD	1MG/ML	A210479	001	Jan 29, 2019	Jan	NEWA
----	--	----------------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

ARIPIPIRAZOLE

AB		ALKEM LABS LTD	2MG	A207105	001	Feb 21, 2019	Feb	NEWA
AB			5MG	A207105	002	Feb 21, 2019	Feb	NEWA
AB			10MG	A207105	003	Feb 21, 2019	Feb	NEWA
AB			15MG	A207105	004	Feb 21, 2019	Feb	NEWA
AB			20MG	A207105	005	Feb 21, 2019	Feb	NEWA
AB			30MG	A207105	006	Feb 21, 2019	Feb	NEWA

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB		APOTEX INC	50MG	A201514	001	Mar 25, 2019	Mar	NEWA
AB			150MG	A201514	002	Mar 25, 2019	Mar	NEWA
AB			250MG	A201514	003	Mar 25, 2019	Mar	NEWA
AB		AUROBINDO PHARMA LTD	200MG	A206069	004	Dec 07, 2018	Mar	NEWA
>A>	AB	MYLAN PHARMS INC	100MG	A200043	004	May 09, 2019	Apr	NEWA
>A>	AB		200MG	A200043	005	May 09, 2019	Apr	NEWA
>D>		NATCO PHARMA LTD	100MG	A202768	004	Sep 28, 2017	Apr	CTEC
>A>	AB		100MG	A202768	004	Sep 28, 2017	Apr	CTEC

ARSENIC TRIOXIDEINJECTABLE; INJECTION
ARSENIC TRIOXIDE

>A>	AP	STI PHARMA LLC	1MG/ML	A209873	001	May 06, 2019	Apr	NEWA
-----	----	----------------	--------	---------	-----	--------------	-----	------

ASENAPINE MALEATETABLET; SUBLINGUAL
ASENAPINE MALEATE

@	SIGMAPHARM LABS LLC	EQ 5MG BASE	A206107	001	Jul 17, 2018	Feb	DISC
@		EQ 10MG BASE	A206107	002	Jul 17, 2018	Feb	DISC

SAPHRIS

+	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CTEC
+	!	EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CTEC

ASPIRIN; DIPYRIDAMOLECAPSULE, EXTENDED RELEASE; ORAL
ASPIRIN AND DIPYRIDAMOLE

AB	LANNETT CO INC	25MG; 200MG	A204552	001	Mar 20, 2019	Mar	NEWA
----	----------------	-------------	---------	-----	--------------	-----	------

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ZYDUS PHARMS	50MG; 25MG	A210028	001	Mar 08, 2019	Feb	NEWA
AB		100MG; 25MG	A210028	002	Mar 08, 2019	Feb	NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17, 2010	Mar	CMFD
AB		25MG	A079017	002	Sep 17, 2010	Mar	CMFD
AB		40MG	A079017	003	Sep 17, 2010	Mar	CMFD
AB		60MG	A079017	004	Sep 17, 2010	Mar	CMFD
AB		80MG	A079017	005	Sep 17, 2010	Mar	CMFD
AB		100MG	A079017	006	Sep 17, 2010	Mar	CMFD

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Feb	NEWA
AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Feb	NEWA
AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Feb	NEWA
AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Feb	NEWA
AB	MSN LABS PVT LTD	EQ 10MG BASE	A211933	001	Feb 08, 2019	Feb	NEWA
AB		EQ 20MG BASE	A211933	002	Feb 08, 2019	Feb	NEWA
AB		EQ 40MG BASE	A211933	003	Feb 08, 2019	Feb	NEWA
AB		EQ 80MG BASE	A211933	004	Feb 08, 2019	Feb	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	HONG KONG	10MG/ML	A091489	001	Feb 17, 2012	Feb	CAHN
		ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	HONG KONG	10MG/ML	A091488	001	Feb 17, 2012	Feb	CAHN

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROPEN

+	!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	Mar	CPOT
+	!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	Mar	CPOT
+	!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	Mar	CPOT
+	!		EQ 2MG SULFATE/0.7ML	N017106	001		Mar	CPOT

ATROPINE

@	ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987	Mar	CDFR
---	--------	----------------------	---------	-----	--------------	-----	------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP	LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019	Feb	NEWA
----	-----------	------------	---------	-----	--------------	-----	------

AZELAIC ACIDCREAM; TOPICAL
AZELEX

>A>	+	ALMIRALL	20%	N020428	001	Sep 13, 1995	Apr	CAHN
>D>	+	AQUA PHARMS LLC	20%	N020428	001	Sep 13, 1995	Apr	CAHN

AZELASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
AZELASTINE HYDROCHLORIDE

AT		ALEMBIC PHARMS LTD	0.05%	A209620	001	Mar 20, 2019	Mar	NEWA
AT		SOMERSET THERAPS LLC	0.05%	A207411	001	Mar 29, 2019	Mar	NEWA

AZITHROMYCINTABLET; ORAL
AZITHROMYCIN

AB		BIONPHARMA INC	EQ 250MG BASE	A210000	001	Feb 26, 2019	Feb	NEWA
AB			EQ 500MG BASE	A210001	001	Feb 26, 2019	Feb	NEWA
>A>	AB	CSPC OUYI	EQ 250MG BASE	A208250	001	Apr 17, 2019	Apr	NEWA

BACLOFENTABLET; ORAL
BACLOFEN

AB		EYWA PHARMA	10MG	A211555	001	Feb 01, 2019	Jan	NEWA
AB			20MG	A211555	002	Feb 01, 2019	Jan	NEWA

BALSALAZIDE DISODIUMCAPSULE; ORAL
BALSALAZIDE DISODIUM
@ MYLAN

>D>			750MG	A077807	001	Dec 28, 2007	Feb	DISC
>D>								
>D>	AB	PAR PHARM INC	1.1GM	A206336	001	Sep 08, 2015	Apr	DISC
>A>		@	1.1GM	A206336	001	Sep 08, 2015	Apr	DISC
>D>		GIAZO						
>D>	AB	+	VALEANT PHARMS INTL	N022205	001	Feb 03, 2012	Apr	DISC
>A>		+ @		N022205	001	Feb 03, 2012	Apr	DISC

BELINOSTATPOWDER; INTRAVENOUS
BELEODAQ

+	ACROTECH	500MG/VIAL	N206256	001	Jul 03, 2014	Mar	CAHN
---	----------	------------	---------	-----	--------------	-----	------

BENAZEPRIL HYDROCHLORIDETABLET; ORAL
BENAZEPRIL HYDROCHLORIDE

@	HERITAGE PHARMA	5MG	A076267	001	Feb 11, 2004	Feb	CAHN
@		10MG	A076267	002	Feb 11, 2004	Feb	CAHN
@		20MG	A076267	003	Feb 11, 2004	Feb	CAHN
@		40MG	A076267	004	Feb 11, 2004	Feb	CAHN

BENDAMUSTINE HYDROCHLORIDEPOWDER; IV (INFUSION)
TREANDA

+	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Feb	CTEC
+		100MG/VIAL	N022249	001	Mar 20, 2008	Feb	CTEC

BENZONATATECAPSULE; ORAL
BENZONATATE

AA		ASCENT PHARMS INC	100MG	A211518	001	Feb 22, 2019	Feb	NEWA
AA			150MG	A211518	002	Feb 22, 2019	Feb	NEWA
AA			200MG	A211518	003	Feb 22, 2019	Feb	NEWA
AA		CSPC OUYI	100MG	A202765	002	Aug 25, 2017	Feb	CAHN
AA			200MG	A202765	001	Jul 31, 2015	Feb	CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	GLENMARK PHARMS	5%;1% BASE	A209252	001	Mar 14, 2019	Mar	NEWA
----	-----------------	------------	---------	-----	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

@ LUITPOLD 1MG/ML

A091152 001 Mar 29, 2010 Feb DISC

TABLET; ORAL

BENZTROPINE MESYLATE

>D>	AA	ASPEN GLOBAL INC	0.5MG	A204713	001	Apr 14, 2015	Apr	CHRS
>A>	AA	!	0.5MG	A204713	001	Apr 14, 2015	Apr	CHRS
>D>	AA		1MG	A204713	002	Apr 14, 2015	Apr	CHRS
>A>	AA	!	1MG	A204713	002	Apr 14, 2015	Apr	CHRS
>D>	AA		2MG	A204713	003	Apr 14, 2015	Apr	CHRS
>A>	AA	!	2MG	A204713	003	Apr 14, 2015	Apr	CHRS
		@ OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008	Mar	DISC
		@	1MG	A040706	003	Feb 14, 2008	Mar	DISC
>D>	AA	! USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Apr	DISC
>A>		@	0.5MG	A040103	001	Dec 12, 1996	Apr	DISC
>D>	AA	!	1MG	A040103	002	Dec 12, 1996	Apr	DISC
>A>		@	1MG	A040103	002	Dec 12, 1996	Apr	DISC
>D>	AA	!	2MG	A040103	003	Dec 12, 1996	Apr	DISC
>A>		@	2MG	A040103	003	Dec 12, 1996	Apr	DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPOTASTINE BESILATE

AT	APOTEX INC	1.5%	A206066	001	Mar 05, 2019	Feb	NFTG	
>D>	AT	MICRO LABS	1.5%	A206220	001	Mar 18, 2019	Apr	CAHN
AT			1.5%	A206220	001	Mar 18, 2019	Mar	NEWA
>A>	AT	MYLAN	1.5%	A206220	001	Mar 18, 2019	Apr	CAHN
		BEPREVE						
AT	+!	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Feb	CFTG

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL

SERNIVO

+! ENCORE DERMAT EQ 0.05% BASE/SPRAY N208079 001 Feb 05, 2016 Mar CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	TOLMAR	0.064%;0.005%	A201615	001	Jan 14, 2013	Mar	CAIN	
AB	+!	LEO PHARMA AS	0.064%;0.005%	N021852	001	Jan 09, 2006	Mar	CAIN
		SUSPENSION; TOPICAL						
		TACLONEX						
	+!	LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008	Mar	CAIN

BETHANECHOL CHLORIDE

TABLET; ORAL

DUVOID

AA	CHARTWELL RX	10MG	A086262	001		Mar	CAHN
AA		25MG	A086263	001		Mar	CAHN
AA		50MG	A085882	003		Mar	CAHN

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	FRESENIUS KABI USA	50MG	A079045	001	May 13, 2010	Feb	CAHN
AB		50MG	A079045	001	May 13, 2010	Feb	CAHN

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

>A>	AT	ALEMBIC PHARMS LTD	0.03%	A210263	001	Apr 12, 2019	Apr	NEWA
AT		GLAND PHARMA LTD	0.03%	A210126	001	Mar 22, 2019	Mar	NEWA

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

@ FRONTIDA BIOPHARM 5MG

A 075474 001 Oct 25, 2002 Jan CAHN

@ 10MG

A 075474 002 Oct 25, 2002 Jan CAHN

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

AP CIPLA EQ 15 UNITS BASE/VIAL

A 209439 001 Mar 11, 2019 Feb NEWA

BORTEZOMIB

POWDER; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

+ @ HOSPIRA INC 1MG/VIAL

N 209191 002 Dec 28, 2018 Mar DISC

BOSENTAN

TABLET; ORAL

BOSENTAN

>A>

>A> AB ALVOGEN PINE BROOK 62.5MG

A 206002 001 Apr 26, 2019 Apr NFTG

>A> AB 125MG

A 206002 002 Apr 26, 2019 Apr NFTG

>A> AB AMNEAL PHARMS CO 62.5MG

A 209742 001 Apr 26, 2019 Apr NFTG

>A> AB 125MG

A 209742 002 Apr 26, 2019 Apr NFTG

>A> AB NATCO PHARMA LTD 62.5MG

A 206987 001 Apr 26, 2019 Apr NFTG

>A> AB 125MG

A 206987 002 Apr 26, 2019 Apr NFTG

>A> AB PAR PHARM INC 62.5MG

A 205699 001 Apr 26, 2019 Apr NFTG

>A> AB 125MG

A 205699 002 Apr 26, 2019 Apr NFTG

>A> AB SUN PHARM 62.5MG

A 209324 001 Apr 26, 2019 Apr NFTG

>A> AB 125MG

A 209324 002 Apr 26, 2019 Apr NFTG

>A> AB WATSON LABS INC 62.5MG

A 207110 001 Apr 26, 2019 Apr NFTG

>A> AB 125MG

A 207110 002 Apr 26, 2019 Apr NFTG

>A> AB WEST-WARD PHARMS INT 62.5MG

A 208695 001 Apr 26, 2019 Apr NFTG

>A> AB 125MG

A 208695 002 Apr 26, 2019 Apr NFTG

>A> AB ZYDUS PHARMS 62.5MG

A 207760 001 Apr 26, 2019 Apr NFTG

>A> AB 125MG

A 207760 002 Apr 26, 2019 Apr NFTG

TRACLEER

>D> + ACTELION PHARMS LTD 62.5MG

N 021290 001 Nov 20, 2001 Apr CFTG

>A> AB + 62.5MG

N 021290 001 Nov 20, 2001 Apr CFTG

>D> +! 125MG

N 021290 002 Nov 20, 2001 Apr CFTG

>A> AB +! 125MG

N 021290 002 Nov 20, 2001 Apr CFTG

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT SOMERSET THERAPS LLC 0.2%

A 208992 001 Mar 11, 2019 Feb NEWA

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

AB APPCO PHARMA LLC 3MG

A 207367 001 Apr 07, 2017 Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

UCERIS

AB +! SALIX 9MG

N 203634 001 Jan 14, 2013 Mar CAHN

BUMETANIDE

TABLET; ORAL

BUMETANIDE

AB HERITAGE PHARMA 0.5MG

A 074225 001 Apr 24, 1995 Feb CAHN

AB 1MG

A 074225 002 Apr 24, 1995 Feb CAHN

AB 2MG

A 074225 003 Apr 24, 1995 Feb CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP NOVOCOL HEALTHCARE 0.5%

A 211096 001 Feb 19, 2019 Feb NEWA

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

AP B BRAUN MEDICAL INC 0.75%

A 209087 001 Apr 02, 2019 Mar NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ALVOGEN PINE BROOK	EQ 2MG BASE;EQ 0.5MG BASE	A205954	001	Jan 24, 2019	Jan	NEWA
AB		EQ 4MG BASE;EQ 1MG BASE	A205954	002	Jan 24, 2019	Jan	NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A205954	003	Jan 24, 2019	Jan	NEWA
AB		EQ 12MG BASE;EQ 3MG BASE	A205954	004	Jan 24, 2019	Jan	NEWA

FILM;SUBLINGUAL

CASSIPA

+ @	TEVA PHARMS USA	EQ 16MG BASE;EQ 4MG BASE	N208042	001	Sep 07, 2018	Mar	DISC
-----	-----------------	--------------------------	---------	-----	--------------	-----	------

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

@	TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149	001	Sep 08, 2014	Jan	DISC
---	-----------------	---------------------------	---------	-----	--------------	-----	------

@		EQ 8MG BASE;EQ 2MG BASE	A091149	002	Sep 08, 2014	Jan	DISC
---	--	-------------------------	---------	-----	--------------	-----	------

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3	GRAVITI PHARMS	150MG	A211020	001	Jan 28, 2019	Jan	NEWA	
AB3		300MG	A211020	002	Jan 28, 2019	Jan	NEWA	
>D>	AB1	YICHANG HUMANWELL	100MG	A211347	001	Oct 16, 2018	Apr	DISC
>A>	@	100MG	A211347	001	Oct 16, 2018	Apr	DISC	
>D>	AB1	150MG	A211347	002	Oct 16, 2018	Apr	DISC	
>A>	@	150MG	A211347	002	Oct 16, 2018	Apr	DISC	
>D>	AB1	200MG	A211347	003	Oct 16, 2018	Apr	DISC	
>A>	@	200MG	A211347	003	Oct 16, 2018	Apr	DISC	

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

>A>	AB	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Apr	NEWA
>A>	AB		7.5MG	A208972	002	Apr 16, 2019	Apr	NEWA
>A>	AB		10MG	A208972	003	Apr 16, 2019	Apr	NEWA
>A>	AB		15MG	A208972	004	Apr 16, 2019	Apr	NEWA
>A>	AB		30MG	A208972	005	Apr 16, 2019	Apr	NEWA

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP	ACCORD HLTHCARE INC	6MG/ML	A210148	001	Feb 22, 2019	Feb	NEWA	
>A>	AP	APOTEX INC	6MG/ML	A210448	001	May 07, 2019	Apr	NEWA
AP	ATHENEX INC	6MG/ML	A205106	001	Sep 21, 2018	Jan	CAHN	
	@	HOSPIRA INC	6MG/ML	A205672	001	Jul 31, 2018	Feb	DISC
>A>	AP	SHILPA MEDICARE LTD	6MG/ML	A210931	001	Apr 18, 2019	Apr	NEWA

CAFFEINE CITRATE

SOLUTION;ORAL

CAFFEINE CITRATE

@	LUITPOLD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009	Mar	DISC
---	----------	------------------------------------	---------	-----	--------------	-----	------

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Feb	NEWA
AB		0.5MCG	A204556	002	Feb 21, 2019	Feb	NEWA

CALCIUM ACETATE

TABLET;ORAL

CALCIUM ACETATE

AB	CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Jan	CAHN
----	---------------------	-------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

>A>	AP	MEDEFIL INC	100MG/ML	A211553	001	May 01, 2019	Apr	NEWA
-----	----	-------------	----------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	A209338	001	Jan 28, 2019	Jan	NEWA
----	--------------------	--	---------	-----	--------------	-----	------

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
CARBATROL

AB	+	SHIRE DEV LLC	100MG	N020712	003	Sep 30, 1997	Jan	CAHN
AB	+		200MG	N020712	001	Sep 30, 1997	Jan	CAHN
AB	+	!	300MG	N020712	002	Sep 30, 1997	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL
CARBAMAZEPINE

AB		ZYDUS PHARMS	100MG	A205571	001	Feb 07, 2019	Jan	NEWA
AB			200MG	A205571	002	Feb 07, 2019	Jan	NEWA
AB			400MG	A205571	003	Feb 07, 2019	Jan	NEWA

CARBINOXAMINE MALEATE

TABLET; ORAL
CARBINOXAMINE MALEATE

!	MIKART	6MG	A207484	001	May 31, 2016	Mar	CHRS
---	--------	-----	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE; INTRAVENOUS
CARBOPLATIN

	@	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Mar	CDFR	
	@		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Mar	CDFR	
	@		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Mar	CDFR	
	@		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Mar	CDFR	
	@	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004	Mar	CDFR	
	@		50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar	CDFR	
	@		150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004	Mar	CDFR	
	@		150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar	CDFR	
AP	@		450MG/45ML (10MG/ML)	A077247	003	Oct 21, 2004	Mar	CDFR	
>A>	@	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Apr	CDFR	
>A>	@		150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Apr	CDFR	
>A>	@		450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Apr	CDFR	
	@	MYLAN LABS LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	Mar	CDFR	
	@	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Mar	CDFR	
	@		150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Mar	CDFR	
	@		450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Mar	CDFR	
	@	TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007	Mar	CDFR	
	@		150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007	Mar	CDFR	
	@		450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007	Mar	CDFR	
		PARAPLATIN							
	+	@	CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar	CDFR
	+	@		150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar	CDFR
	+	@		450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar	CDFR
	+	@		600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar	CDFR

>D>		INJECTABLE; IV (INFUSION)						
>D>		CARBOPLATIN						
>D>	@	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Apr	CDFR
	@		50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Mar	DISC
>D>	@		150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Apr	CDFR
	@		150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Mar	DISC
>D>	@		450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Apr	CDFR
	@		450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Mar	DISC

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

@	VINTAGE PHARMS	350MG	A040245	001	Sep 08, 1997	Feb	DISC
---	----------------	-------	---------	-----	--------------	-----	------

CARMUSTINE

INJECTABLE; INJECTION
CARMUSTINE

AP	STI PHARMA LLC	100MG/VIAL	A209278	001	Apr 02, 2019	Mar	NEWA
----	----------------	------------	---------	-----	--------------	-----	------

CASPOFUNGIN ACETATEPOWDER; INTRAVENOUS
CASPOFUNGIN ACETATE

@ CIPLA	50MG/VIAL	A209489	001	Jul 12, 2018	Jan DISC
@	70MG/VIAL	A209489	002	Jul 12, 2018	Jan DISC

CEFIXIMEFOR SUSPENSION; ORAL
CEFIXIME

@ SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017	Feb DISC	
@	200MG/5ML	A206144	002	Nov 17, 2017	Feb DISC	
SUPRAX						
>D> AB	LUPIN PHARMS	200MG/5ML	A065355	001	Apr 10, 2007	Apr CHRS
>A> AB	!	200MG/5ML	A065355	001	Apr 10, 2007	Apr CHRS

CEFPODOXIME PROXETILFOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007	Jan CTEC
!	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CHRS
	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CTEC
@ SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jan DISC
@	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jan DISC

CEPHALEXINFOR SUSPENSION; ORAL
CEPHALEXIN

AB	ALKEM LABS LTD	EQ 125MG BASE/5ML	A210221	001	Mar 26, 2019	Mar NEWA
AB		EQ 250MG BASE/5ML	A210221	002	Mar 26, 2019	Mar NEWA

CERITINIBTABLET; ORAL
ZYKADIA

+!	NOVARTIS PHARMS CORP	150MG	N211225	001	Mar 18, 2019	Mar NEWA
----	----------------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDESYRUP; ORAL
CETIRIZINE HYDROCHLORIDE

AA	SAPTALIS PHARMS	5MG/5ML	A090191	001	Nov 12, 2009	Feb CAHN
AA	TORRENT	5MG/5ML	A078870	001	Apr 27, 2009	Jan CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDEINJECTABLE; INJECTION
LIBRIUM

@ BAUSCH	100MG/AMP	N012301	001		Mar CAHN
----------	-----------	---------	-----	--	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATESOLUTION; ORAL
VITUZ

>D> AA	+!	CYPRESS PHARM	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Apr CAHN
>A> AA	+!	PERSION	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Apr CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION; ORAL
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ TORRENT	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Jan CAHN		
ZUTRIPRO							
>D> AA	+!	CYPRESS PHARM	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Apr CAHN
>A> AA	+!	PERSION	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Apr CAHN

CHLOROTHALIDONETABLET; ORAL
CHLOROTHALIDONE

AB	INVATECH PHARMA	25MG	A211063	001	Feb 26, 2019	Feb NEWA
AB		50MG	A211063	002	Feb 26, 2019	Feb NEWA
>A> AB	ZYDUS PHARMS	25MG	A207813	001	May 10, 2019	Apr NEWA
>A> AB		50MG	A207813	002	May 10, 2019	Apr NEWA

CHOLINE C-11

INJECTABLE; INTRAVENOUS
CHOLINE C-11

>A>	AP	DECATUR	4-33.1mCi/ML	A206319	001	Nov 13, 2015	Apr	CAHN
>D>	AP	GLOBAL ISOTOPE LLC	4-33.1mCi/ML	A206319	001	Nov 13, 2015	Apr	CAHN

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION
PHOSPHOCOL P32
@ CURIUM

5mCi/ML

N017084 001

Jan CAHN

CICLESONIDE

AEROSOL, METERED; INHALATION
ALVESCO

+! COVIS PHARMA BV 0.08MG/INH
+! 0.16MG/INH

N021658 002 Jan 10, 2008 Mar CAHN
N021658 003 Jan 10, 2008 Mar CAHN

AEROSOL, METERED; NASAL
ZETONNA

+! COVIS PHARMA BV 0.037MG/INH
SPRAY, METERED; NASAL
OMNARIS

N202129 001 Jan 20, 2012 Mar CAHN

+! COVIS PHARMA BV 0.05MG/INH

N022004 001 Oct 20, 2006 Mar CAHN

CICLOPIROX

SHAMPOO; TOPICAL
LOPROX

>A>	AT	+! BAUSCH	1%	N021159	001	Feb 28, 2003	Apr	CAHN
>D>	AT	+! MEDICIS	1%	N021159	001	Feb 28, 2003	Apr	CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION
CISATRACURIUM BESYLATE

>A>	AP	@ ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Feb	DISC
>A>	AP	NANJING KING-FRIEND	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr	NEWA
>A>	AP		EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr	NEWA
>A>	AP		EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr	NEWA
>A>	AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Apr	NEWA
		CISATRACURIUM BESYLATE PRESERVATIVE FREE						
		@ ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Feb	DISC
		@	EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Feb	DISC
	AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A206791	001	Feb 20, 2019	Feb	NEWA
	AP		EQ 10MG BASE/ML	A206791	002	Feb 20, 2019	Feb	NEWA
		NIMBEX PRESERVATIVE FREE						
	AP	+! ABBVIE	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Feb	CTEC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

>D> FOR SOLUTION; ORAL
>D> PREPOPIK

>D>		+! FERRING PHARMS INC	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK	N202535	001	Jul 16, 2012	Apr	DISC
>A>		+ @	ET 12GM/PACKET; 3.5GM/PACKET; 10MG/PACK	N202535	001	Jul 16, 2012	Apr	DISC
			ET					

CLADRIBINE

TABLET; ORAL
MAVENCLAD

+! EMD SERONO INC 10MG

N022561 001 Mar 29, 2019 Mar NEWA

CLARITHROMYCIN

TABLET; ORAL
CLARITHROMYCIN

>A>	AB	AJANTA PHARMA LTD	250MG	A206714	001	Apr 25, 2019	Apr	NEWA
>A>	AB		500MG	A206714	002	Apr 25, 2019	Apr	NEWA
	AB	STRIDES PHARMA	250MG	A202710	001	Jun 10, 2013	Feb	CAHN
	AB		500MG	A202710	002	Jun 10, 2013	Feb	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

@ MYLAN

EQ 75MG BASE/5ML

A203063 001 May 25, 2016 Mar DISC

CLINDAMYCIN PHOSPHATE

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT

ENCUBE ETHICALS

EQ 1% BASE

A209914 001 Jan 28, 2019 Jan NEWA

CLINDAMYCIN PHOSPHATE; TRETINOLIN

GEL;TOPICAL

VELTIN

BX

+! ALMIRALL

1.2%;0.025%

N050803 001 Jul 16, 2010 Feb CAHN

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

>A> AB

TARO PHARM

2.5MG/ML

A210978 001 Apr 15, 2019 Apr NEWA

TABLET;ORAL

CLOBAZAM

AB

MICRO LABS

10MG

A211711 001 Jan 30, 2019 Jan NEWA

AB

20MG

A211711 002 Jan 30, 2019 Jan NEWA

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1

GLENMARK PHARMS LTD

0.05%

A210809 001 Feb 15, 2019 Feb NEWA

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB

ALEOR DERMACEUTICALS

0.05%

A211800 001 Mar 04, 2019 Feb NEWA

@ AMNEAL PHARMS LLC

0.05%

A210551 001 Aug 21, 2018 Feb DISC

AB

TELLIGENT PHARMA INC

0.05%

A208589 001 Jan 23, 2019 Jan NEWA

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP

ACCORD HLTHCARE

20MG/20ML (1MG/ML)

A212034 001 Feb 22, 2019 Feb NEWA

@ HOSPIRA INC

20MG/20ML (1MG/ML)

A210283 001 Dec 27, 2018 Feb DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB

MANKIND PHARMA

25MG

A211767 001 Apr 08, 2019 Mar NEWA

AB

50MG

A211767 002 Apr 08, 2019 Mar NEWA

AB

75MG

A211767 003 Apr 08, 2019 Mar NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

@ LUITPOLD

1MG/10ML (0.1MG/ML)

A091104 001 Oct 08, 2009 Feb DISC

@

5MG/10ML (0.5MG/ML)

A091104 002 Oct 08, 2009 Feb DISC

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

>A> AB

FRONTIDA BIOPHARM

0.1MG

A070923 003 Sep 04, 1987 Apr CMS1

>A> AB

0.2MG

A070923 002 Sep 04, 1987 Apr CMS1

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB1

NOVAST LABS

0.1MG

A209675 001 Mar 05, 2019 Feb NEWA

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

>A> AB

CADILA

EQ 75MG BASE

A201686 001 Oct 10, 2012 Apr CAHN

@ MYLAN PHARMS INC

EQ 300MG BASE

A077665 002 May 17, 2012 Feb DISC

>D> AB

ZYDUS PHARMS USA INC

EQ 75MG BASE

A201686 001 Oct 10, 2012 Apr CAHN

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG
 @ 7.5MG

A072514 002 May 11, 1990 Jan CMS1
 A072514 003 May 11, 1990 Jan CMS1

CLOTRIMAZOLE

SOLUTION; TOPICAL

CLOTRIMAZOLE

AT NOVITIUM PHARMA 1%

A209815 001 Feb 14, 2019 Feb NEWA

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

@ HIKMA 30MG/5ML

N202245 001 Jun 30, 2011 Mar CAHN

TABLET; ORAL

CODEINE SULFATE

AB + HIKMA 15MG
 AB + 30MG
 AB +! 60MG

N022402 001 Jul 16, 2009 Mar CAHN
 N022402 002 Jul 16, 2009 Mar CAHN
 N022402 003 Jul 16, 2009 Mar CAHN

COLCHICINE

SOLUTION; ORAL

GLOPERBA

+! ROMEG THERAPS LLC 0.6MG/5ML

N210942 001 Jan 30, 2019 Jan NEWA

TABLET; ORAL

COLCHICINE

AB ALKEM LABS LTD 0.6MG
 AB AMNEAL PHARMS 0.6MG
 AB ZYDUS PHARMS 0.6MG
 COLCRYS
 AB +! TAKEDA PHARMS USA 0.6MG

A211250 001 Feb 08, 2019 Feb NEWA
 A204711 001 Sep 28, 2016 Jan NEWA
 A211519 001 Feb 19, 2019 Feb NEWA
 N022352 001 Jul 29, 2009 Jan CTEC

COLESEVELAM HYDROCHLORIDE

>A> BAR, CHEWABLE; ORAL

>A> WELCHOL

>A> +! DAIICHI SANKYO INC 3.75GM

N210895 001 Apr 03, 2019 Apr NEWA

FOR SUSPENSION; ORAL

COLESEVELAM HYDROCHLORIDE

>A> AB ALKEM LABS LTD 3.75GM/PACKET
 GLENMARK PHARMS LTD 1.875GM/PACKET
 WELCHOL
 + @ DAIICHI SANKYO 1.875GM/PACKET

A210316 001 May 06, 2019 Apr NEWA
 A202190 001 Jul 16, 2018 Mar CTEC
 N022362 001 Oct 02, 2009 Mar DISC

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

@ MYLAN SPECIALITY LP 10MG/ML

A074209 001 Apr 26, 1994 Mar DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB + TEVA PHARMS INTL 15MG
 + 15MG
 AB +! 30MG
 +! 30MG

N021777 001 Feb 01, 2007 Mar CTEC
 N021777 001 Feb 01, 2007 Jan CTEC
 N021777 002 Feb 01, 2007 Mar CTEC
 N021777 002 Feb 01, 2007 Jan CTEC

CYCLOBENZAPRINE HYDROCHLORIDE

AB APOTEX INC 15MG
 @ 15MG
 AB 30MG
 @ 30MG
 AB TWI PHARMS INC 15MG
 AB 30MG

A206703 001 Jul 24, 2018 Feb CMFD
 A206703 001 Jul 24, 2018 Jan DISC
 A206703 002 Jul 24, 2018 Feb CMFD
 A206703 002 Jul 24, 2018 Jan DISC
 A091281 001 Jan 31, 2013 Mar CMFD
 A091281 002 Jan 31, 2013 Mar CMFD

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

AB CIPLA 25MG
 AB 50MG

A211608 001 Jan 18, 2019 Jan NEWA
 A211608 002 Jan 18, 2019 Jan NEWA

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA TORRENT 2MG/5ML A204823 001 Dec 27, 2016 Jan CAHN

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A> AA BEXIMCO PHARMS USA 4MG A206676 001 Apr 12, 2019 Apr NEWA
AA ! HERITAGE PHARMA 4MG A087056 001 Feb CAHNCYSTEINE HYDROCHLORIDE

>A> SOLUTION; INTRAVENOUS

>A> ELCYS

>A> +! EXELA PHARMA SCS LLC 500MG/10ML (50MG/ML) N210660 001 Apr 16, 2019 Apr NEWA

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

+ @ BRISTOL-MYERS SQUIBB EQ 90MG BASE

N206843 003 Apr 13, 2016 Feb DISC

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

@ LUITPOLD 0.5MG/VIAL

A202562 001 Aug 23, 2013 Mar DISC

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

DALFAMPRIDINE

AB MICRO LABS 10MG A210158 001 Mar 11, 2019 Feb NEWA

DANTROLENE SODIUM

INJECTABLE; INJECTION

DANTROLENE SODIUM

@ MYLAN INSTITUTIONAL 20MG/VIAL

A205239 001 Feb 18, 2016 Mar DISC

DAPSONE

GEL; TOPICAL

ACZONE

+! ALMIRALL 7.5%

N207154 001 Feb 24, 2016 Feb CAHN

TABLET; ORAL

DAPSONE

>A> AB SAI LIFE SCIENCES 100MG A207165 001 May 08, 2019 Apr NEWA

AB TARO PHARM 25MG A209430 001 Mar 01, 2019 Feb NEWA

AB 100MG A209430 002 Mar 01, 2019 Feb NEWA

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

>A> AP DR REDDYS LABS LTD 500MG/VIAL A208375 001 May 01, 2019 Apr NEWA

AP XELLIA PHARMS APS 500MG/VIAL A206005 001 Jun 15, 2016 Mar CAHN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

>D> TABLET, EXTENDED RELEASE; ORAL

>D> VIEKIRA XR

>D> +! ABBVIE INC EQ 200MG BASE; 8.33MG; 50MG; 33.33MG N208624 001 Jul 22, 2016 Apr DISC

>A> + @ EQ 200MG BASE; 8.33MG; 50MG; 33.33MG N208624 001 Jul 22, 2016 Apr DISC

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DAUNORUBICIN HYDROCHLORIDE

>A> AP HISUN PHARM HANGZHOU EQ 5MG BASE/ML A208759 001 Apr 12, 2019 Apr NEWA

>A> AP EQ 20MG BASE/VIAL A206195 001 Apr 25, 2019 Apr NEWA

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

AP WOCHKHARDT BIO AG 50MG/VIAL A209056 001 Apr 09, 2019 Mar NEWA

DESLORATADINE

TABLET; ORAL
DESLORATADINE

>A>	AB	PERRIGO	5MG	A078361	001	Dec 22, 2011	Apr	CAHN
>D>	AB	PERRIGO R AND D	5MG	A078361	001	Dec 22, 2011	Apr	CAHN

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

AP		LUITPOLD	0.004MG/ML	A091374	001	Feb 14, 2019	Feb	NEWA
AP		TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Mar	CMFD

SPRAY, METERED; NASAL
NOCTIVA

>A>	+	ALYVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Apr	CAHN
>A>	+	!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Apr	CAHN
>D>	+	AVADEL SPECLT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Apr	CAHN
>D>	+	!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Apr	CAHN

TABLET; ORAL
DESMOPRESSIN ACETATE

AB		ABHAI LLC	0.1MG	A210371	001	Jan 28, 2019	Jan	NEWA
AB			0.2MG	A210371	002	Jan 28, 2019	Jan	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL
@ ACCORD HLTHCARE 0.15MG; 0.03MG

A207067	001	Sep 13, 2018	Mar	DISC
---------	-----	--------------	-----	------

DESONIDE

AEROSOL, FOAM; TOPICAL
VERDESO

+! ALMIRALL 0.05%

N021978	001	Sep 19, 2006	Feb	CAHN
---------	-----	--------------	-----	------

OINTMENT; TOPICAL
DESONIDE

AB		ENCUBE ETHICALS	0.05%	A210998	001	Jan 30, 2019	Jan	NEWA
AB		TELIGENT PHARMA INC	0.05%	A212002	001	Mar 12, 2019	Feb	NEWA

DESOXIMETASONE

CREAM; TOPICAL
DESOXIMETASONE

@ ZYDUS PHARMS 0.25%

A205620	001	Sep 28, 2018	Feb	DISC
---------	-----	--------------	-----	------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE SUCCINATE

>A>	AB	INTELLIPHARMACEUTICS	EQ 50MG BASE	A204805	001	May 07, 2019	Apr	NEWA
>A>	AB		EQ 100MG BASE	A204805	002	May 07, 2019	Apr	NEWA
		@ YICHANG HUMANWELL	EQ 50MG BASE	A210014	001	Oct 01, 2018	Mar	DISC
		@	EQ 100MG BASE	A210014	002	Oct 01, 2018	Mar	DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP	!	FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001		Feb	CHRS
		@ LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982	Feb	DISC
>A>	AP	SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A211036	001	May 10, 2019	Apr	NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP		CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jan	NEWA
		@ LUITPOLD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	Mar	DISC

SOLUTION; INTRAVENOUS
DEXMEDETOMIDINE HYDROCHLORIDE

+		HQ SPCLT PHARMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Mar	CPOT
+			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Mar	CPOT

DIAZEPAM

	GEL;RECTAL							
	DIASTAT							
	+	BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	Feb	CAHN
	+	@	5MG/ML (5MG/ML)	N020648	002	Jul 29, 1997	Feb	CAHN
	+	@	10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997	Feb	CAHN
	+	@	15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997	Feb	CAHN
	+	@	20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997	Feb	CAHN
	DIASTAT ACUDIAL							
	+	BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	Feb	CAHN
	+	!	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	Feb	CAHN
	INJECTABLE;INJECTION							
	DIAZEPAM							
AP		BELOTECA INC	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Mar	NEWA
AP	!	HOSPIRA	10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Mar	CTEC

DICLOFENAC

	CAPSULE;ORAL							
	ZORVOLEX							
	+	EGALET	18MG	N204592	001	Oct 18, 2013	Feb	CAHN
	+	!	35MG	N204592	002	Oct 18, 2013	Feb	CAHN

DICLOFENAC EPOLAMINE

	SYSTEM;TOPICAL							
	LICART							
	+	@ IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Feb	DISC

DICLOFENAC SODIUM

	GEL;TOPICAL							
	DICLOFENAC SODIUM							
>A>	AB	MYLAN	1%	A204306	001	May 06, 2019	Apr	NEWA

DICYCLOMINE HYDROCHLORIDE

	INJECTABLE;INJECTION							
	DICYCLOMINE HYDROCHLORIDE							
	@	APC PHARMS LLC	10MG/ML	A210979	001	Jul 02, 2018	Feb	DISC
AP		CUSTOPHARM INC	10MG/ML	A210788	001	Feb 11, 2019	Jan	NEWA
AP		FRESENIUS KABI USA	10MG/ML	A210257	001	Jan 25, 2019	Jan	NEWA
AP		NEXUS PHARMS	10MG/ML	A206468	001	Feb 01, 2019	Jan	NEWA
AP		SLATE	10MG/ML	A207076	001	Nov 02, 2018	Feb	CAHN
>A>	AP	SUNGEN PHARMA	10MG/ML	A212058	001	Apr 26, 2019	Apr	NEWA

DIGOXIN

	ELIXIR;ORAL							
	DIGOXIN							
>A>	+	HIKMA	0.05MG/ML	N021648	001	Aug 26, 2004	Apr	CAHN
>D>	+	WEST-WARD PHARMS INT	0.05MG/ML	N021648	001	Aug 26, 2004	Apr	CAHN

DIHYDROERGOTAMINE MESYLATE

	INJECTABLE;INJECTION							
	D.H.E. 45							
>A>	AP	+	BAUSCH	1MG/ML	N005929	001		Apr
>D>	AP	+	VALEANT	1MG/ML	N005929	001		Apr
	SPRAY, METERED;NASAL							
	MIGRANAL							
>A>	+	BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Apr	CAHN
>D>	+	VALEANT	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Apr	CAHN
	+	!	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Jan	CPOT

DILTIAZEM HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL							
	CARDIZEM CD							
AB3	+	BAUSCH	120MG	N020062	001	Aug 10, 1992	Feb	CAHN
AB3	+		180MG	N020062	002	Dec 27, 1991	Feb	CAHN
AB3	+		240MG	N020062	003	Dec 27, 1991	Feb	CAHN
AB3	+		300MG	N020062	004	Dec 27, 1991	Feb	CAHN
AB3	+	!	360MG	N020062	005	Aug 24, 1999	Feb	CAHN
	DILTIAZEM HYDROCHLORIDE							
	@	PAR PHARM	360MG	A209766	001	May 30, 2018	Mar	DISC

CAPSULE, EXTENDED RELEASE;ORAL

TIAZAC

AB4	+	BAUSCH	120MG	N020401	001	Sep 11, 1995	Feb	CAHN
AB4	+		180MG	N020401	002	Sep 11, 1995	Feb	CAHN
AB4	+		240MG	N020401	003	Sep 11, 1995	Feb	CAHN
AB4	+		300MG	N020401	004	Sep 11, 1995	Feb	CAHN
AB4	+		360MG	N020401	005	Sep 11, 1995	Feb	CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb	CAHN

TABLET;ORAL

CARDIZEM

AB	+	BAUSCH	30MG	N018602	001	Nov 05, 1982	Mar	CAHN
AB	+		60MG	N018602	002	Nov 05, 1982	Mar	CAHN
AB	+		90MG	N018602	003	Dec 08, 1986	Mar	CAHN
AB	+		120MG	N018602	004	Dec 08, 1986	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

CARDIZEM LA

AB	+	BAUSCH	120MG	N021392	001	Feb 06, 2003	Mar	CAHN
AB	+		180MG	N021392	002	Feb 06, 2003	Mar	CAHN
AB	+		240MG	N021392	003	Feb 06, 2003	Mar	CAHN
AB	+		300MG	N021392	004	Feb 06, 2003	Mar	CAHN
AB	+		360MG	N021392	005	Feb 06, 2003	Mar	CAHN
AB	+		420MG	N021392	006	Feb 06, 2003	Mar	CAHN

DIMETHYL SULFOXIDE

SOLUTION;INTRAVESICAL

DIMETHYL SULFOXIDE

	@	MYLAN INSTITUTIONAL	50%	A076185	001	Nov 29, 2002	Mar	DISC
		RIMSO-50						
	+	MYLAN INSTITUTIONAL	50%	N017788	001		Mar	CTEC

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

	@	CIPLA	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Mar	DISC
	@		80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Mar	DISC
	@		160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Mar	DISC
AP		MYLAN LABS LTD	160MG/8ML (20MG/ML)	A208137	001	Apr 01, 2019	Mar	NEWA
AP		TEIKOKU PHARMA	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Mar	CAHN
AP			80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Mar	CAHN
AP			160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Mar	CAHN

SOLUTION;INTRAVENOUS

DOCETAXEL

AP		SUN PHARMA GLOBAL	20MG/ML (20MG/ML)	N022534	003	Jan 08, 2019	Jan	NEWA
AP			80MG/4ML (20MG/ML)	N022534	004	Jan 08, 2019	Jan	NEWA
AP			160MG/8ML (20MG/ML)	N022534	005	Jan 08, 2019	Jan	NEWA

DOFETILIDE

CAPSULE;ORAL

DOFETILDE

AB		AUROBINDO PHARMA LTD	0.125MG	A210740	001	Jan 22, 2019	Jan	NEWA
AB			0.25MG	A210740	002	Jan 22, 2019	Jan	NEWA
AB			0.5MG	A210740	003	Jan 22, 2019	Jan	NEWA

>A> DOLUTEGRAVIR SODIUM; LAMIVUDINE

>A> TABLET;ORAL

>A> DOVATO

>A>	+	VIIV HLTHCARE	EQ 50MG BASE;300MG	N211994	001	Apr 08, 2019	Apr	NEWA
-----	---	---------------	--------------------	---------	-----	--------------	-----	------

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB		CADILA	5MG	A090100	001	Oct 24, 2012	Mar	CAHN
AB			10MG	A090100	002	Oct 24, 2012	Mar	CAHN
	@	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Mar	DISC
>A>	AB	STRIDES PHARMA	5MG	A090551	001	May 31, 2011	Apr	CAHN
>A>	AB		10MG	A090551	002	May 31, 2011	Apr	CAHN
>D>	AB	STRIDES VIVIMED	5MG	A090551	001	May 31, 2011	Apr	CAHN
>D>	AB		10MG	A090551	002	May 31, 2011	Apr	CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE
@ LUITPOLD 40MG/ML
@ 80MG/ML

A070799 001 Feb 11, 1987 Feb DISC
A070820 001 Feb 11, 1987 Feb DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

AT FDC LTD EQ 2% BASE
@ LUITPOLD EQ 2% BASE

A205294 001 Jan 24, 2019 Jan NEWA
A079186 001 Nov 18, 2009 Mar DISC

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION
DOPRAM

AP +! HIKMA 20MG/ML

N014879 001 Mar CAHN

DOXEFIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEFIN HYDROCHLORIDE

AB AUROBINDO PHARMA LTD EQ 10MG BASE
AB EQ 25MG BASE
AB EQ 50MG BASE
AB EQ 75MG BASE
AB EQ 100MG BASE
AB PAR PHARM EQ 10MG BASE
AB EQ 25MG BASE
AB EQ 75MG BASE

A211603 001 Mar 27, 2019 Mar NEWA
A211603 002 Mar 27, 2019 Mar NEWA
A211603 003 Mar 27, 2019 Mar NEWA
A211603 004 Mar 27, 2019 Mar NEWA
A211603 005 Mar 27, 2019 Mar NEWA
A071697 001 Nov 09, 1987 Jan CMFD
A071437 001 Nov 09, 1987 Jan CMFD
A071608 001 Nov 09, 1987 Jan CMFD

TABLET; ORAL
SILENOR

>A> + CURRAX EQ 3MG BASE
>A> +! EQ 6MG BASE
>D> + PERNIX EQ 3MG BASE
+ EQ 3MG BASE
>D> +! EQ 6MG BASE
+! EQ 6MG BASE

N022036 001 Mar 17, 2010 Apr CAHN
N022036 002 Mar 17, 2010 Apr CAHN
N022036 001 Mar 17, 2010 Apr CAHN
N022036 001 Mar 17, 2010 Feb CAHN
N022036 002 Mar 17, 2010 Apr CAHN
N022036 002 Mar 17, 2010 Feb CAHN

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

>A> AP HISUN PHARM HANGZHOU 20MG/VIAL

A206062 001 May 13, 2019 Apr NEWA

DOXYCYCLINE

CAPSULE; ORAL
MONODOX

AB + ALMIRALL EQ 50MG BASE
AB + EQ 75MG BASE
AB +! EQ 100MG BASE

N050641 002 Feb 10, 1992 Feb CAHN
N050641 003 Oct 18, 2006 Feb CAHN
N050641 001 Dec 29, 1989 Feb CAHN

TABLET; ORAL
DOXYCYCLINE

>D> AB MYLAN EQ 50MG BASE
>A> @ EQ 50MG BASE
>D> AB EQ 75MG BASE
>A> @ EQ 75MG BASE

A065377 001 Nov 07, 2006 Apr DISC
A065377 001 Nov 07, 2006 Apr DISC
A065377 002 Nov 07, 2006 Apr DISC
A065377 002 Nov 07, 2006 Apr DISC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
ACTICLATE CAP

+ @ ALMIRALL EQ 75MG BASE

N208253 001 Apr 26, 2016 Feb CAHN

DOXYCYCLINE HYCLATE
@ AJANTA PHARMA LTD EQ 50MG BASE
@ EQ 100MG BASE

A211012 001 Sep 24, 2018 Mar DISC
A211012 002 Sep 24, 2018 Mar DISC

>D> AB MYLAN EQ 50MG BASE
>A> @ EQ 50MG BASE
>D> AB EQ 100MG BASE
>A> @ EQ 100MG BASE

A062337 001 Mar 29, 1982 Apr DISC
A062337 001 Mar 29, 1982 Apr DISC
A062337 002 Mar 29, 1982 Apr DISC
A062337 002 Mar 29, 1982 Apr DISC

TABLET; ORAL
ACTICLATE

AB + ALMIRALL EQ 75MG BASE
AB +! EQ 150MG BASE

N205931 001 Jul 25, 2014 Feb CAHN
N205931 002 Jul 25, 2014 Feb CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

>A>	AB	APOTEX INC	EQ 75MG BASE	A209243	001	Apr 15, 2019	Apr	NEWA
>A>	AB		EQ 150MG BASE	A209243	002	Apr 15, 2019	Apr	NEWA
	AB	CADILA	EQ 100MG BASE	A207773	001	Oct 30, 2017	Feb	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

	AB	HETERO LABS LTD	3MG;0.02MG	A211944	001	Mar 22, 2019	Mar	NEWA
	AB	KEMEYA						
	AB	SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019	Feb	NEWA

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

	AB	AJANTA PHARMA LTD	EQ 40MG BASE	A208706	004	Mar 11, 2019	Feb	NEWA
>A>	AB	QINGDAO BAHEAL PHARM	EQ 20MG BASE	A210599	001	Apr 17, 2019	Apr	NEWA
>A>	AB		EQ 30MG BASE	A210599	002	Apr 17, 2019	Apr	NEWA
>A>	AB		EQ 60MG BASE	A210599	003	Apr 17, 2019	Apr	NEWA

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

	AB	CADILA	0.5MG	A204373	001	Oct 04, 2017	Feb	CAHN
--	----	--------	-------	---------	-----	--------------	-----	------

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

@ AUROBINDO PHARMA LTD 600MG

A077673	001	Sep 21, 2018	Feb	DISC
---------	-----	--------------	-----	------

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

MACLEODS PHARMS LTD 400MG;300MG;300MG

N210649	001	Mar 15, 2019	Mar	NEWA
---------	-----	--------------	-----	------

EFINACONAZOLE

SOLUTION;TOPICAL

JUBLIA

+!	BAUSCH	10%	N203567	001	Jun 06, 2014	Feb	CAHN
----	--------	-----	---------	-----	--------------	-----	------

ELTROMBOPAG OLAMINE

TABLET;ORAL

PROMACTA

+	@ NOVARTIS PHARMS CORP	EQ 100MG ACID	N022291	005	Nov 16, 2012	Feb	DISC
---	------------------------	---------------	---------	-----	--------------	-----	------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@ AMNEAL PHARMS CO 100MG;150MG

A209721	001	Aug 22, 2018	Feb	DISC
---------	-----	--------------	-----	------

@ 133MG;200MG

A209721	002	Aug 22, 2018	Feb	DISC
---------	-----	--------------	-----	------

@ 167MG;250MG

A209721	003	Aug 22, 2018	Feb	DISC
---------	-----	--------------	-----	------

@ 200MG;300MG

A209721	004	Aug 22, 2018	Feb	DISC
---------	-----	--------------	-----	------

TRUVADA

+	GILEAD	100MG;150MG	N021752	002	Mar 10, 2016	Feb	CTEC
---	--------	-------------	---------	-----	--------------	-----	------

+		133MG;200MG	N021752	003	Mar 10, 2016	Feb	CTEC
---	--	-------------	---------	-----	--------------	-----	------

+		167MG;250MG	N021752	004	Mar 10, 2016	Feb	CTEC
---	--	-------------	---------	-----	--------------	-----	------

ENALAPRIL MALEATE

FOR SOLUTION;ORAL

EPANED KIT

+	@ SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013	Mar	DISC
---	---------------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

ENALAPRIL MALEATE

@ BEXIMCO PHARMS USA 2.5MG

A075621	001	Aug 22, 2000	Feb	CAHN
---------	-----	--------------	-----	------

@ 5MG

A075621	002	Aug 22, 2000	Feb	CAHN
---------	-----	--------------	-----	------

@ 10MG

A075621	003	Aug 22, 2000	Feb	CAHN
---------	-----	--------------	-----	------

@ 20MG

A075621	004	Aug 22, 2000	Feb	CAHN
---------	-----	--------------	-----	------

AB	HERITAGE PHARMA	2.5MG	A075479	001	Aug 22, 2000	Feb	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

AB		5MG	A075479	002	Aug 22, 2000	Feb	CAHN
----	--	-----	---------	-----	--------------	-----	------

AB		10MG	A075479	003	Aug 22, 2000	Feb	CAHN
----	--	------	---------	-----	--------------	-----	------

TABLET;ORAL

ENALAPRIL MALEATE

AB		20MG	A075479	004	Aug 22, 2000	Feb	CAHN
	@ MYLAN	10MG	A075480	003	Aug 22, 2000	Feb	DISC
	VASOTEC						
AB	+ BAUSCH	2.5MG	N018998	005	Jul 26, 1988	Mar	CAHN
AB	+	5MG	N018998	001	Dec 24, 1985	Mar	CAHN
AB	+	10MG	N018998	002	Dec 24, 1985	Mar	CAHN
AB	+!	20MG	N018998	003	Dec 24, 1985	Mar	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

VASERETIC

AB	+ BAUSCH	5MG;12.5MG	N019221	003	Jul 12, 1995	Mar	CAHN
AB	+!	10MG;25MG	N019221	001	Oct 31, 1986	Mar	CAHN

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB	AMPHASTAR PHARMS INC	300MG/3ML (100MG/ML)	A208600	001	Mar 14, 2019	Mar	NEWA
----	----------------------	----------------------	---------	-----	--------------	-----	------

ENTECAVIR

TABLET;ORAL

ENTECAVIR

AB	MYLAN	0.5MG	A206226	001	Mar 26, 2019	Mar	NEWA
AB		1MG	A206226	002	Mar 26, 2019	Mar	NEWA

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE (AUTOINJECTOR)

	@ TEVA PHARMS USA	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Mar	DISC
	EPIPEN JR.						
	+! MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Mar	CTEC
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS						
	ADRENALIN						
AP	+! PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jan	CDFR
	+!	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jan	CDFR

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

EPIRUBICIN HYDROCHLORIDE

	FRESENIUS KABI USA	150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007	Mar	CTEC
--	--------------------	---------------------	---------	-----	--------------	-----	------

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP	BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Jan	CAHN
AP		75MG/100ML	A208554	002	Nov 23, 2018	Jan	CAHN
AP	HAINAN POLY PHARM	2MG/ML	A209864	001	Jan 25, 2019	Jan	NEWA
AP		75MG/100ML	A209864	002	Jan 25, 2019	Jan	NEWA
AP	USV	2MG/ML	A204361	001	Mar 14, 2019	Mar	NEWA
AP		2MG/ML	A204362	001	Mar 11, 2019	Feb	NEWA
AP		75MG/100ML	A204361	002	Mar 14, 2019	Mar	NEWA

>A> ERDAFITINIB

>A> TABLET;ORAL

>A> BALVERSA

>A>	+ JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019	Apr	NEWA
>A>	+	4MG	N212018	002	Apr 12, 2019	Apr	NEWA
>A>	+!	5MG	N212018	003	Apr 12, 2019	Apr	NEWA

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB	MYLAN	EQ 25MG BASE	A091002	001	Jun 11, 2014	Feb	CMFD
AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	Feb	CMFD
AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	Feb	CMFD
AB	TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015	Mar	CMFD
AB		EQ 150MG BASE	A091059	003	Aug 28, 2015	Mar	CMFD
	TARCEVA						
AB	+ OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Mar	CAHN
AB	+	EQ 25MG BASE	N021743	001	Nov 18, 2004	Feb	CTEC

TABLET;ORAL

TARCEVA									
AB	+	EQ 100MG BASE	N021743	002	Nov 18, 2004	Mar	CAHN		
AB	+	EQ 100MG BASE	N021743	002	Nov 18, 2004	Feb	CTEC		
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	Mar	CAHN		
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	Feb	CTEC		

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS		ERTAPENEM SODIUM							
AP	SAVIOR LIFETEC CORP	EQ 1GM BASE/VIAL	A207647	001	Mar 19, 2019	Mar	NEWA		

ERYTHROMYCIN

OINTMENT; TOPICAL		AKNE-MYCIN							
>A>	+ @ BAUSCH	2%	N050584	001	Jan 10, 1985	Apr	CAHN		
>D>	+ @ DOW PHARM	2%	N050584	001	Jan 10, 1985	Apr	CAHN		
SOLUTION; TOPICAL		ERYTHRA-DERM							
	@ SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Feb	CAHN		

ESCITALOPRAM OXALATE

TABLET; ORAL		ESCITALOPRAM OXALATE							
>A>	AB	CADILA	EQ 5MG BASE	A077734	001	Sep 11, 2012	Apr	CAHN	
>A>	AB		EQ 10MG BASE	A077734	002	Sep 11, 2012	Apr	CAHN	
>A>	AB		EQ 20MG BASE	A077734	003	Sep 11, 2012	Apr	CAHN	
>D>	AB	ZYDUS PHARMS USA INC	EQ 5MG BASE	A077734	001	Sep 11, 2012	Apr	CAHN	
>D>	AB		EQ 10MG BASE	A077734	002	Sep 11, 2012	Apr	CAHN	
>D>	AB		EQ 20MG BASE	A077734	003	Sep 11, 2012	Apr	CAHN	

ESKETAMINE HYDROCHLORIDE

SPRAY; NASAL		SPRAVATO							
+	JANSSEN PHARMS	EQ 28MG BASE	N211243	001	Mar 05, 2019	Mar	NEWA		

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION		ESMOLOL HYDROCHLORIDE							
	@ LUITPOLD	10MG/ML	A201126	001	Feb 20, 2015	Mar	DISC		

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL		ESOMEPRAZOLE MAGNESIUM							
AB	AMNEAL PHARMS NY	EQ 20MG BASE	A209647	001	Apr 10, 2019	Mar	NEWA		
AB		EQ 40MG BASE	A209647	002	Apr 10, 2019	Mar	NEWA		
>A>	AB	GLENMARK PHARMS	EQ 20MG BASE	A209495	001	May 10, 2019	Apr	NEWA	
>A>	AB		EQ 40MG BASE	A209495	002	May 10, 2019	Apr	NEWA	
	@ HEC PHARM	EQ 20MG BASE	A207265	002	May 18, 2018	Mar	DISC		
	@	EQ 40MG BASE	A207265	001	May 18, 2018	Mar	DISC		

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL		ESTRADIOL							
AB1	AMNEAL PHARMS LLC	0.025MG/24HR	A211293	001	Feb 04, 2019	Jan	NEWA		
AB1		0.0375MG/24HR	A211293	002	Feb 04, 2019	Jan	NEWA		
AB1		0.05MG/24HR	A211293	003	Feb 04, 2019	Jan	NEWA		
AB1		0.075MG/24HR	A211293	004	Feb 04, 2019	Jan	NEWA		
AB1		0.1MG/24HR	A211293	005	Feb 04, 2019	Jan	NEWA		
GEL; TRANSDERMAL		DIVIGEL							
+	VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007	Jan	CHRS		

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL		ESTRADIOL AND NORETHINDRONE ACETATE							
	@ ACCORD HLTHCARE	1MG; 0.5MG	A210233	001	Feb 28, 2018	Mar	DISC		
AB	NOVAST LABS	0.5MG; 0.1MG	A210612	001	Apr 03, 2019	Mar	NEWA		
AB		1MG; 0.5MG	A210612	002	Apr 03, 2019	Mar	NEWA		

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

	@ MYLAN LABS LTD	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG	A 202132	001	Sep 09, 2015	Jan	DISC
--	------------------	--	----------	-----	--------------	-----	------

>D> ORTHO CYCLEN-28

>D> AB	+!	JANSSEN PHARMS	0.035MG; 0.25MG	N 019653	002	Dec 29, 1989	Apr	DISC
--------	----	----------------	-----------------	----------	-----	--------------	-----	------

>A>	+	@	0.035MG; 0.25MG	N 019653	002	Dec 29, 1989	Apr	DISC
-----	---	---	-----------------	----------	-----	--------------	-----	------

SPRINTEC

>D> AB		BARR	0.035MG; 0.25MG	A 075804	001	Sep 25, 2002	Apr	CHRS
--------	--	------	-----------------	----------	-----	--------------	-----	------

>A> AB	!		0.035MG; 0.25MG	A 075804	001	Sep 25, 2002	Apr	CHRS
--------	---	--	-----------------	----------	-----	--------------	-----	------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB		STRIDES PHARMA	250MG	A 211928	001	Feb 19, 2019	Feb	NEWA
----	--	----------------	-------	----------	-----	--------------	-----	------

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

>D> AP		@ LUITPOLD	2MG/ML	A 078867	001	Dec 22, 2009	Feb	DISC
--------	--	------------	--------	----------	-----	--------------	-----	------

>A>		PAR STERILE PRODUCTS	2MG/ML	A 091297	001	Jun 20, 2012	Apr	DISC
-----	--	----------------------	--------	----------	-----	--------------	-----	------

>A>		@	2MG/ML	A 091297	001	Jun 20, 2012	Apr	DISC
-----	--	---	--------	----------	-----	--------------	-----	------

EVEROLIMUS

TABLET; ORAL

AFINITOR

>D>	+	NOVARTIS	5MG	N 022334	001	Mar 30, 2009	Apr	CHRS
-----	---	----------	-----	----------	-----	--------------	-----	------

>A>	+	!	5MG	N 022334	001	Mar 30, 2009	Apr	CHRS
-----	---	---	-----	----------	-----	--------------	-----	------

>D>	+	!	10MG	N 022334	002	Mar 30, 2009	Apr	CHRS
-----	---	---	------	----------	-----	--------------	-----	------

>A>	+		10MG	N 022334	002	Mar 30, 2009	Apr	CHRS
-----	---	--	------	----------	-----	--------------	-----	------

ZORTRESS

+ NOVARTIS 1MG

N 021560	004	Aug 10, 2018	Mar	NEWA
----------	-----	--------------	-----	------

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

>D>	+	NOVARTIS PHARM	2MG	N 203985	001	Aug 29, 2012	Apr	CFTG
-----	---	----------------	-----	----------	-----	--------------	-----	------

>A>	+		2MG	N 203985	001	Aug 29, 2012	Apr	CFTG
-----	---	--	-----	----------	-----	--------------	-----	------

>A> AB	+		2MG	N 203985	001	Aug 29, 2012	Apr	CFTG
--------	---	--	-----	----------	-----	--------------	-----	------

>D>	+		3MG	N 203985	002	Aug 29, 2012	Apr	CFTG
-----	---	--	-----	----------	-----	--------------	-----	------

>A>	+		3MG	N 203985	002	Aug 29, 2012	Apr	CFTG
-----	---	--	-----	----------	-----	--------------	-----	------

>A> AB	+		3MG	N 203985	002	Aug 29, 2012	Apr	CFTG
--------	---	--	-----	----------	-----	--------------	-----	------

>D>	+	!	5MG	N 203985	003	Aug 29, 2012	Apr	CFTG
-----	---	---	-----	----------	-----	--------------	-----	------

>A>	+	!	5MG	N 203985	003	Aug 29, 2012	Apr	CFTG
-----	---	---	-----	----------	-----	--------------	-----	------

>A> AB	+	!	5MG	N 203985	003	Aug 29, 2012	Apr	CFTG
--------	---	---	-----	----------	-----	--------------	-----	------

>A>		EVEROLIMUS						
-----	--	------------	--	--	--	--	--	--

>A>		@ MYLAN	2MG	A 210130	001	Apr 19, 2019	Apr	NFTG
-----	--	---------	-----	----------	-----	--------------	-----	------

>A>		@	3MG	A 210130	002	Apr 19, 2019	Apr	NFTG
-----	--	---	-----	----------	-----	--------------	-----	------

>A>		@	5MG	A 210130	003	Apr 19, 2019	Apr	NFTG
-----	--	---	-----	----------	-----	--------------	-----	------

EXEMESTANE

TABLET; ORAL

EXEMESTANE

AB		BRECKENRIDGE PHARM	25MG	A 211031	001	Feb 21, 2019	Feb	NEWA
----	--	--------------------	------	----------	-----	--------------	-----	------

EZETIMIBE

TABLET; ORAL

EZETIMIBE

>D> AB		ACCORD HLTHCARE	10MG	A 211550	001	Oct 26, 2018	Apr	DISC
--------	--	-----------------	------	----------	-----	--------------	-----	------

>A>		@	10MG	A 211550	001	Oct 26, 2018	Apr	DISC
-----	--	---	------	----------	-----	--------------	-----	------

>A> AB		MYLAN	10MG	A 201790	001	Apr 26, 2019	Apr	NEWA
--------	--	-------	------	----------	-----	--------------	-----	------

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

>D> AB		MYLAN	40MG	A 075704	002	Apr 16, 2001	Apr	DISC
--------	--	-------	------	----------	-----	--------------	-----	------

>A>		@	40MG	A 075704	002	Apr 16, 2001	Apr	DISC
-----	--	---	------	----------	-----	--------------	-----	------

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL
FELODIPINE

>A>	AB	YUNG SHIN PHARM	2.5MG	A204800	001	Apr 29, 2019	Apr	NEWA
>A>	AB		5MG	A204800	002	Apr 29, 2019	Apr	NEWA
>A>	AB		10MG	A204800	003	Apr 29, 2019	Apr	NEWA

FENOFIBRATE

CAPSULE;ORAL
FENOFIBRATE (MICRONIZED)

	AB	AUSTARPHARMA	67MG	A207805	001	Nov 16, 2017	Jan	CAHN
	AB		134MG	A207805	002	Nov 16, 2017	Jan	CAHN
	AB		200MG	A207805	003	Nov 16, 2017	Jan	CAHN
>A>	AB	INGENUS PHARMS LLC	67MG	A207564	001	Apr 19, 2019	Apr	NEWA
>A>	AB		134MG	A207564	002	Apr 19, 2019	Apr	NEWA
>A>	AB		200MG	A207564	003	Apr 19, 2019	Apr	NEWA

TABLET;ORAL
FENOFIBRATE

	AB	AUSTARPHARMA	54MG	A207803	001	Dec 19, 2017	Jan	CAHN
	AB		160MG	A207803	002	Dec 19, 2017	Jan	CAHN
		@ GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018	Feb	DISC
		@	160MG	A210606	002	Aug 17, 2018	Feb	DISC
	AB	ORIT LABS LLC	54MG	A209660	001	Feb 11, 2019	Jan	NEWA
	AB		160MG	A209660	002	Feb 11, 2019	Jan	NEWA
		FENOGLIDE						
	AB	+ SALIX	40MG	N022118	001	Aug 10, 2007	Mar	CAHN
	AB	+!	120MG	N022118	002	Aug 10, 2007	Mar	CAHN

FENOFIBRIC ACID

TABLET;ORAL
FIBRICOR

		+ ATHENA	35MG	N022418	001	Aug 14, 2009	Feb	CAHN
		+!	105MG	N022418	002	Aug 14, 2009	Feb	CAHN

FENTANYL CITRATE

INJECTABLE;INJECTION
FENTANYL CITRATE PRESERVATIVE FREE

>A>	AP	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A210762	001	May 03, 2019	Apr	NEWA
-----	----	--------------------	-------------------	---------	-----	--------------	-----	------

>D> FINAFLOXACIN

>D> SUSPENSION/DROPS;OTIC
>D> XTORO

>D>		+! MERLION PHARMS GMBH	0.3%	N206307	001	Dec 17, 2014	Apr	DISC
>A>		+ @	0.3%	N206307	001	Dec 17, 2014	Apr	DISC

FLOXURIDINE

INJECTABLE;INJECTION
FLOXURIDINE

		@ LUITPOLD	500MG/VIAL	A203008	001	Nov 22, 2017	Mar	DISC
--	--	------------	------------	---------	-----	--------------	-----	------

FLUCYTOSINE

CAPSULE;ORAL
ANCOBON

	AB	+ BAUSCH	250MG	N017001	001		Feb	CAHN
	AB	+!	500MG	N017001	002		Feb	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

>A>	AP	DECATUR	20-300mCi/ML	A204463	001	Oct 21, 2014	Apr	CAHN
>D>	AP	GLOBAL ISOTOPES LLC	20-300mCi/ML	A204463	001	Oct 21, 2014	Apr	CAHN

FLUOCINOLONE ACETONIDE

SOLUTION;TOPICAL
FLUOCINOLONE ACETONIDE

		@ ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016	Mar	DISC
	AT	ENCUBE ETHICALS	0.01%	A209913	001	Feb 13, 2019	Jan	NEWA
	AT	GLASSHOUSE PHARMS	0.01%	A209596	001	Dec 26, 2017	Jan	CMFD
	AT	LUPIN	0.01%	A206422	001	Sep 02, 2015	Feb	CAHN

FLUOCINONIDE

		CREAM; TOPICAL							
		FLUOCINONIDE							
		@ AMNEAL PHARMS LLC	0.05%		A210554	001	Aug 21, 2018	Feb	DISC
AB		TELIGENT PHARMA INC	0.1%		A211758	001	Apr 03, 2019	Mar	NEWA
		SOLUTION; TOPICAL							
		FLUOCINONIDE							
AT		TELIGENT PHARMA INC	0.05%		A207554	001	Mar 18, 2019	Mar	NEWA

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
FLAREX

+! EYEVANCE 0.1% N019079 001 Feb 11, 1986 Feb CAHN

FLUOROURACIL

CREAM; TOPICAL
FLUOROPLEX

+! ALMIRALL 1% N016988 001 Feb CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

@ BEXIMCO PHARMS USA EQ 10MG BASE A075807 001 Jan 29, 2002 Feb CAHN

@ EQ 20MG BASE A075807 002 Jan 29, 2002 Feb CAHN

@ PAR PHARM EQ 40MG BASE A076922 003 Dec 16, 2004 Mar DISC

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE

>D> AB BARR EQ 90MG BASE A076237 001 Mar 24, 2010 Apr DISC

>A> @ EQ 90MG BASE A076237 001 Mar 24, 2010 Apr DISC

>D> AB DR REDDYS LABS LTD EQ 90MG BASE A078572 001 Mar 22, 2010 Apr CHRS

>A> ! EQ 90MG BASE A078572 001 Mar 22, 2010 Apr CTEC

>A> AB ! EQ 90MG BASE A078572 001 Mar 22, 2010 Apr CHRS

>D> PROZAC WEEKLY

>D> AB +! LILLY EQ 90MG BASE N021235 001 Feb 26, 2001 Apr DISC

>A> + @ EQ 90MG BASE N021235 001 Feb 26, 2001 Apr DISC

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB APPCO PHARMA LLC EQ 10MG BASE A211696 001 Jan 30, 2019 Jan NEWA

AB EQ 20MG BASE A211696 002 Jan 30, 2019 Jan NEWA

AB DR REDDYS LABS LTD EQ 60MG BASE A211721 001 Jan 25, 2019 Jan NEWA

>A> AB LUPIN LTD EQ 10MG BASE A211653 001 Apr 15, 2019 Apr NEWA

>A> AB EQ 20MG BASE A211653 002 Apr 15, 2019 Apr NEWA

AB EQ 60MG BASE A211632 001 Feb 08, 2019 Feb NEWA

AB SCIEGEN PHARMS INC EQ 10MG BASE A210935 001 Mar 20, 2019 Mar NEWA

AB EQ 20MG BASE A210935 002 Mar 20, 2019 Mar NEWA

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+! ALMIRALL 0.025% N012806 003 Feb CAHN

AT +! 0.05% N012806 002 Feb CAHN

LOTION; TOPICAL

CORDRAN

AT +! ALMIRALL 0.05% N013790 001 Feb CAHN

OINTMENT; TOPICAL

CORDRAN

+ @ ALMIRALL 0.025% N012806 004 Feb CAHN

AT +! 0.05% N012806 001 Feb CAHN

TAPE; TOPICAL

CORDRAN

+! ALMIRALL 0.004MG/SQ CM N016455 001 Feb CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

>D> AB ACTAVIS LABS FL INC 125MG A075820 001 Sep 18, 2001 Apr DISC

>A> @ 125MG A075820 001 Sep 18, 2001 Apr DISC

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

ADVAIR DISKUS 100/50

AB	+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000	Jan CFTG
		ADVAIR DISKUS 250/50					
AB	+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000	Jan CFTG
		ADVAIR DISKUS 500/50					
AB	+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000	Jan CFTG
		WIXELA INHUB					
AB		MYLAN	0.1MG/INH;EQ 0.05MG BASE/INH	A208891	001	Jan 30, 2019	Jan NFTG
AB			0.25MG/INH;EQ 0.05MG BASE/INH	A208891	002	Jan 30, 2019	Jan NFTG
AB			0.5MG/INH;EQ 0.05MG BASE/INH	A208891	003	Jan 30, 2019	Jan NFTG

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA		INVATECH PHARMA	1MG	A211064	001	Mar 08, 2019	Feb NEWA
----	--	-----------------	-----	---------	-----	--------------	----------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@ LUITPOLD

EQ 50MG PHENYTOIN NA/ML

A078277 001 Aug 06, 2007 Feb DISC

@

EQ 50MG PHENYTOIN NA/ML

A090099 001 May 13, 2010 Feb DISC

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

>D>	AP	+	ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002	Apr CMS1
>A>	AO	+		50MG/ML	N021344	001	Apr 25, 2002	Apr CMS1
	AP	+		50MG/ML	N021344	001	Apr 25, 2002	Feb CFTG

FULVESTRANT

>D>	AP		AMNEAL PHARMS CO	50MG/ML	A210044	001	Mar 04, 2019	Apr CMS1
>A>	AO			50MG/ML	A210044	001	Mar 04, 2019	Apr CMS1
	AP			50MG/ML	A210044	001	Mar 04, 2019	Feb NFTG
>A>	AO		SANDOZ INC	50MG/ML	A205935	001	May 14, 2019	Apr NEWA

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

>A>	AP		AUROBINDO PHARMA LTD	10MG/ML	A212174	001	May 03, 2019	Apr NEWA
-----	----	--	----------------------	---------	---------	-----	--------------	----------

TABLET; ORAL

FUROSEMIDE

	AB		HERITAGE PHARMA	20MG	N018413	001	Nov 30, 1983	Feb CAHN
	AB			40MG	N018413	002	Nov 30, 1983	Feb CAHN
>A>	AB		HIKMA	20MG	N018823	001	Nov 10, 1983	Apr CAHN
>A>	AB			40MG	N018823	002	Nov 10, 1983	Apr CAHN
>D>	AB		WEST-WARD PHARMS INT	20MG	N018823	001	Nov 10, 1983	Apr CAHN
>D>	AB			40MG	N018823	002	Nov 10, 1983	Apr CAHN

GABAPENTIN

TABLET; ORAL

GABAPENTIN

@ LUPIN LTD

600MG

A209306 001 Aug 24, 2018 Mar DISC

@

800MG

A209306 002 Aug 24, 2018 Mar DISC

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

BS		CURIUM	2mCi/ML	N018058	001		Jan CAHN
----	--	--------	---------	---------	-----	--	----------

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR

@ LUITPOLD

EQ 500MG BASE/VIAL

A202624 001 Sep 18, 2013 Feb DISC

GANIRELIX ACETATEINJECTABLE; INJECTION
GANIRELIX ACETATE

AP	+	ORGANON USA INC	250MCG/0.5ML	N021057	001	Jul 29, 1999	Mar CPOT
AP		SUN PHARM	250MCG/0.5ML	A204246	001	Nov 30, 2018	Mar CPOT

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A090799	001	Jul 25, 2011	Jan CAHN
AP			EQ 1GM BASE/VIAL	A090799	002	Jul 25, 2011	Jan CAHN
AP			EQ 2GM BASE/VIAL	A090799	003	May 16, 2011	Jan CAHN
AP		INGENUS PHARMS LLC	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb NEWA
AP			1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb NEWA
AP			2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb NEWA
	@	LUITPOLD	EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Feb DISC
	@		EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Feb DISC
AP		SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Feb NEWA
AP			EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Feb NEWA

GLASDEGIB MALEATETABLET; ORAL
DAURISMO

	+	PFIZER INC	EQ 25MG BASE	N210656	001	Nov 21, 2018	Feb CAIN
	+		EQ 100MG BASE	N210656	002	Nov 21, 2018	Feb CAIN

GLIMEPIRIDETABLET; ORAL
GLIMEPIRIDE

AB		MICRO LABS	1MG	A091220	001	Jun 29, 2012	Mar CAHN
AB			2MG	A091220	002	Jun 29, 2012	Mar CAHN
			3MG	A091220	003	Jun 29, 2012	Mar CAHN
AB			4MG	A091220	004	Jun 29, 2012	Mar CAHN
			6MG	A091220	005	Jun 29, 2012	Mar CAHN
AB			8MG	A091220	006	Jun 29, 2012	Mar CAHN

GLIPIZIDETABLET; ORAL
GLIPIZIDE

	@	BEXIMCO PHARMS USA	5MG	A074542	001	Jun 20, 1995	Feb CAHN
	@		10MG	A074542	002	Jun 20, 1995	Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

	@	MYLAN	2.5MG	A202298	001	May 19, 2015	Feb DISC
	@		5MG	A202298	002	May 19, 2015	Feb DISC
	@		10MG	A202298	003	May 19, 2015	Feb DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

>D>	AB	MYLAN	2.5MG; 250MG	A078083	001	Apr 12, 2007	Apr DISC
>A>		@	2.5MG; 250MG	A078083	001	Apr 12, 2007	Apr DISC

GLYBURIDETABLET; ORAL
GLYBURIDE

AB1		ORIENT PHARMA CO LTD	1.25MG	A206483	001	Feb 22, 2019	Feb NEWA
AB1			2.5MG	A206483	002	Feb 22, 2019	Feb NEWA
AB1			5MG	A206483	003	Feb 22, 2019	Feb NEWA

GLYCEROL PHENYLBUTYRATELIQUID; ORAL
RAVICTI

	+	HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013	Feb CAHN
--	---	----------------	----------	---------	-----	--------------	----------

GLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATE

AP		CAPLIN	0.2MG/ML	A211705	001	Mar 20, 2019	Mar NEWA
>A>	AP	SANDOZ INC	0.2MG/ML	A211334	001	May 14, 2019	Apr NEWA

TABLET; ORAL
GLYCOPYRROLATE

AA	KENTON	1MG	A091182	001	Feb 03, 2014	Mar	CAHN
AA		2MG	A091182	002	Feb 03, 2014	Mar	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>A>	AP	BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Apr	CAHN	
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Apr	CAHN	
>D>	AP	BLUEPHARMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Apr	CAHN	
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Apr	CAHN	
		@ LUITPOLD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274	001	Sep 22, 2010	Feb	DISC	
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE							
>A>	AP	BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Apr	CAHN	
>D>	AP	BLUEPHARMA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Apr	CAHN	

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

		@ TEVA PHARMS	EQ 1MG BASE	A078080	001	Dec 31, 2007	Jan	DISC
AB	!	WEST-WARD PHARMS INT	EQ 1MG BASE	A077842	001	Dec 31, 2007	Jan	CHRS

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

>D>		@ EPIC PHARMA LLC	EQ 1MG BASE	A074673	001	Feb 28, 1997	Apr	CMFD
>A>	AB		EQ 1MG BASE	A074673	001	Feb 28, 1997	Apr	CMFD
>D>		@	EQ 2MG BASE	A074673	002	Feb 28, 1997	Apr	CMFD
>A>	AB		EQ 2MG BASE	A074673	002	Feb 28, 1997	Apr	CMFD

HALOBETASOL PROPIONATE

LOTION; TOPICAL

BRYHALI

>A>	+	!	BAUSCH	0.01%	N209355	001	Nov 06, 2018	Apr	CAHN
>D>	+	!	DOW PHARM	0.01%	N209355	001	Nov 06, 2018	Apr	CAHN
		+		0.01%	N209355	001	Nov 06, 2018	Jan	CHRS
		+		0.01%	N209355	001	Nov 06, 2018	Jan	CRLD

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION; TOPICAL

DUOBRII

>A>	+	!	BAUSCH	0.01%;0.045%	N209354	001	Apr 25, 2019	Apr	NEWA
-----	---	---	--------	--------------	---------	-----	--------------	-----	------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

		@ INNOGENIX	0.5MG	A071156	001	Jan 02, 1987	Mar	CAHN
		@	1MG	A071157	001	Jan 02, 1987	Mar	CAHN
		@	2MG	A071172	001	Jan 02, 1987	Mar	CAHN
		@	5MG	A071212	001	Jan 07, 1988	Mar	CAHN
		@	10MG	A071173	001	Jan 07, 1988	Mar	CAHN
		@	20MG	A071177	001	Jan 07, 1988	Mar	CAHN
	!	MYLAN	2MG	A070278	001	Jun 10, 1986	Jan	CTEC
AB	!		2MG	A070278	001	Jun 10, 1986	Jan	CHRS
		@ SANDOZ	2MG	A071208	001	Nov 17, 1986	Jan	DISC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	+	!	HIKMA	1,000 UNITS/ML	N017037	001		Feb	CAHN
AP	+	!		5,000 UNITS/ML	N017037	002		Feb	CAHN
		@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Feb	CAHN
AP	+	!		10,000 UNITS/ML	N017037	003		Feb	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

		@ LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb	DISC
--	--	------------	---------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	HERITAGE PHARMA	12.5MG;10MG	A075776	001	Jul 01, 2002	Feb CAHN
AB		12.5MG;20MG	A075776	002	Jul 01, 2002	Feb CAHN
AB		25MG;20MG	A075776	003	Jul 01, 2002	Feb CAHN

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	ACCORD HLTHCARE	12.5MG;20MG	A209281	001	Feb 07, 2019	Jan NEWA
AB		12.5MG;40MG	A209281	002	Feb 07, 2019	Jan NEWA
AB		25MG;40MG	A209281	003	Feb 07, 2019	Jan NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINARETIC

AB	LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Feb CAHN
AB		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Feb CAHN
AB		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Feb CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	GLENMARK PHARMS LTD	12.5MG;40MG	A202544	001	Mar 04, 2019	Feb NEWA
AB		12.5MG;80MG	A202544	002	Mar 04, 2019	Feb NEWA
AB		25MG;80MG	A202544	003	Mar 04, 2019	Feb NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	ZYDUS PHARMS	25MG;37.5MG	A208358	001	Feb 11, 2019	Jan NEWA
----	--------------	-------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ZYDUS PHARMS	12.5MG;80MG	A203000	001	Mar 15, 2019	Mar NEWA
AB		12.5MG;160MG	A203000	002	Mar 15, 2019	Mar NEWA
AB		12.5MG;320MG	A203000	003	Mar 15, 2019	Mar NEWA
AB		25MG;160MG	A203000	004	Mar 15, 2019	Mar NEWA
AB		25MG;320MG	A203000	005	Mar 15, 2019	Mar NEWA

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

>D>	+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013	Apr CAHN
>D>	+		15MG	N202880	002	Oct 25, 2013	Apr CAHN
>D>	+		20MG	N202880	003	Oct 25, 2013	Apr CAHN
>D>	+		30MG	N202880	004	Oct 25, 2013	Apr CAHN
>D>	+		40MG	N202880	005	Oct 25, 2013	Apr CAHN
>D>	+		50MG	N202880	006	Oct 25, 2013	Apr CAHN
>A>	+	PERSION	10MG	N202880	001	Oct 25, 2013	Apr CAHN
>A>	+		15MG	N202880	002	Oct 25, 2013	Apr CAHN
>A>	+		20MG	N202880	003	Oct 25, 2013	Apr CAHN
>A>	+		30MG	N202880	004	Oct 25, 2013	Apr CAHN
>A>	+		40MG	N202880	005	Oct 25, 2013	Apr CAHN
>A>	+		50MG	N202880	006	Oct 25, 2013	Apr CAHN

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

@	TEVA	7.5MG;200MG	A076023	001	Apr 11, 2003	Feb DISC
---	------	-------------	---------	-----	--------------	----------

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	TORRENT	5MG/5ML; 60MG/5ML	A206661	001	Jan 23, 2019	Feb DISC		
AA		5MG/5ML; 60MG/5ML	A206661	001	Jan 23, 2019	Jan NEWA		
	REZIRA							
>D>	AA	+	CYPRESS PHARM	5MG/5ML; 60MG/5ML	N022442	001	Jun 08, 2011	Apr CAHN
>A>	AA	+	PERSION	5MG/5ML; 60MG/5ML	N022442	001	Jun 08, 2011	Apr CAHN

HYDROCORTISONE

CREAM; TOPICAL

NUTRACORT

@ BAUSCH 0.5% A 080442 002 Feb CAHN
 @ 1% A 080442 003 Feb CAHN

LOTION; TOPICAL

CETACORT

@ BAUSCH 0.5% A 080426 002 Feb CAHN
 @ 1% A 080426 001 Feb CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

+ @ SPECGX LLC 8MG N 021217 001 Mar 01, 2010 Mar DISC
 + @ 12MG N 021217 002 Mar 01, 2010 Mar DISC
 + @ 16MG N 021217 003 Mar 01, 2010 Mar DISC
 + @ 32MG N 021217 004 Aug 24, 2012 Mar DISC

HYDROMORPHONE HYDROCHLORIDE

AB ! OSMOTICA 32MG A 205629 004 Jul 07, 2016 Mar CHRS

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB LAURUS LABS LTD 200MG A 210959 001 Jan 15, 2019 Jan CAHN
 @ LUPIN LTD 200MG A 210543 001 Jul 06, 2018 Feb DISC

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

>D> ! ASPEN GLOBAL INC 250MG/ML (250MG/ML) A 200271 001 Aug 24, 2015 Apr CTEC
 >A> AP2 ! 1250MG/5ML (250MG/ML) A 200271 001 Aug 24, 2015 Apr CPOT
 >A> AP2 ! 250MG/ML (250MG/ML) A 200271 001 Aug 24, 2015 Apr CTEC
 >A> AP EUGIA PHARMA 250MG/ML (250MG/ML) A 211071 001 Apr 16, 2019 Apr NEWA
 >A> AP1 1250MG/5ML (250MG/ML) A 211070 001 Apr 16, 2019 Apr NEWA
 >A> AP2 1250MG/5ML (250MG/ML) A 211142 001 May 09, 2019 Apr NEWA
 AP SLAYBACK PHARMA LLC 250MG/ML (250MG/ML) A 210877 001 Mar 22, 2019 Mar NEWA
 >D> AP 1250MG/5ML (250MG/ML) A 210618 001 Dec 28, 2018 Apr CTEC
 >A> AP1 1250MG/5ML (250MG/ML) A 210618 001 Dec 28, 2018 Apr CTEC
 >D> AP SUN PHARM 1250MG/5ML (250MG/ML) A 208381 001 Apr 09, 2019 Apr CTEC
 >A> AP1 1250MG/5ML (250MG/ML) A 208381 001 Apr 09, 2019 Apr CTEC
 AP 1250MG/5ML (250MG/ML) A 208381 001 Apr 09, 2019 Mar NEWA

MAKENA

>D> AP +! AMAG PHARMA USA 1250MG/5ML (250MG/ML) N 021945 001 Feb 03, 2011 Apr CTEC
 >A> AP1 +! 1250MG/5ML (250MG/ML) N 021945 001 Feb 03, 2011 Apr CTEC

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+! VALEANT PHARMS INTL 5MG N 018771 001 Jan CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

! LUITPOLD 50MG/ML A 087408 002 Mar CMFD
 @ 50MG/ML A 087408 002 Feb DISC

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA TORRENT 10MG/5ML A 210634 001 Feb 26, 2019 Feb NEWA

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB EPIC PHARMA LLC 10MG A 040604 002 Dec 28, 2004 Jan CAHN
 AB 25MG A 040604 003 Dec 28, 2004 Jan CAHN
 AB 50MG A 040604 001 Dec 28, 2004 Jan CAHN
 AB KVK TECH 25MG A 040786 002 Mar 20, 2007 Feb CMS1
 AB 50MG A 040786 003 Mar 20, 2007 Feb CMS1

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

@ BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991	Feb CAHN
----------------------	-----------------------	---------	-----	--------------	----------

IBUPROFEN

SOLUTION;INTRAVENOUS

CALDOLOR

+! CUMBERLAND PHARMS	800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019	Jan NEWA
----------------------	----------------------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

@ HEC PHARM	400MG	A204062	001	Sep 10, 2018	Mar DISC
@	600MG	A204062	002	Sep 10, 2018	Mar DISC
@	800MG	A204062	003	Sep 10, 2018	Mar DISC

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE

@ LUITPOLD	0.1MG/ML	A090240	001	Jan 11, 2010	Feb DISC
------------	----------	---------	-----	--------------	----------

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019	Feb NEWA
AB		EQ 400MG BASE	A207495	002	Feb 08, 2019	Feb NEWA
AB	BRECKENRIDGE PHARM	EQ 100MG BASE	A205990	001	Feb 08, 2019	Feb NEWA
AB		EQ 400MG BASE	A205990	002	Feb 08, 2019	Feb NEWA
AB	NATCO PHARMA LTD	EQ 100MG BASE	A207818	001	Mar 01, 2019	Feb NEWA
AB		EQ 400MG BASE	A207818	002	Mar 01, 2019	Feb NEWA
AB	SHILPA MEDICARE LTD	EQ 100MG BASE	A208302	001	Jan 17, 2019	Jan NEWA
AB		EQ 400MG BASE	A208302	002	Jan 17, 2019	Jan NEWA
AB	WOCKHARDT BIO AG	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan NEWA
AB		EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

@ OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Mar DISC
@	25MG	A040751	002	Feb 28, 2008	Mar DISC

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION

INDIUM IN 111 CHLORIDE

+! CURIUM	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan CAHN
-----------	------------	---------	-----	--------------	----------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

OCTREOSCAN

+! CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jan CAHN
-----------	---------	---------	-----	--------------	----------

INDOMETHACIN

CAPSULE;ORAL

INDOCIN

+ @ EGALET	25MG	N016059	001		Feb CAHN
+ @	50MG	N016059	002		Feb CAHN

INDOMETHACIN

AB	HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986	Feb CAHN
AB		50MG	A070756	001	Feb 12, 1986	Feb CAHN

TIVORBEX

+ EGALET	20MG	N204768	001	Feb 24, 2014	Feb CAHN
+!	40MG	N204768	002	Feb 24, 2014	Feb CAHN

CAPSULE, EXTENDED RELEASE;ORAL

INDOCIN SR

+ @ EGALET	75MG	N018185	001	Feb 23, 1982	Feb CAHN
------------	------	---------	-----	--------------	----------

SUPPOSITORY;RECTAL

INDOCIN

+ @ EGALET	50MG	N017814	001	Aug 13, 1984	Feb CAHN
------------	------	---------	-----	--------------	----------

SUSPENSION;ORAL

INDOCIN

+! EGALET	25MG/5ML	N018332	001	Oct 10, 1985	Feb CAHN
-----------	----------	---------	-----	--------------	----------

IOPROMIDE

		INJECTABLE; INJECTION		ULTRAVIST (PHARMACY BULK)					
>D>	+ @	BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004	Apr	CMFD	
>A>	+!		49.9%	N021425	003	Mar 12, 2004	Apr	CMFD	
	+ @		49.9%	N021425	003	Mar 12, 2004	Feb	DISC	
		ULTRAVIST 240							
>D>	+ @	BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995	Apr	CMFD	
>A>	+!		49.9%	N020220	003	May 10, 1995	Apr	CMFD	
	+ @		49.9%	N020220	003	May 10, 1995	Feb	DISC	

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

@ MYLAN SPECIALITY LP

@

0.021MG/SPRAY

0.042MG/SPRAY

A075552 001 Mar 31, 2003 Mar DISC
A075553 001 Mar 31, 2003 Mar DISCIRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP FRESENIUS KABI USA

AP

40MG/2ML (20MG/ML)

100MG/5ML (20MG/ML)

A078188 001 Feb 27, 2008 Jan CAHN
A078188 002 Feb 27, 2008 Jan CAHNIRON DEXTRAN

INJECTABLE; INJECTION

DEXFERRUM

@ LUITPOLD

PROFERDEX

@ NEW RIVER

EQ 50MG IRON/ML

EQ 50MG IRON/ML

N040024 001 Feb 23, 1996 Mar DISC
N017807 001 Mar DISCIRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

>A> + AM REGENT

EQ 50MG BASE/2.5ML (EQ 20MG
BASE/ML)

N021135 002 Mar 20, 2005 Apr CAHN

>A> @

EQ 65MG BASE/3.25ML (EQ 20MG
BASE/ML)

N021135 005 Mar 29, 2013 Apr CAHN

>A> @

EQ 75MG BASE/3.75ML (EQ 20MG
BASE/ML)

N021135 003 Mar 29, 2005 Apr CAHN

>A> +!

EQ 100MG BASE/5ML (EQ 20MG
BASE/ML)

N021135 001 Nov 06, 2000 Apr CAHN

>A> +

EQ 200MG BASE/10ML (EQ 20MG
BASE/ML)

N021135 004 Feb 09, 2007 Apr CAHN

>D> +

LUITPOLD

EQ 50MG BASE/2.5ML (EQ 20MG
BASE/ML)

N021135 002 Mar 20, 2005 Apr CAHN

>D> @

EQ 65MG BASE/3.25ML (EQ 20MG
BASE/ML)

N021135 005 Mar 29, 2013 Apr CAHN

>D> @

EQ 75MG BASE/3.75ML (EQ 20MG
BASE/ML)

N021135 003 Mar 29, 2005 Apr CAHN

>D> +!

EQ 100MG BASE/5ML (EQ 20MG
BASE/ML)

N021135 001 Nov 06, 2000 Apr CAHN

>D> +

EQ 200MG BASE/10ML (EQ 20MG
BASE/ML)

N021135 004 Feb 09, 2007 Apr CAHN

>A> ISOPROPYL ALCOHOL

>A> SOLUTION; TOPICAL

>A> ZURAGARD

>A> +! ZUREX PHARMA

70% (10.5ML)

N210872 001 Apr 26, 2019 Apr NEWA

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISUPREL

AP +! BAUSCH

0.2MG/ML

N010515 001 Mar CAHN

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB + BAUSCH

5MG

N012093 007 Jul 29, 1988 Mar CAHN

+ @

10MG

N012093 002 Jul 29, 1988 Mar CAHN

+ @

20MG

N012093 006 Jul 29, 1988 Mar CAHN

+ @

30MG

N012093 005 Jul 29, 1988 Mar CAHN

+!

40MG

N012093 001 Jul 29, 1988 Mar CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL
ISOSORBIDE MONONITRATE

AB	HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Mar	CAHN
AB		60MG	A076813	001	Jan 07, 2005	Mar	CAHN

IVABRADINE

>A>	SOLUTION;ORAL						
>A>	CORLANOR						
>A>	+! AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Apr	NEWA

KETOCONAZOLE

GEL;TOPICAL
XOLEGEL

+!	ALMIRALL	2%	N021946	001	Jul 28, 2006	Feb	CAHN
----	----------	----	---------	-----	--------------	-----	------

TABLET;ORAL

KETOCONAZOLE

>D>	AB	TARO	200MG	A075319	001	Jun 15, 1999	Apr	CHRS
>A>	AB	!	200MG	A075319	001	Jun 15, 1999	Apr	CHRS
>D>	AB	! TEVA	200MG	A075273	001	Jun 15, 1999	Apr	DISC
>A>		@	200MG	A075273	001	Jun 15, 1999	Apr	DISC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

AP	WEST-WARD PHARMS INT	15MG/ML	A075772	001	Jul 21, 2004	Feb	CMFD
AP		30MG/ML	A075772	002	Jul 21, 2004	Feb	CMFD

SOLUTION/DROPS;OPHTHALMIC

KETOROLAC TROMETHAMINE

AT	MICRO LABS LTD INDIA	0.5%	A203410	001	Apr 05, 2019	Mar	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

TABLET;ORAL

LABETALOL HYDROCHLORIDE

>A>	AB	CADILA PHARMS LTD	100MG	A211325	001	May 13, 2019	Apr	NEWA
>A>	AB		200MG	A211325	002	May 13, 2019	Apr	NEWA
>A>	AB		300MG	A211325	003	May 13, 2019	Apr	NEWA
	AB	HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998	Feb	CAHN
	AB		200MG	A074787	002	Aug 03, 1998	Feb	CAHN
	AB		300MG	A074787	003	Aug 03, 1998	Feb	CAHN
	AB	INVATECH PHARMA	100MG	A207863	001	Feb 04, 2019	Jan	NEWA
	AB		200MG	A207863	002	Feb 04, 2019	Jan	NEWA
	AB		300MG	A207863	003	Feb 04, 2019	Jan	NEWA
		TRANDATE						
AB	+	CNTY LINE PHARMS	100MG	N018716	001	May 24, 1985	Jan	CRLD
AB	+		200MG	N018716	002	Aug 01, 1984	Jan	CRLD
AB	+		300MG	N018716	003	Aug 01, 1984	Jan	CRLD

LACTULOSE

SOLUTION;ORAL

LACTULOSE

	@	BAJAJ	10GM/15ML	A075911	001	Feb 21, 2002	Jan	CAHN
AA		TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Jan	CAHN
	@	XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Mar	CAHN

SOLUTION;ORAL, RECTAL

LACTULOSE

	@	BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Jan	CAHN
AA		TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Jan	CAHN

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

	AB	ANNORA	100MG	A211306	001	Mar 21, 2019	Mar	NEWA
>A>	AB	MACLEODS PHARMS LTD	150MG	A090198	001	May 01, 2019	Apr	NEWA
>A>	AB		300MG	A090198	002	May 01, 2019	Apr	NEWA
>A>		@ MYLAN	150MG	A204528	001	Mar 04, 2016	Apr	DISC
>A>		@	300MG	A204528	002	Mar 04, 2016	Apr	DISC
	AB	MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Feb	NEWA
	AB		300MG	A078545	002	Mar 05, 2019	Feb	NEWA
>D>	AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Apr	DISC
>D>	AB		300MG	A204528	002	Mar 04, 2016	Apr	DISC

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

@ MYLAN	150MG;300MG	A204005	001	Aug 28, 2014	Jan DISC
---------	-------------	---------	-----	--------------	----------

LAMOTRIGINE

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

@ RUBICON	25MG	A202887	001	Jun 17, 2013	Mar CAHN
@	50MG	A202887	002	Jun 17, 2013	Mar CAHN
AB	100MG	A202887	003	Jun 17, 2013	Mar CAHN
AB	200MG	A202887	004	Jun 17, 2013	Mar CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

AB	ALKEM LABS LTD	15MG	A207394	001	Jan 18, 2019	Jan NEWA
AB		30MG	A207394	002	Jan 18, 2019	Jan NEWA
	@ KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Feb DISC
	@	30MG	A091212	002	Sep 16, 2013	Feb DISC

LAROTRECTINIB

CAPSULE; ORAL

VITRAKVI

+	BAYER HLTHCARE	25MG	N210861	001	Nov 26, 2018	Feb CAHN
+	!	100MG	N210861	002	Nov 26, 2018	Feb CAHN

SOLUTION; ORAL

VITRAKVI

+	!	BAYER HEALTHCARE	20MG/ML	N211710	001	Nov 26, 2018	Feb CAHN
---	---	------------------	---------	---------	-----	--------------	----------

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS; OPHTHALMIC

ROCKLATAN

+	!	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	Mar NEWA
---	---	------------------	----------------------	---------	-----	--------------	----------

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

>A>	AB	ZYDUS	10MG	A212308	001	Apr 24, 2019	Apr NEWA
>A>	AB		20MG	A212308	002	Apr 24, 2019	Apr NEWA

>D> LESINURAD

>D> TABLET; ORAL

>D> ZURAMPIC

>D>		+	!	IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015	Apr DISC
>A>				+	@	N207988	001	Dec 22, 2015	Apr DISC

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011	Feb CAHN
----	--------------------	-------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

AP	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Feb CPOT
----	--------------------	-----------------	---------	-----	--------------	----------

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

@	LUITPOLD	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Mar DISC
---	----------	----------------------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE HYDROCHLORIDE

AA	HETERO LABS LTD III	2.5MG/5ML	A210914	001	Apr 01, 2019	Mar NEWA
----	---------------------	-----------	---------	-----	--------------	----------

LEVOFLOXACIN

	SOLUTION/DROPS;OPHTHALMIC						
	LEVOFLOXACIN						
	MICRO LABS LTD INDIA	1.5%	A205600	001	Feb 27, 2019	Feb	NEWA
	TABLET;ORAL						
	LEVOFLOXACIN						
AB	HEC PHARM	250MG	A204968	001	Feb 05, 2019	Jan	NEWA
AB		500MG	A204968	002	Feb 05, 2019	Jan	NEWA
AB		750MG	A204968	003	Feb 05, 2019	Jan	NEWA

LEVOLEUCOVORIN

	POWDER;INTRAVENOUS						
	KHAPZORY						
	+! ACROTECH	175MG/VIAL	N211226	001	Oct 19, 2018	Mar	CAHN
	+!	300MG/VIAL	N211226	002	Oct 19, 2018	Mar	CAHN

LEVOLEUCOVORIN CALCIUM

	POWDER;INTRAVENOUS						
	FUSILEV						
AP	+! ACROTECH	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar	CAHN
	SOLUTION;INTRAVENOUS						
	FUSILEV						
	+ @ ACROTECH	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	Mar	CAHN
	+ @	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	Mar	CAHN

LEVOMILNACIPRAN HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL						
	FETZIMA						
AB	+ ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan	CFTG
AB	+	EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan	CFTG
AB	+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan	CFTG
AB	+!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan	CFTG
	LEVOMILNACIPRAN HYDROCHLORIDE						
AB	AMNEAL PHARMS CO	EQ 20MG BASE	A210790	001	Feb 04, 2019	Jan	NFTG
AB		EQ 40MG BASE	A210790	002	Feb 04, 2019	Jan	NFTG
AB		EQ 80MG BASE	A210790	003	Feb 04, 2019	Jan	NFTG
AB		EQ 120MG BASE	A210790	004	Feb 04, 2019	Jan	NFTG

LEVORPHANOL TARTRATE

	TABLET;ORAL						
	LEVORPHANOL TARTRATE						
	@ SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018	Feb	DISC

LEVOTHYROXINE SODIUM

	POWDER;INTRAVENOUS						
	LEVOTHYROXINE SODIUM						
>D>	AP	PAR STERILE PRODUCTS	200MCG/VIAL	A205366	001	Dec 07, 2015	Apr DISC
>A>		@	200MCG/VIAL	A205366	001	Dec 07, 2015	Apr DISC
>A>	SOLUTION;INTRAVENOUS						
>A>	LEVOTHYROXINE SODIUM						
>A>	+!	FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)	N210632	001	Apr 11, 2019	Apr NEWA
>A>	+!		200MCG/5ML (40MCG/ML)	N210632	002	Apr 11, 2019	Apr NEWA
>A>	+!		500MCG/5ML (100MCG/ML)	N210632	003	Apr 11, 2019	Apr NEWA
	SOLUTION;ORAL						
	TIROSINT-SOL						
	+	INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jan CMFD
	+		25MCG/ML	N206977	002	Dec 15, 2016	Jan CMFD
	+		50MCG/ML	N206977	003	Dec 15, 2016	Jan CMFD
	+		75MCG/ML	N206977	004	Dec 15, 2016	Jan CMFD
	+		88MCG/ML	N206977	005	Dec 15, 2016	Jan CMFD
	+		100MCG/ML	N206977	006	Dec 15, 2016	Jan CMFD
	+		112MCG/ML	N206977	007	Dec 15, 2016	Jan CMFD
	+		125MCG/ML	N206977	008	Dec 15, 2016	Jan CMFD
	+		137MCG/ML	N206977	009	Dec 15, 2016	Jan CMFD
	+		150MCG/ML	N206977	010	Dec 15, 2016	Jan CMFD
	+		175MCG/ML	N206977	011	Dec 15, 2016	Jan CMFD
	+		200MCG/ML	N206977	012	Dec 15, 2016	Jan CMFD

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM							
AB1,	AMNEAL PHARMS LLC	0.025MG	A210831	001	Feb 19, 2019	Feb	NEWA
AB2							
AB1,		0.05MG	A210831	002	Feb 19, 2019	Feb	NEWA
AB2							
AB1,		0.075MG	A210831	003	Feb 19, 2019	Feb	NEWA
AB2							
AB1,		0.088MG	A210831	004	Feb 19, 2019	Feb	NEWA
AB2							
AB1,		0.1MG	A210831	005	Feb 19, 2019	Feb	NEWA
AB2							
AB1,		0.112MG	A210831	006	Feb 19, 2019	Feb	NEWA
AB2							
AB1,		0.125MG	A210831	007	Feb 19, 2019	Feb	NEWA
AB2							
AB1,		0.137MG	A210831	008	Feb 19, 2019	Feb	NEWA
AB2							
AB1,		0.15MG	A210831	009	Feb 19, 2019	Feb	NEWA
AB2							
AB1,		0.175MG	A210831	010	Feb 19, 2019	Feb	NEWA
AB2							
AB1,		0.2MG	A210831	011	Feb 19, 2019	Feb	NEWA
AB2							
AB1,		0.3MG	A210831	012	Feb 19, 2019	Feb	NEWA
AB2							
AB2	LUPIN ATLANTIS	0.025MG	A209713	001	Jan 18, 2019	Jan	NEWA
AB2		0.05MG	A209713	002	Jan 18, 2019	Jan	NEWA
AB2		0.075MG	A209713	003	Jan 18, 2019	Jan	NEWA
AB2		0.088MG	A209713	004	Jan 18, 2019	Jan	NEWA
AB2		0.1MG	A209713	005	Jan 18, 2019	Jan	NEWA
AB2		0.112MG	A209713	006	Jan 18, 2019	Jan	NEWA
AB2		0.125MG	A209713	007	Jan 18, 2019	Jan	NEWA
AB2		0.137MG	A209713	008	Jan 18, 2019	Jan	NEWA
AB2		0.15MG	A209713	009	Jan 18, 2019	Jan	NEWA
AB2		0.175MG	A209713	010	Jan 18, 2019	Jan	NEWA
AB2		0.2MG	A209713	011	Jan 18, 2019	Jan	NEWA
AB2		0.3MG	A209713	012	Jan 18, 2019	Jan	NEWA
THYRO-TABS							
AB2, +	ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.05MG	N021116	002	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.075MG	N021116	003	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.088MG	N021116	010	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.1MG	N021116	004	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.112MG	N021116	011	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.125MG	N021116	005	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.137MG	N021116	012	Dec 07, 2004	Mar	CAHN
AB4							
AB2, +		0.15MG	N021116	006	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.175MG	N021116	007	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.2MG	N021116	008	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +!		0.3MG	N021116	009	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +	LLOYD	0.025MG	N021116	001	Oct 24, 2002	Feb	CMFD
AB4							
AB2, +		0.05MG	N021116	002	Oct 24, 2002	Feb	CMFD
AB4							
AB2, +		0.075MG	N021116	003	Oct 24, 2002	Feb	CMFD
AB4							
AB2, +		0.088MG	N021116	010	Oct 24, 2002	Feb	CMFD
AB4							
AB2, +		0.1MG	N021116	004	Oct 24, 2002	Feb	CMFD
AB4							
AB2, +		0.112MG	N021116	011	Oct 24, 2002	Feb	CMFD
AB4							
AB2, +		0.125MG	N021116	005	Oct 24, 2002	Feb	CMFD
AB4							

TABLET;ORAL
THYRO-TABS

AB2, +		0.137MG	N021116	012	Dec 07, 2004	Feb	CMFD
AB4							
AB2, +		0.15MG	N021116	006	Oct 24, 2002	Feb	CMFD
AB4							
AB2, +		0.175MG	N021116	007	Oct 24, 2002	Feb	CMFD
AB4							
AB2, +		0.2MG	N021116	008	Oct 24, 2002	Feb	CMFD
AB4							
AB2, +!		0.3MG	N021116	009	Oct 24, 2002	Feb	CMFD
AB4							

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HYDROCHLORIDE

@ LUITPOLD	1%	A080850	001			Mar	DISC
@	1%	A091564	001	Aug 14, 2015		Feb	DISC

JELLY; TOPICAL
ANESTACON

>A>	@ BIONPHARMA INC	2%	A080429	001		Apr	CAHN
>D>	@ BLUEPHARMA	2%	A080429	001		Apr	CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL
EMLA

>D>	AB	+!	ACTAVIS LABS UT INC	2.5%;2.5%	N019941	001	Dec 30, 1992	Apr	CAHN
>A>	AB	+!	TEVA BRANDED PHARM	2.5%;2.5%	N019941	001	Dec 30, 1992	Apr	CAHN

LINEZOLID

TABLET; ORAL
LINEZOLID

>A>	AB		CELLTRION	600MG	A210702	001	Apr 25, 2019	Apr	NEWA
-----	----	--	-----------	-------	---------	-----	--------------	-----	------

LIOETHYRONINE SODIUM

TABLET; ORAL
LIOETHYRONINE SODIUM

	@ MYLAN	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Mar	DISC	
	@	EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Mar	DISC	
	@	EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Mar	DISC	
>D>	AB	TEVA PHARMS USA	EQ 0.005MG BASE	A211510	001	Oct 26, 2018	Apr	DISC
>A>	@	EQ 0.005MG BASE	A211510	001	Oct 26, 2018	Apr	DISC	
>D>	AB		EQ 0.025MG BASE	A211510	002	Oct 26, 2018	Apr	DISC
>A>	@	EQ 0.025MG BASE	A211510	002	Oct 26, 2018	Apr	DISC	
>D>	AB		EQ 0.05MG BASE	A211510	003	Oct 26, 2018	Apr	DISC
>A>	@	EQ 0.05MG BASE	A211510	003	Oct 26, 2018	Apr	DISC	

LISINAPRIL

TABLET; ORAL
LISINAPRIL

AB	HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Feb	CAHN
AB		5MG	A075752	002	Jul 01, 2002	Feb	CAHN
AB		10MG	A075752	003	Jul 01, 2002	Feb	CAHN
AB		20MG	A075752	004	Jul 01, 2002	Feb	CAHN
AB		30MG	A075752	005	Jul 01, 2002	Feb	CAHN
AB		40MG	A075752	006	Jul 01, 2002	Feb	CAHN

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE

>A>	AB	+	HIKMA	150MG	N017812	002	Jan 28, 1987	Apr	CAHN
>A>	AB	+		300MG	N017812	001		Apr	CAHN
>A>	AB	+!		600MG	N017812	003	Jan 28, 1987	Apr	CAHN
>D>	AB	+	WEST-WARD PHARMS INT	150MG	N017812	002	Jan 28, 1987	Apr	CAHN
>D>	AB	+		300MG	N017812	001		Apr	CAHN
>D>	AB	+!		600MG	N017812	003	Jan 28, 1987	Apr	CAHN

LITHIUM CITRATE

SYRUP; ORAL
LITHIUM CITRATE

>A>	AA	+!	HIKMA	EQ 300MG CARBONATE/5ML	N018421	001		Apr	CAHN
>D>	AA	+!	WEST-WARD PHARMS INT	EQ 300MG CARBONATE/5ML	N018421	001		Apr	CAHN

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA		SAPTALIS PHARMS	2MG/ML	A079244	001	Apr 28, 2009	Feb	CAHN
		INJECTABLE; INJECTION						
		ATIVAN						
AP	+	HIKMA	2MG/ML	N018140	001		Mar	CAHN
AP	+		4MG/ML	N018140	002		Mar	CAHN
		TABLET; ORAL						
		ATIVAN						
AB	+	BAUSCH	0.5MG	N017794	001		Feb	CAHN
AB	+		1MG	N017794	002		Feb	CAHN
AB	+		2MG	N017794	003		Feb	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB		HISUN PHARM HANGZHOU	25MG	A204795	001	Apr 04, 2019	Mar	NEWA
AB			50MG	A204795	002	Apr 04, 2019	Mar	NEWA
AB			100MG	A204795	003	Apr 04, 2019	Mar	NEWA
AB		MICRO LABS	25MG	A091541	001	Sep 24, 2012	Mar	CAHN
AB			50MG	A091541	002	Sep 24, 2012	Mar	CAHN
AB			100MG	A091541	003	Sep 24, 2012	Mar	CAHN
>A>	AB	STRIDES PHARMA	25MG	A090382	001	Oct 06, 2010	Apr	CAHN
>A>	AB		50MG	A090382	002	Oct 06, 2010	Apr	CAHN
>A>	AB		100MG	A090382	003	Oct 06, 2010	Apr	CAHN
>D>	AB	STRIDES VIVIMED	25MG	A090382	001	Oct 06, 2010	Apr	CAHN
>D>	AB		50MG	A090382	002	Oct 06, 2010	Apr	CAHN
>D>	AB		100MG	A090382	003	Oct 06, 2010	Apr	CAHN

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX SM

	+	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019	Feb	NEWA
		SUSPENSION/DROPS; OPHTHALMIC						
		LOTEMAX						
>D>	+	BAUSCH AND LOMB	0.5%	N020583	001	Mar 09, 1998	Apr	CFTG
>A>	AB	+	0.5%	N020583	001	Mar 09, 1998	Apr	CFTG
>A>		LOTEPREDNOL ETABONATE						
>A>	AB	HI TECH	0.5%	A207609	001	Apr 17, 2019	Apr	NFTG

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB		BEXIMCO PHARMS USA	10MG	A075300	001	Dec 17, 2001	Feb	CAHN
AB			20MG	A075300	002	Dec 17, 2001	Feb	CAHN
AB			40MG	A075300	003	Dec 17, 2001	Feb	CAHN
		@ MYLAN	10MG	A075451	001	Dec 17, 2001	Feb	DISC
		@	20MG	A075451	002	Dec 17, 2001	Feb	DISC
		@	40MG	A075451	003	Dec 17, 2001	Feb	DISC

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

@ TEVA BRANDED PHARM EQ 25MG BASE/ML

N017658 001 Feb CAHN

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

	+	@ TEVA BRANDED PHARM	EQ 5MG BASE	N017525	001		Feb	CAHN
	+	@	EQ 10MG BASE	N017525	002		Feb	CAHN
	+	@	EQ 25MG BASE	N017525	003		Feb	CAHN
	+	@	EQ 50MG BASE	N017525	004		Feb	CAHN
		TABLET; ORAL						
		LOXITANE						
	+	@ TEVA BRANDED PHARM	EQ 10MG BASE	N017525	006		Feb	CAHN
	+	@	EQ 25MG BASE	N017525	007		Feb	CAHN
	+	@	EQ 50MG BASE	N017525	008		Feb	CAHN
	+	@	EQ 50MG BASE	N017525	008		Feb	CAHN

LURASIDONE HYDROCHLORIDE

TABLET; ORAL		LURASIDONE HYDROCHLORIDE							
	@ TORRENT	20MG		A208055	001	Jan 03, 2019	Feb	DISC	
	@	40MG		A208055	002	Jan 03, 2019	Feb	DISC	
	@	80MG		A208055	003	Jan 03, 2019	Feb	DISC	
	@	120MG		A208055	004	Jan 03, 2019	Feb	DISC	
AB	ZYDUS PHARMS	20MG		A208052	001	Mar 19, 2019	Mar	NEWA	
AB		40MG		A208052	002	Mar 19, 2019	Mar	NEWA	
AB		60MG		A208052	003	Mar 19, 2019	Mar	NEWA	
AB		80MG		A208052	004	Mar 19, 2019	Mar	NEWA	
AB		120MG		A208052	005	Mar 19, 2019	Mar	NEWA	

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS		MAGNESIUM SULFATE							
AP	+! FRESENIUS KABI USA	10GM/20ML (500MG/ML)		N019316	003	Jan 29, 2016	Jan	CTEC	
AP	HOSPIRA INC	10GM/20ML (500MG/ML)		A202411	001	May 14, 2015	Jan	CTEC	

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER; ORAL		COLPREP KIT							
	+ @ GATOR PHARMS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT		N204553	001	Dec 27, 2016	Mar	DISC	

MANNITOL

INJECTABLE; INJECTION		MANNITOL 25%							
	@ LUITPOLD	12.5GM/50ML		A087409	001	Jan 21, 1982	Mar	DISC	

MECLIZINE HYDROCHLORIDE

TABLET; ORAL		ANTIVERT							
AA	+ CASPER PHARMA LLC	12.5MG		N010721	006		Feb	CMFD	
	+ @	12.5MG		N010721	006		Jan	CRLD	
AA	+ CASPER PHARMA LLC	25MG		N010721	004		Feb	CMFD	
	+ @	25MG		N010721	004		Jan	CRLD	
AA	+ CASPER PHARMA LLC	50MG		N010721	001	Jan 20, 1982	Feb	CMFD	
	+ @	50MG		N010721	001	Jan 20, 1982	Jan	CRLD	
TABLET, CHEWABLE; ORAL		ANTIVERT							
AA	+ CASPER PHARMA LLC	25MG		N010721	005		Feb	CMFD	
	+ @	25MG		N010721	005		Jan	CRLD	

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION		MEDROXYPROGESTERONE ACETATE							
AB	CIPLA	150MG/ML		A210335	001	Jan 25, 2019	Jan	NEWA	
>A>	AB	SUN PHARM	150MG/ML	A210760	001	May 01, 2019	Apr	NEWA	
>A>	AB		150MG/ML	A210761	001	Apr 24, 2019	Apr	NEWA	

MEFENAMIC ACID

CAPSULE; ORAL		MEFENAMIC ACID							
	@ BRECKENRIDGE PHARM	250MG		A090359	001	Feb 05, 2013	Feb	DISC	

MELOXICAM

CAPSULE; ORAL		VIVLODEX							
	+ EGALET	5MG		N207233	001	Oct 22, 2015	Feb	CAHN	
	+!	10MG		N207233	002	Oct 22, 2015	Feb	CAHN	
TABLET; ORAL		MELOXICAM							
AB	HERITAGE PHARMA	7.5MG		A077936	001	Jul 19, 2006	Feb	CAHN	
AB		15MG		A077936	002	Jul 19, 2006	Feb	CAHN	

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION
ALKERAN

AP	+	APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Feb	CMFD
>A>	AP	US WORLDMEDS LLC	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019	Apr	NEWA
		POWDER; INTRAVENOUS						
		EVOMELA						
	+	ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar	CAHN

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL
MEMANTINE HYDROCHLORIDE

AA	!	TORRENT	2MG/ML	A205446	001	Dec 07, 2015	Jan	CAHN
		TABLET; ORAL						
		MEMANTINE HYDROCHLORIDE						
		@ APOTEX INC	5MG	A090244	001	Jul 11, 2018	Jan	DISC
		@	10MG	A090244	002	Jul 11, 2018	Jan	DISC
AB		CADILA	5MG	A090961	001	Jul 10, 2017	Feb	CAHN
AB			10MG	A090961	002	Jul 10, 2017	Feb	CAHN

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
SOLAGE
@ ALMIRALL

2%; 0.01%

N020922 001 Dec 10, 1999 Feb CAHN

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL
DELZICOL

>D>	+	APIL	400MG	N204412	001	Feb 01, 2013	Apr	CFTG
>A>	AB	+	400MG	N204412	001	Feb 01, 2013	Apr	CFTG
>A>		MESALAMINE						
>A>	AB	TEVA PHARMS USA	400MG	A207873	001	May 09, 2019	Apr	NFTG
		SUPPOSITORY; RECTAL						
		MESALAMINE						
>A>	AB	PHARM SOURCING	1GM	A207448	001	Apr 19, 2019	Apr	NEWA
		TABLET, DELAYED RELEASE; ORAL						
		MESALAMINE						
AB		SUN PHARM	1.2GM	A211858	001	Jan 25, 2019	Jan	NEWA

METAXALONE

TABLET; ORAL
METAXALONE

AB		APPCO PHARMA LLC	800MG	A208774	001	Sep 24, 2018	Feb	CAHN
----	--	------------------	-------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

AB		HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002	Feb	CAHN	
AB			850MG	A075978	002	Jan 25, 2002	Feb	CAHN	
AB			1GM	A075978	003	Nov 05, 2002	Feb	CAHN	
>D>	AB	SUNSHINE LAKE	500MG	A208999	001	Oct 12, 2018	Apr	DISC	
>A>		@	500MG	A208999	001	Oct 12, 2018	Apr	DISC	
>D>	AB		850MG	A208999	002	Oct 12, 2018	Apr	DISC	
>A>		@	850MG	A208999	002	Oct 12, 2018	Apr	DISC	
>D>	AB		1GM	A208999	003	Oct 12, 2018	Apr	DISC	
>A>		@	1GM	A208999	003	Oct 12, 2018	Apr	DISC	
		TABLET, EXTENDED RELEASE; ORAL							
>D>		FORTAMET							
>D>	AB2	+	ANDRX LABS LLC	500MG	N021574	001	Apr 27, 2004	Apr	DISC
>A>		+	@	500MG	N021574	001	Apr 27, 2004	Apr	DISC
>D>	AB2	+	1GM	N021574	002	Apr 27, 2004	Apr	DISC	
>A>		+	@	1GM	N021574	002	Apr 27, 2004	Apr	DISC
		METFORMIN HYDROCHLORIDE							
AB1		CADILA	500MG	A077060	001	Apr 20, 2005	Feb	CAHN	
AB			750MG	A077078	001	Apr 21, 2005	Feb	CAHN	
>D>	AB2	LUPIN LTD	1GM	A090692	002	Jun 29, 2011	Apr	CHRS	
>A>	AB2	!	1GM	A090692	002	Jun 29, 2011	Apr	CHRS	
		@ YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018	Mar	DISC	
		@	750MG	A211052	002	Sep 24, 2018	Mar	DISC	

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+ @ TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009	Mar	DISC
+ @	1GM;EQ 30MG BASE	N022024	002	May 12, 2009	Mar	DISC

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

@ MICRO LABS	25MG	A207438	001	Oct 05, 2018	Mar	DISC
@	50MG	A207438	002	Oct 05, 2018	Mar	DISC

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP	SLATE	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Feb	CAHN
	ROBAXIN						
AP	+! HIKMA	1GM/10ML (100MG/ML)	N011790	001		Feb	CAHN

METHOTREXATE

SOLUTION;SUBCUTANEOUS

RASUVO

>D>	+!	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr	CAHN
>D>	+!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr	CAHN
>D>	+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr	CAHN
>D>	+!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr	CAHN
>D>	+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr	CAHN
>D>	+!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr	CAHN
>D>	+!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr	CAHN
>D>	+!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr	CAHN
>D>	+ @		27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Apr	CAHN
>D>	+!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr	CAHN
>A>	+!	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr	CAHN
>A>	+!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr	CAHN
>A>	+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr	CAHN
>A>	+!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr	CAHN
>A>	+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr	CAHN
>A>	+!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr	CAHN
>A>	+!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr	CAHN
>A>	+!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr	CAHN
>A>	+ @		27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Apr	CAHN
>A>	+!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr	CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

AB	HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986	Feb	CAHN
AB		500MG	A070343	001	Feb 20, 1986	Feb	CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION

METHYLDOPATE HYDROCHLORIDE

@ LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Mar	DISC
------------	---------	---------	-----	--------------	-----	------

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB	TEVA PHARMS USA	0.2MG	A211455	001	Mar 20, 2019	Mar	NEWA
----	-----------------	-------	---------	-----	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

ADHANSIA XR

+	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019	Mar	CRLD
		25MG	N212038	001	Feb 27, 2019	Feb	NEWA
+		35MG	N212038	002	Feb 27, 2019	Feb	NEWA
+		45MG	N212038	003	Feb 27, 2019	Feb	NEWA
+		55MG	N212038	004	Feb 27, 2019	Feb	NEWA
+		70MG	N212038	005	Feb 27, 2019	Feb	NEWA
+		85MG	N212038	006	Feb 27, 2019	Feb	NEWA

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ ACTAVIS LABS FL INC 5MG/ML
QUILLIVANT XR

A206049 001 May 17, 2018 Jan DISC

+! NEXTWAVE 5MG/ML

N202100 001 Sep 27, 2012 Feb CAHN

+! NEXTWAVE PHARMS 5MG/ML

N202100 001 Sep 27, 2012 Jan CTEC

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D> AB AUROLIFE PHARMA LLC 5MG

A209276 001 Oct 25, 2018 Apr DISC

>A> @ 5MG

A209276 001 Oct 25, 2018 Apr DISC

>D> AB 10MG

A209276 002 Oct 25, 2018 Apr DISC

>A> @ 10MG

A209276 002 Oct 25, 2018 Apr DISC

>D> AB 20MG

A209276 003 Oct 25, 2018 Apr DISC

>A> @ 20MG

A209276 003 Oct 25, 2018 Apr DISC

AB CEDIPROF INC 5MG

A208737 001 Feb 01, 2019 Jan NEWA

AB 10MG

A208737 002 Feb 01, 2019 Jan NEWA

AB 20MG

A208737 003 Feb 01, 2019 Jan NEWA

@ LANNETT CO INC 5MG

A086429 001 Jan DISC

@ 10MG

A085799 001 Jan DISC

@ 20MG

A086428 001 Jan DISC

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

@ LANNETT CO INC 20MG

A089601 001 Jun 01, 1988 Jan DISC

METHYLPHENIDATE HYDROCHLORIDE

AB ! ABHAI LLC 20MG

A207488 002 Jun 09, 2015 Jan NEWA

>A> AB ANDOR PHARMS 18MG

A211918 001 Apr 24, 2019 Apr NEWA

>A> AB 27MG

A211918 002 Apr 24, 2019 Apr NEWA

>A> AB 36MG

A211918 003 Apr 24, 2019 Apr NEWA

>A> AB 54MG

A211918 004 Apr 24, 2019 Apr NEWA

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB + PHARMACIA AND UPJOHN 2MG

N011153 002 Mar CFTG

METHYLPREDNISOLONE

AB LUPIN LTD 2MG

A209097 001 Feb 22, 2019 Mar NFTG

AB 2MG

A209097 001 Feb 22, 2019 Feb NEWA

AB 4MG

A209097 002 Feb 22, 2019 Feb NEWA

AB 8MG

A209097 003 Feb 22, 2019 Feb NEWA

AB 16MG

A209097 004 Feb 22, 2019 Feb NEWA

AB 32MG

A209097 005 Feb 22, 2019 Feb NEWA

>D> @ TIANJIN TIANYAO 4MG

A204072 001 May 14, 2018 Apr CMFD

>A> AB 4MG

A204072 001 May 14, 2018 Apr CMFD

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

A-METHAPRED

@ HOSPIRA EQ 40MG BASE/VIAL

A040664 001 Dec 20, 2005 Mar DISC

@ EQ 125MG BASE/VIAL

A040665 001 Dec 20, 2005 Mar DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

TOPROL-XL

AB + TOPROL EQ 25MG TARTRATE

N019962 004 Feb 05, 2001 Mar CAHN

AB +! EQ 50MG TARTRATE

N019962 001 Jan 10, 1992 Mar CAHN

AB + EQ 100MG TARTRATE

N019962 002 Jan 10, 1992 Mar CAHN

AB +! EQ 200MG TARTRATE

N019962 003 Jan 10, 1992 Mar CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

@ LUITPOLD 1MG/ML

A090386 001 Sep 30, 2009 Mar DISC

@ 1MG/ML

A091307 001 Dec 29, 2010 Feb DISC

TABLET;ORAL

METOPROLOL TARTRATE

>A> AB HERITAGE PHARMA 50MG

A074141 001 Jan 31, 1995 Apr CAHN

>A> AB 100MG

A074141 002 Jan 31, 1995 Apr CAHN

>D> AB TEVA 50MG

A074141 001 Jan 31, 1995 Apr CAHN

>D> AB 100MG

A074141 002 Jan 31, 1995 Apr CAHN

METRONIDAZOLE

GEL; VAGINAL

METROGEL-VAGINAL

AB	+!	BAUSCH	0.75%	N020208	001	Aug 17, 1992	Mar	CAHN
----	----	--------	-------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP		INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Feb	NEWA
----	--	-----------	-------------	---------	-----	--------------	-----	------

TABLET; ORAL

METRONIDAZOLE

AB		CADILA	250MG	A206560	001	Nov 16, 2016	Mar	CAHN
AB			500MG	A206560	002	Nov 16, 2016	Mar	CAHN
>A>	AB	STRIDES PHARMA	250MG	A070040	001	Jan 29, 1985	Apr	CAHN
>A>	AB		500MG	A070039	001	Jan 29, 1985	Apr	CAHN
>D>	AB	STRIDES VIVIMED	250MG	A070040	001	Jan 29, 1985	Apr	CAHN
>D>	AB		500MG	A070039	001	Jan 29, 1985	Apr	CAHN

METYROSINE

CAPSULE; ORAL

DEMSEER

+!	BAUSCH	250MG	N017871	001			Mar	CAHN
----	--------	-------	---------	-----	--	--	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDOZALAM HYDROCHLORIDE

>A>	AP	MYLAN ASI	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr	CAHN
>A>	AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr	CAHN
>D>	AP	SAGENT STRIDES	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr	CAHN
>D>	AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr	CAHN

MIFEPRISTONE

TABLET; ORAL

MIFEPREX

AB	+!	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000	Mar	CFTG
----	----	----------------	-------	---------	-----	--------------	-----	------

MIFEPRISTONE

AB		GENBIOPRO	200MG	A091178	001	Apr 11, 2019	Mar	NFTG
----	--	-----------	-------	---------	-----	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

@ GLAND PHARMA LTD

EQ 1MG BASE/ML

A077190	001	Oct 31, 2006	Feb	DISC
---------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB		BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Jan	CMFD
AB			EQ 105MG BASE	A065485	008	Apr 26, 2017	Jan	CMFD

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP		WEST-WARD PHARMS INT	20MG/VIAL	A064117	002	Apr 19, 1995	Jan	CMFD
AP			40MG/VIAL	A064117	003	Jun 02, 1999	Jan	CMFD

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

@ MYLAN INSTITUTIONAL

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A078980	001	Apr 13, 2009	Mar	DISC
---------	-----	--------------	-----	------

@

EQ 30MG BASE/15ML (EQ 2MG BASE/ML)

A078980	002	Apr 13, 2009	Mar	DISC
---------	-----	--------------	-----	------

MODAFINIL

TABLET; ORAL

MODAFINIL

>D>	AB	ZYDUS PHARMS	100MG	A209966	001	Sep 14, 2017	Apr	DISC
>A>		@	100MG	A209966	001	Sep 14, 2017	Apr	DISC
>D>	AB		200MG	A209966	002	Sep 14, 2017	Apr	DISC
>A>		@	200MG	A209966	002	Sep 14, 2017	Apr	DISC

MONTELUKAST SODIUM

		GRANULE;ORAL							
		MONTELUKAST SODIUM							
		@ MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012	Feb	DISC	
AB		TORRENT	EQ 4MG BASE/PACKET	A210431	001	Jul 31, 2018	Mar	CAHN	
		TABLET;ORAL							
		MONTELUKAST SODIUM							
		@ VINTAGE PHARMS LLC	EQ 10MG BASE	A091576	001	Aug 03, 2012	Feb	DISC	
		TABLET, CHEWABLE;ORAL							
		MONTELUKAST SODIUM							
>D>	AB	MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012	Apr	DISC	
>A>		@	EQ 4MG BASE	A079142	001	Aug 03, 2012	Apr	DISC	
>D>	AB		EQ 5MG BASE	A079142	002	Aug 03, 2012	Apr	DISC	
>A>		@	EQ 5MG BASE	A079142	002	Aug 03, 2012	Apr	DISC	
		@ VINTAGE PHARMS LLC	EQ 4MG BASE	A091588	001	Aug 03, 2012	Feb	DISC	
		@	EQ 5MG BASE	A091588	002	Aug 03, 2012	Feb	DISC	

MORPHINE SULFATE

INJECTABLE;INJECTION

ASTRAMORPH PF

		@ FRESENIUS KABI USA	0.5MG/ML	A071050	001	Oct 07, 1986	Mar	DISC	
		@	0.5MG/ML	A071051	001	Oct 07, 1986	Mar	DISC	
		@	1MG/ML	A071052	001	Oct 07, 1986	Mar	DISC	
		@	1MG/ML	A071053	001	Oct 07, 1986	Mar	DISC	

SOLUTION;ORAL

MORPHINE SULFATE

		@ LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015	Feb	DISC	
		@	20MG/5ML	A202310	001	Oct 30, 2015	Jan	DISC	
		@	100MG/5ML	N201517	001	Jun 23, 2011	Jan	DISC	

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

		+ @ EGALET	15MG	N208603	001	Jan 09, 2017	Mar	CAHN	
		+ @	30MG	N208603	002	Jan 09, 2017	Mar	CAHN	
		+ @	60MG	N208603	003	Jan 09, 2017	Mar	CAHN	
		MORPHINE SULFATE							
		@ MYLAN PHARMS INC	200MG	A200824	005	Oct 18, 2011	Feb	DISC	

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1		ALEMBIC PHARMS LTD	EQ 0.5% BASE	A209469	001	Feb 13, 2019	Jan	NEWA	
-----	--	--------------------	--------------	---------	-----	--------------	-----	------	--

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

		@ SUNSHINE LAKE	EQ 400MG BASE	A206295	001	Sep 28, 2018	Mar	DISC	
--	--	-----------------	---------------	---------	-----	--------------	-----	------	--

MYCOPHENOLATE MOFETIL

SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB		VISTAPHARM	200MG/ML	A210370	001	Feb 12, 2019	Jan	NEWA	
----	--	------------	----------	---------	-----	--------------	-----	------	--

NADOLOL

TABLET;ORAL

NADOLOL

>A>	AB	HERITAGE PHARMA	20MG	A074229	001	Aug 30, 1996	Apr	CAHN	
>A>	AB		40MG	A074229	002	Aug 30, 1996	Apr	CAHN	
>A>	AB		80MG	A074255	001	Jan 24, 1996	Apr	CAHN	
>A>		@	120MG	A074255	002	Jan 24, 1996	Apr	CAHN	
>A>		@	160MG	A074255	003	Jan 24, 1996	Apr	CAHN	
>D>	AB	IVAX SUB TEVA PHARMS	20MG	A074229	001	Aug 30, 1996	Apr	CAHN	
>D>	AB		40MG	A074229	002	Aug 30, 1996	Apr	CAHN	
>D>	AB		80MG	A074255	001	Jan 24, 1996	Apr	CAHN	
>D>		@	120MG	A074255	002	Jan 24, 1996	Apr	CAHN	
>D>		@	160MG	A074255	003	Jan 24, 1996	Apr	CAHN	

NAFTIFINE HYDROCHLORIDE

GEL;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		TARO	2%	A208201	001	Apr 10, 2019	Mar	NFTG	
AB		TOLMAR	1%	A206165	001	Mar 20, 2019	Mar	NFTG	

GEL;TOPICALNAFTIN

AB	+	!	SEBELA IRELAND LTD	1%	N019356	001	Jun 18, 1990	Mar	CFTG
AB	+	!		2%	N204286	001	Jun 27, 2013	Mar	CFTG

NALBUPHINE HYDROCHLORIDEINJECTABLE;INJECTIONNALBUPHINE HYDROCHLORIDE

AP			MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Jan	NEWA
AP				20MG/ML	A206506	002	Feb 06, 2019	Jan	NEWA

NALDEMEDINE TOSYLATETABLET;ORALSYMPROIC

>A>	+	!	BDSI	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Apr	CAHN
>D>	+	!	SHIONOGI INC	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Apr	CAHN

NALOXONE HYDROCHLORIDESOLUTION;INTRAMUSCULAR, SUBCUTANEOUSEVZIO (AUTOINJECTOR)

+	!		KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016	Feb	CTNA
---	---	--	-----------	-----------------------	---------	-----	--------------	-----	------

SPRAY, METERED;NASALNALOXONE HYDROCHLORIDE

>A>									
>A>	AB		TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	Apr	NFTG
			NARCAN						
>D>	+	!	ADAPT	4MG/SPRAY	N208411	001	Nov 18, 2015	Apr	CFTG
>A>	AB	+		4MG/SPRAY	N208411	001	Nov 18, 2015	Apr	CFTG

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDETABLET;ORALNALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB			LUPIN	EQ 0.5MG BASE;EQ 50MG BASE	A075735	001	Jul 11, 2001	Feb	CAHN
----	--	--	-------	----------------------------	---------	-----	--------------	-----	------

NANDROLONE DECANOATEINJECTABLE;INJECTIONNANDROLONE DECANOATE

@			LUITPOLD	200MG/ML	A091252	001	Aug 30, 2010	Feb	DISC
---	--	--	----------	----------	---------	-----	--------------	-----	------

NAPROXENTABLET;ORALNAPROXEN

>A>	AB		PERRIGO PHARMS CO	250MG	A077339	001	Apr 27, 2005	Apr	CAHN
>A>	AB			375MG	A077339	002	Apr 27, 2005	Apr	CAHN
>A>	AB			500MG	A077339	003	Apr 27, 2005	Apr	CAHN
>D>	AB		PERRIGO R AND D	250MG	A077339	001	Apr 27, 2005	Apr	CAHN
>D>	AB			375MG	A077339	002	Apr 27, 2005	Apr	CAHN
>D>	AB			500MG	A077339	003	Apr 27, 2005	Apr	CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATETABLET;ORALTREXIMET

>A>	+	@	CURRAX	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Apr	CAHN
>A>	AB	+		500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Apr	CAHN
>D>	+	@	PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Apr	CAHN
>D>	AB	+		500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Apr	CAHN

NATEGLINIDETABLET;ORALNATEGLINIDE

>A>	AB		CADILA PHARMS LTD	60MG	A206432	001	Apr 19, 2019	Apr	NEWA
>A>	AB			120MG	A206432	002	Apr 19, 2019	Apr	NEWA

NEOSTIGMINE METHYLSULFATESOLUTION;INTRAVENOUSNEOSTIGMINE METHYLSULFATE

AP			AMRING PHARMS	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Jan	CAHN
AP				10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Jan	CAHN
>A>	AP		BE PHARMS	5MG/10ML (0.5MG/ML)	A212512	001	May 13, 2019	Apr	NEWA
>A>	AP			10MG/10ML (1MG/ML)	A212512	002	May 13, 2019	Apr	NEWA

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

>D>	AB	JUBILANT GENERICS	500MG	A209156	001	May 14, 2018	Apr	DISC
>A>		@	500MG	A209156	001	May 14, 2018	Apr	DISC
>D>	AB		750MG	A209156	002	May 14, 2018	Apr	DISC
>A>		@	750MG	A209156	002	May 14, 2018	Apr	DISC
>D>	AB		1GM	A209156	003	May 14, 2018	Apr	DISC
>A>		@	1GM	A209156	003	May 14, 2018	Apr	DISC
	AB	MYLAN	500MG	A203742	001	Feb 22, 2019	Feb	NEWA
	AB		750MG	A203742	002	Feb 22, 2019	Feb	NEWA
	AB		1GM	A203742	003	Feb 22, 2019	Feb	NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

	AB2	NOVAST LABS	30MG	A210614	001	Mar 12, 2019	Feb	NEWA
	AB2		60MG	A210614	002	Mar 12, 2019	Feb	NEWA
	AB2		90MG	A210614	003	Mar 12, 2019	Feb	NEWA
>A>	AB2	OSMOTICA PHARM US	90MG	A077127	003	Oct 03, 2007	Apr	CMS1
>A>	AB2	SPIL	30MG	A210838	001	Apr 16, 2019	Apr	NEWA
>A>	AB2		60MG	A210838	002	Apr 16, 2019	Apr	NEWA
>A>	AB2		90MG	A210838	003	Apr 16, 2019	Apr	NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITROGLYCERIN

	AB2	HERCON PHARM	0.1MG/HR	A089885	002	Oct 30, 2017	Feb	NEWA
	AB2	! MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	Feb	CTEC

TABLET;SUBLINGUAL

NITROGLYCERIN

>A>	AB	ALVOGEN MALTA	0.3MG	A211604	001	Apr 30, 2019	Apr	NEWA
>A>	AB		0.4MG	A211604	002	Apr 30, 2019	Apr	NEWA
>A>	AB		0.6MG	A211604	003	Apr 30, 2019	Apr	NEWA

NORETHINDRONE

TABLET;ORAL-28

MICRONOR

		+ @ JANSSEN PHARMS	0.35MG	N016954	001		Mar	DISC
	AB2	! MYLAN LABS LTD	0.35MG	A200980	001	Jun 12, 2013	Mar	CHRS

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

	AT	TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Jan	NEWA
--	----	---------	------------------	---------	-----	--------------	-----	------

POWDER;TOPICAL

NYSTATIN

	AT	LUPIN	100,000 UNITS/GM	A065138	001	Jul 23, 2004	Feb	CAHN
--	----	-------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

		@ ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar	DISC
--	--	----------------	-----------------------	---------	-----	--------------	-----	------

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

>A>	AP	HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Apr	CAHN
>A>	AP		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Apr	CAHN
		@	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Mar	DISC
	AP		EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Jan	CAHN
>A>	AP		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Apr	CAHN
		@	EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Mar	DISC
	AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Jan	CAHN
>D>	AP	USV NORTH AMERICA	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Apr	CAHN
>D>	AP		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Apr	CAHN
>D>	AP		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Apr	CAHN

OFLOXACINSOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

AT	APOTEX INC	0.3%	A076513	001	May 14, 2004	Feb	CMFD
	@ SANDOZ INC	0.3%	A076231	001	May 14, 2004	Mar	DISC

SOLUTION/DROPS;OTIC
OFLOXACIN

	@ SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Mar	DISC
--	--------------	------	---------	-----	--------------	-----	------

OLANZAPINETABLET;ORAL
OLANZAPINE

>D>	AB	SUNSHINE LAKE	2.5MG	A206238	001	Nov 19, 2018	Apr	DISC
>A>		@	2.5MG	A206238	001	Nov 19, 2018	Apr	DISC
>D>	AB		5MG	A206238	002	Nov 19, 2018	Apr	DISC
>A>		@	5MG	A206238	002	Nov 19, 2018	Apr	DISC
>D>	AB		7.5MG	A206238	003	Nov 19, 2018	Apr	DISC
>A>		@	7.5MG	A206238	003	Nov 19, 2018	Apr	DISC
>D>	AB		10MG	A206238	004	Nov 19, 2018	Apr	DISC
>A>		@	10MG	A206238	004	Nov 19, 2018	Apr	DISC
>D>	AB		15MG	A206238	005	Nov 19, 2018	Apr	DISC
>A>		@	15MG	A206238	005	Nov 19, 2018	Apr	DISC
>D>	AB		20MG	A206238	006	Nov 19, 2018	Apr	DISC
>A>		@	20MG	A206238	006	Nov 19, 2018	Apr	DISC

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

	@ HEC PHARM	5MG	A208146	001	Jul 02, 2018	Feb	DISC
	@	10MG	A208146	002	Jul 02, 2018	Feb	DISC
	@	15MG	A208146	003	Jul 02, 2018	Feb	DISC
	@	20MG	A208146	004	Jul 02, 2018	Feb	DISC

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	SUNSHINE LAKE	5MG	A211049	001	Feb 22, 2019	Feb	NEWA
AB		20MG	A211049	002	Feb 22, 2019	Feb	NEWA
AB		40MG	A211049	003	Feb 22, 2019	Feb	NEWA

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>A>	AT	ALEMbic PHARMS LTD	EQ 0.2% BASE	A209420	001	Apr 29, 2019	Apr	NEWA
	AT	AUROBINDO PHARMA LTD	EQ 0.2% BASE	A209995	001	Apr 04, 2019	Mar	NEWA

>D> OMBITASVIR; PARITAPREVIR; RITONAVIR

>D> TABLET;ORAL

>D> TECHNIVIE

>D>	+	ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 24, 2015	Apr	DISC
>A>	+	@	12.5MG;75MG;50MG	N207931	001	Jul 24, 2015	Apr	DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	ASCENT PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A207420	001	Feb 25, 2019	Feb	NEWA
----	-------------------	--	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

ZEGERID

>A>	AB	+	SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr	CAHN
>A>	AB	+	!	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr	CAHN
>D>	AB	+	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr	CAHN
>D>	AB	+	!	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

@ LUITPOLD EQ 2MG BASE/ML

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

@ HIKMA FARMACEUTICA EQ 2MG BASE/ML

A079039	001	Nov 18, 2008	Feb	DISC
A076780	001	Dec 26, 2006	Feb	DISC

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

@ LUITPOLD EQ 2MG BASE/ML A079032 001 Nov 18, 2008 Feb DISC

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

@ MYLAN EQ 24MG BASE A076930 004 Jun 25, 2007 Feb DISC

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

+ @ TELIGENT 30MG/ML N013055 001 Jan CRLD

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB LUPIN 100MG A040284 001 Jun 19, 1998 Feb CAHN

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

AB TEVA PHARMS USA EQ 6MG BASE/ML A211125 001 Feb 27, 2019 Feb NEWA

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

+ @ SANOFI AVENTIS US 50MG/VIAL N021492 001 Aug 09, 2002 Feb CDFR

AP +! 50MG/10ML (5MG/ML) N021759 001 Jan 31, 2005 Feb CDFR

+ @ 100MG/VIAL N021492 002 Aug 09, 2002 Feb CDFR

AP +! 100MG/20ML (5MG/ML) N021759 002 Jan 31, 2005 Feb CDFR

+ @ 200MG/40ML (5MG/ML) N021759 003 Nov 17, 2006 Feb CDFR

OXALIPLATIN

AP ACCORD HLTHCARE 50MG/10ML (5MG/ML) A207474 001 Mar 21, 2017 Feb CDFR

AP 100MG/20ML (5MG/ML) A207474 002 Mar 21, 2017 Feb CDFR

AP 200MG/40ML (5MG/ML) A207474 003 Mar 21, 2017 Feb CDFR

AP ACTAVIS LLC 50MG/10ML (5MG/ML) A204880 001 Mar 05, 2018 Feb CDFR

AP 100MG/20ML (5MG/ML) A204880 002 Mar 05, 2018 Feb CDFR

AP ACTAVIS TOTOWA 50MG/VIAL A078803 001 Aug 08, 2012 Feb CDFR

AP 100MG/VIAL A078803 002 Aug 08, 2012 Feb CDFR

AP CIPLA 50MG/10ML (5MG/ML) A208523 001 Feb 10, 2017 Feb CDFR

AP 100MG/20ML (5MG/ML) A208523 002 Feb 10, 2017 Feb CDFR

AP EUGIA PHARMA 50MG/10ML (5MG/ML) A205529 001 Sep 06, 2017 Feb CDFR

AP 100MG/20ML (5MG/ML) A205529 002 Sep 06, 2017 Feb CDFR

AP FRESENIUS KABI USA 50MG/10ML (5MG/ML) A078811 001 Jun 10, 2010 Feb CDFR

AP 100MG/20ML (5MG/ML) A078811 002 Jun 10, 2010 Feb CDFR

AP 50MG/VIAL A078819 001 Jun 02, 2010 Feb CDFR

AP 50MG/10ML (5MG/ML) A090030 001 Jan 31, 2017 Feb CDFR

AP 100MG/VIAL A078819 002 Jun 02, 2010 Feb CDFR

AP 100MG/20ML (5MG/ML) A090030 002 Jan 31, 2017 Feb CDFR

AP 200MG/40ML (5MG/ML) A090030 003 Jan 31, 2017 Feb CDFR

AP GLAND PHARMA LTD 50MG/10ML (5MG/ML) A207325 001 Feb 10, 2017 Feb CDFR

AP 50MG/VIAL A207385 001 May 23, 2017 Feb CDFR

AP 100MG/20ML (5MG/ML) A207325 002 Feb 10, 2017 Feb CDFR

AP 100MG/VIAL A207385 002 May 23, 2017 Feb CDFR

AP 200MG/40ML (5MG/ML) A207325 003 Oct 18, 2017 Feb CDFR

>D> AP HOSPIRA INC 50MG/VIAL A078815 001 Sep 30, 2009 Apr DISC

>A> @ 50MG/VIAL A078815 001 Sep 30, 2009 Apr DISC

AP 50MG/VIAL A078815 001 Sep 30, 2009 Feb CDFR

>D> AP 100MG/VIAL A078815 002 Sep 30, 2009 Apr DISC

>A> @ 100MG/VIAL A078815 002 Sep 30, 2009 Apr DISC

AP 100MG/VIAL A078815 002 Sep 30, 2009 Feb CDFR

AP HOSPIRA WORLDWIDE 50MG/10ML (5MG/ML) A078813 001 Aug 07, 2009 Feb CDFR

AP 100MG/20ML (5MG/ML) A078813 002 Aug 07, 2009 Feb CDFR

AP INGENUS PHARMS LLC 50MG/10ML (5MG/ML) A207562 001 Oct 16, 2018 Feb CDFR

AP 100MG/20ML (5MG/ML) A207562 002 Oct 16, 2018 Feb CDFR

AP JIANGSU HENGRUI MED 50MG/10ML (5MG/ML) A203869 001 Jun 18, 2014 Feb CDFR

AP 100MG/20ML (5MG/ML) A203869 002 Jun 18, 2014 Feb CDFR

@ LUITPOLD 50MG/10ML (5MG/ML) A204378 001 May 12, 2017 Feb DISC

AP 50MG/10ML (5MG/ML) A204378 001 May 12, 2017 Feb CDFR

@ 100MG/20ML (5MG/ML) A204378 002 May 12, 2017 Feb DISC

AP 100MG/20ML (5MG/ML) A204378 002 May 12, 2017 Feb CDFR

AP MYLAN LABS LTD 50MG/10ML (5MG/ML) A091358 001 Aug 07, 2012 Feb CDFR

AP 50MG/VIAL A200979 001 Aug 08, 2012 Feb CDFR

AP 100MG/20ML (5MG/ML) A091358 002 Aug 07, 2012 Feb CDFR

AP 100MG/VIAL A200979 002 Aug 08, 2012 Feb CDFR

AP 200MG/40ML (5MG/ML) A091358 003 Nov 14, 2017 Feb CDFR

INJECTABLE; INTRAVENOUS
OXALIPLATIN

AP		QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	Feb CDFR
AP			50MG/VIAL	A204616	001	May 11, 2016	Feb CDFR
AP			100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	Feb CDFR
AP			100MG/VIAL	A204616	002	May 11, 2016	Feb CDFR
AP	!		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Feb CDFR
AP		SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Feb CDFR
		@	50MG/VIAL	A090849	001	Apr 28, 2011	Feb CDFR
AP			100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Feb CDFR
		@	100MG/VIAL	A090849	002	Apr 28, 2011	Feb CDFR
		@ SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Feb CDFR
		@	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Feb CDFR
>A>	AP	SUN PHARM	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Apr CDFR
	AP	+! TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Feb CDFR
	AP	+!	100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Feb CDFR
>D>		INJECTABLE; IV (INFUSION)					
>D>		OXALIPLATIN					
>D>	AP	SUN PHARM	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Apr CDFR
	AP	SUN PHARMA GLOBAL	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Feb NEWA

OXAPROZIN

TABLET; ORAL
OXAPROZIN

		@ BEXIMCO PHARMS USA	600MG	A075842	001	Apr 12, 2001	Mar CAHN
--	--	----------------------	-------	---------	-----	--------------	----------

OXYBUTYNIN CHLORIDE

TABLET; ORAL

OXYBUTYNIN CHLORIDE

>A>	AB	EMCURE PHARMS LTD	5MG	A211682	001	May 10, 2019	Apr NEWA
	AB	INVATECH PHARMA	5MG	A211062	001	Feb 06, 2019	Jan NEWA

TABLET, EXTENDED RELEASE; ORAL
OXYBUTYNIN CHLORIDE

	AB	AJANTA PHARMA LTD	5MG	A211655	001	Feb 28, 2019	Feb NEWA
	AB		10MG	A211655	002	Feb 28, 2019	Feb NEWA
	AB		15MG	A211655	003	Feb 28, 2019	Feb NEWA

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA		ALKEM LABS LTD	5MG/5ML	A211748	001	Feb 07, 2019	Feb NEWA
AA			100MG/5ML	A211749	001	Feb 04, 2019	Jan NEWA
		@ LANNETT CO INC	100MG/5ML	A204085	001	Sep 09, 2014	Jan DISC
AA		PHARM ASSOC	5MG/ML	A206914	001	Feb 01, 2019	Jan NEWA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

>D>	AB	VINTAGE PHARMS	5MG	A077712	003	Mar 02, 2009	Apr DISC
>A>		@	5MG	A077712	003	Mar 02, 2009	Apr DISC
>D>	AB		10MG	A077712	004	Apr 13, 2015	Apr DISC
>A>		@	10MG	A077712	004	Apr 13, 2015	Apr DISC
>D>	AB		15MG	A077712	001	Jan 31, 2007	Apr DISC
>A>		@	15MG	A077712	001	Jan 31, 2007	Apr DISC
>D>	AB		20MG	A077712	005	Apr 13, 2015	Apr DISC
>A>		@	20MG	A077712	005	Apr 13, 2015	Apr DISC
>D>	AB		30MG	A077712	002	Jan 31, 2007	Apr DISC
>A>		@	30MG	A077712	002	Jan 31, 2007	Apr DISC

PACLITAXEL

INJECTABLE; INJECTION
PACLITAXEL

		@ ACCORD HLTHCARE	6MG/ML	A205720	001	Aug 17, 2018	Mar DISC
--	--	-------------------	--------	---------	-----	--------------	----------

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

		@ DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Mar DISC
--	--	----------------------	---	---------	-----	--------------	----------

PAMIDRONATE DISODIUMINJECTABLE; INJECTION
PAMIDRONATE DISODIUM

@	LUITPOLD	30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008	Mar	DISC
@		90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008	Mar	DISC
@	SUN PHARMA GLOBAL	30MG/VIAL	A077703	001	Dec 24, 2008	Jan	DISC
@		90MG/VIAL	A077703	002	Dec 24, 2008	Jan	DISC

PANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

AB	INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Feb	NEWA
----	--------------------	--------------	---------	-----	--------------	-----	------

PENICILLAMINECAPSULE; ORAL
CUPRIMINE

	@	VALEANT PHARMS INTL	125MG	N019853	002		Jan	CAHN
>D>	+	!	250MG	N019853	001		Apr	CFTG
>A>	AB		250MG	N019853	001		Apr	CFTG
			250MG	N019853	001		Jan	CAHN
>A>		PENICILLAMINE						
>A>	AB	AMERIGEN PHARMS LTD	250MG	A209921	001	May 07, 2019	Apr	NFTG

PENTAMIDINE ISETHIONATEFOR SOLUTION; INHALATION
NEBUPENT

>D>	+	!	FRESENIUS KABI USA	300MG/VIAL	N019887	001	Jun 15, 1989	Apr	CFTG
>A>	AN			300MG/VIAL	N019887	001	Jun 15, 1989	Apr	CFTG
>A>	AN		PENTAMIDINE ISETHIONATE						
		SETON PHARMS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr	NFTG	

PENTOSTATININJECTABLE; INJECTION
PENTOSTATIN

@	MYLAN INSTITUTIONAL	10MG/VIAL	A203554	001	Sep 19, 2014	Mar	DISC
---	---------------------	-----------	---------	-----	--------------	-----	------

PERMETHRINCREAM; TOPICAL
PERMETHRIN

AB	ENCUBE ETHICALS	5%	A211303	001	Apr 03, 2019	Mar	NEWA
----	-----------------	----	---------	-----	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDESOLUTION; INTRAVENOUS
PHENYLEPHRINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	10MG/ML (10MG/ML)	A210665	001	Jan 29, 2019	Jan	NEWA
AP			50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019	Jan	NEWA
AP			100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019	Jan	NEWA
AP		SANDOZ INC	10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Jan	NEWA
AP			50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Jan	NEWA
AP			100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Jan	NEWA

SOLUTION/DROPS; OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

AT	+	!	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan	CTEC
AT	+	!		10%	N207926	002	Jan 15, 2015	Jan	CTEC
AT	+	!	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Jan	CTEC
AT	+	!		10%	N203510	002	Mar 21, 2013	Jan	CTEC

PHENYTOIN SODIUMINJECTABLE; INJECTION
PHENYTOIN SODIUM

@	LUITPOLD	50MG/ML	A040781	001	Dec 04, 2007	Feb	DISC
---	----------	---------	---------	-----	--------------	-----	------

PHYTONADIONETABLET; ORAL
MEPHYTON

AB	+	!	BAUSCH	5MG	N010104	003		Feb	CAHN
AB	+	!	VALEANT PHARMS INTL	5MG	N010104	003		Jan	CAHN
AB			PHYTONADIONE						
AB			ZYDUS	5MG	A210189	001	Feb 20, 2019	Feb	NEWA

PIMAVANSERIN TARTRATE

TABLET; ORAL
 NUPLAZID

+ @ ACADIA PHARMS INC EQ 17MG BASE N207318 001 Apr 29, 2016 Jan DISC

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION
 MAXAIR

@ BAUSCH EQ 0.2MG BASE/INH N019009 001 Dec 30, 1986 Mar CAHN

PIROXICAM

CAPSULE; ORAL
 PIROXICAM

@ BRECKENRIDGE PHARM 10MG A208991 001 Feb 21, 2018 Jan DISC
 @ 20MG A208991 002 Feb 21, 2018 Jan DISC
 AB CADILA 10MG A205585 001 Jul 17, 2018 Feb CAHN
 AB 20MG A205585 002 Jul 17, 2018 Feb CAHN

PITAVASTATIN CALCIUM

TABLET; ORAL
 PITAVASTATIN CALCIUM

>A> @ MYLAN EQ 1MG BASE A206070 001 Apr 04, 2019 Apr DISC
 >A> @ EQ 2MG BASE A206070 002 Apr 04, 2019 Apr DISC
 >A> @ EQ 4MG BASE A206070 003 Apr 04, 2019 Apr DISC
 >D> AB MYLAN PHARMS INC EQ 1MG BASE A206070 001 Apr 04, 2019 Apr DISC
 AB EQ 1MG BASE A206070 001 Apr 04, 2019 Mar NEWA
 >D> AB EQ 2MG BASE A206070 002 Apr 04, 2019 Apr DISC
 AB EQ 2MG BASE A206070 002 Apr 04, 2019 Mar NEWA
 >D> AB EQ 4MG BASE A206070 003 Apr 04, 2019 Apr DISC
 AB EQ 4MG BASE A206070 003 Apr 04, 2019 Mar NEWA

PLECANATIDE

TABLET; ORAL
 TRULANCE

>D> +! BAUSCH 3MG N208745 001 Jan 19, 2017 Apr CAHN
 +! 3MG N208745 001 Jan 19, 2017 Mar CAHN
 >A> +! SALIX 3MG N208745 001 Jan 19, 2017 Apr CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
 POTASSIUM CHLORIDE

AB ZYDUS PHARMS 8MEQ A208445 001 Mar 11, 2019 Feb NEWA
 AB 10MEQ A208445 002 Mar 11, 2019 Feb NEWA

FOR SOLUTION; ORAL
 POTASSIUM CHLORIDE

>A> AA BELCHER PHARMS LLC 20MEQ A212183 001 May 06, 2019 Apr NEWA

SOLUTION; ORAL
 POTASSIUM CHLORIDE

AA PHARM ASSOC 20MEQ/15ML A210766 001 Mar 29, 2019 Mar NEWA
 AA 40MEQ/15ML A210766 002 Mar 29, 2019 Mar NEWA

TABLET, EXTENDED RELEASE; ORAL
 KLOR-CON M15

AB1 UPSHER SMITH LABS 15MEQ A074726 003 Jun 06, 2003 Mar CTEC
 POTASSIUM CHLORIDE
 AB2 PII 8MEQ A206881 001 Jan 22, 2019 Jan NEWA
 AB1 10MEQ A206630 001 Mar 29, 2019 Mar NEWA
 AB2 10MEQ A206881 002 Jan 22, 2019 Jan NEWA
 AB1 15MEQ A206630 002 Mar 29, 2019 Mar NEWA
 AB1 20MEQ A206630 003 Mar 29, 2019 Mar NEWA
 >A> AB2 20MEQ A210098 001 Apr 26, 2019 Apr NEWA
 >A> AB1 PRINSTON INC 10MEQ A209922 001 Apr 30, 2019 Apr NEWA
 >A> AB1 15MEQ A209922 002 Apr 30, 2019 Apr NEWA
 >A> AB1 20MEQ A209922 003 Apr 30, 2019 Apr NEWA

PRALATREXATE

SOLUTION; INTRAVENOUS
 FOLOTYN

+ ACROTECH 20MG/ML (20MG/ML) N022468 001 Sep 24, 2009 Mar CAHN
 +! 40MG/2ML (20MG/ML) N022468 002 Sep 24, 2009 Mar CAHN

PREDNISONE

	TABLET; ORAL						
	PREDNISONE						
AB	SUN PHARM INDUSTRIES	5MG	A089247	002	Dec 04, 1985	Jan	CMS1
AB		10MG	A089247	003	Dec 04, 1985	Jan	CMS1

PROCHLORPERAZINE EDISYLATE

	INJECTABLE; INJECTION						
	PROCHLORPERAZINE EDISYLATE						
AP	NEXUS PHARMS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Feb	NEWA

PROGESTERONE

	INJECTABLE; INJECTION						
	PROGESTERONE						
	@ LUITPOLD	50MG/ML	A090845	001	Jun 22, 2009	Mar	DISC

PROMETHAZINE HYDROCHLORIDE

	TABLET; ORAL						
	PROMETHAZINE HYDROCHLORIDE						
	@ IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008	Mar	DISC
	@	25MG	A040791	003	Feb 12, 2008	Mar	DISC

PROPRANOLOL HYDROCHLORIDE

	TABLET; ORAL						
	PROPRANOLOL HYDROCHLORIDE						
	@ INNOGENIX	10MG	A070319	001	Oct 22, 1985	Mar	CAHN
	@	10MG	A070319	001	Oct 22, 1985	Mar	CAHN
	@	20MG	A070320	001	Oct 22, 1985	Mar	CAHN
	@	40MG	A070103	001	Oct 22, 1985	Mar	CAHN
	@	60MG	A070321	001	Sep 24, 1986	Mar	CAHN
	@	60MG	A070321	001	Sep 24, 1986	Mar	CAHN
	@	80MG	A070322	001	Aug 04, 1986	Mar	CAHN

PYRIDOSTIGMINE BROMIDE

	INJECTABLE; INJECTION						
	MESTINON						
AP	+! BAUSCH	5MG/ML	N009830	001		Feb	CAHN
	SYRUP; ORAL						
	MESTINON						
AA	+! BAUSCH	60MG/5ML	N015193	001		Feb	CFTG
	+!	60MG/5ML	N015193	001		Feb	CAHN
	PYRIDOSTIGMINE BROMIDE						
AA	NOVITIUM PHARMA	60MG/5ML	A211694	001	Mar 08, 2019	Feb	NFTG
	TABLET; ORAL						
	MESTINON						
AB	+! BAUSCH	60MG	N009829	002		Feb	CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	MESTINON						
AB	+! BAUSCH	180MG	N011665	001		Feb	CAHN

QUETIAPINE FUMARATE

	TABLET, EXTENDED RELEASE; ORAL						
	QUETIAPINE FUMARATE						
>D> AB	AMNEAL PHARMS	EQ 400MG BASE	A211405	001	Oct 26, 2018	Apr	DISC
>A>	@	EQ 400MG BASE	A211405	001	Oct 26, 2018	Apr	DISC

QUININE SULFATE

	CAPSULE; ORAL						
	QUININE SULFATE						
	@ MYLAN PHARMS INC	324MG	A202581	001	Dec 14, 2012	Mar	DISC

RABEPRAZOLE SODIUM

	TABLET, DELAYED RELEASE; ORAL						
	RABEPRAZOLE SODIUM						
AB	RUBICON	20MG	A204237	001	Nov 18, 2015	Feb	CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

AB	APPCO PHARMA LLC	EQ 150MG BASE	A211893	001	Apr 05, 2019	Mar	NEWA
AB		EQ 300MG BASE	A211893	002	Apr 05, 2019	Mar	NEWA

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA	TORRENT	EQ 15MG BASE/ML	A090102	001	May 26, 2009	Jan	CAHN
----	---------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 150MG BASE	A075165	001	Sep 30, 1998	Feb	CAHN
AB		EQ 300MG BASE	A075165	002	Sep 30, 1998	Feb	CAHN
>A>	STRIDES PHARMA	EQ 150MG BASE	A210010	001	Aug 01, 2018	Apr	CAHN
>A>		EQ 300MG BASE	A210010	002	Aug 01, 2018	Apr	CAHN
>D>	VIVIMED GLOBAL	EQ 150MG BASE	A210010	001	Aug 01, 2018	Apr	CAHN
>D>		EQ 300MG BASE	A210010	002	Aug 01, 2018	Apr	CAHN
AB	VKT PHARMA PVT LTD	EQ 150MG BASE	A211289	001	Jan 31, 2019	Jan	NEWA
AB		EQ 300MG BASE	A211289	002	Jan 31, 2019	Jan	NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

AB	+ GILEAD	500MG	N021526	002	Jan 27, 2006	Feb	CTEC
AB	+!	1GM	N021526	001	Feb 12, 2007	Feb	CTEC

RANOLAZINE

AB	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb	CMFD
AB		1GM	A201046	002	Jul 29, 2013	Feb	CMFD

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB	MICRO LABS	EQ 0.5MG BASE	A207004	001	Mar 29, 2019	Mar	NEWA
AB		EQ 1MG BASE	A207004	002	Mar 29, 2019	Mar	NEWA

REPAGLINIDE

TABLET;ORAL

PRANDIN

	+ @ GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Mar	DISC
	+ @	1MG	N020741	002	Dec 22, 1997	Mar	DISC
	+ @	2MG	N020741	003	Dec 22, 1997	Mar	DISC

REPAGLINIDE

AB	! AUROBINDO PHARMA LTD	2MG	A203820	003	Jan 22, 2014	Mar	CHRS
	@ MYLAN	0.5MG	A090252	001	Aug 23, 2013	Feb	DISC

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

	+! ALMIRALL	1%	N022055	001	Apr 12, 2007	Mar	CAHN
--	-------------	----	---------	-----	--------------	-----	------

RIBAVIRIN

TABLET;ORAL

RIBAVIRIN

AB	BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb	CAHN
AB		400MG	A202546	002	Aug 12, 2014	Feb	CAHN
AB		500MG	A202546	003	Aug 12, 2014	Feb	CAHN
AB		600MG	A202546	004	Aug 12, 2014	Feb	CAHN

RILUZOLE

TABLET;ORAL

RILUZOLE

	@ DAITO PHARMS CO LTD	50MG	A204430	001	Oct 16, 2018	Mar	DISC
--	-----------------------	------	---------	-----	--------------	-----	------

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM

AB	HANGZHOU BINJIANG	35MG	A207516	001	Feb 15, 2019	Feb	NEWA
>A>	ORCHID HLTHCARE	30MG	A205280	001	May 13, 2019	Apr	NEWA
>A>		35MG	A205280	002	May 13, 2019	Apr	NEWA

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

@ ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018	Feb DISC
----------------	------	---------	-----	--------------	----------

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

AA	TORRENT	1MG/ML	A078909	001	Jul 29, 2009	Jan CAHN
----	---------	--------	---------	-----	--------------	----------

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

AB	ZYDUS NOVELTECH INC	4.6MG/24HR	A206318	001	Mar 04, 2019	Feb NEWA
AB		9.5MG/24HR	A206318	002	Mar 04, 2019	Feb NEWA
AB		13.3MG/24HR	A206318	003	Mar 04, 2019	Feb NEWA

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB	MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Mar NEWA
----	------------	--------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	CADILA	EQ 0.25MG BASE	A090411	001	Jun 01, 2009	Feb CAHN
AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009	Feb CAHN
AB		EQ 1MG BASE	A090411	003	Jun 01, 2009	Feb CAHN
AB		EQ 2MG BASE	A090411	004	Jun 01, 2009	Feb CAHN
AB		EQ 3MG BASE	A090411	005	Jun 01, 2009	Feb CAHN
AB		EQ 4MG BASE	A090411	006	Jun 01, 2009	Feb CAHN
AB		EQ 5MG BASE	A090411	007	Jun 01, 2009	Feb CAHN
AB	LAX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Mar CAHN
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Mar CAHN
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Mar CAHN
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Mar CAHN
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Mar CAHN
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Mar CAHN
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Mar CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

>D>	AB	AMNEAL PHARMS CO	5MG	A208850	001	Oct 16, 2018	Apr DISC
>A>		@	5MG	A208850	001	Oct 16, 2018	Apr DISC
>D>	AB		10MG	A208850	002	Oct 16, 2018	Apr DISC
>A>		@	10MG	A208850	002	Oct 16, 2018	Apr DISC
>D>	AB		20MG	A208850	003	Oct 16, 2018	Apr DISC
>A>		@	20MG	A208850	003	Oct 16, 2018	Apr DISC
>D>	AB		40MG	A208850	004	Oct 16, 2018	Apr DISC
>A>		@	40MG	A208850	004	Oct 16, 2018	Apr DISC
>A>	AB	SCIEGEN PHARMS INC	5MG	A206381	001	Apr 24, 2019	Apr NEWA
>A>	AB		10MG	A206381	002	Apr 24, 2019	Apr NEWA
>A>	AB		20MG	A206381	003	Apr 24, 2019	Apr NEWA
>A>	AB		40MG	A206381	004	Apr 24, 2019	Apr NEWA
>A>	AB	SHANDONG	5MG	A207375	001	May 07, 2019	Apr NEWA
>A>	AB		10MG	A207375	002	May 07, 2019	Apr NEWA
>A>	AB		20MG	A207375	003	May 07, 2019	Apr NEWA
>A>	AB		40MG	A207375	004	May 07, 2019	Apr NEWA
	AB	UMEDICA LABS PVT LTD	5MG	A207626	001	Apr 09, 2019	Mar NEWA
	AB		10MG	A207626	002	Apr 09, 2019	Mar NEWA
	AB		20MG	A207626	003	Apr 09, 2019	Mar NEWA
	AB		40MG	A207626	004	Apr 09, 2019	Mar NEWA
	AB	ZYDUS PHARMS	5MG	A206513	001	Mar 01, 2019	Feb NEWA
	AB		10MG	A206513	002	Mar 01, 2019	Feb NEWA
	AB		20MG	A206513	003	Mar 01, 2019	Feb NEWA
	AB		40MG	A206513	004	Mar 01, 2019	Feb NEWA

RUFINAMIDESUSPENSION;ORAL
BANZEL

>D>	+	EISAI INC	40MG/ML	N201367	001	Mar 03, 2011	Apr CFTG
>A>	AB	+	40MG/ML	N201367	001	Mar 03, 2011	Apr CFTG
>A>		RUFINAMIDE					
>A>	AB	BIONPHARMA INC	40MG/ML	A211388	001	Apr 23, 2019	Apr NFTG
>A>	AB	HIKMA	40MG/ML	A207363	001	Apr 23, 2019	Apr NFTG
		TABLET;ORAL					
		RUFINAMIDE					
		@ MYLAN	200MG	A205095	001	May 16, 2016	Feb DISC
		@	400MG	A205095	002	May 16, 2016	Feb DISC

SAPROPTERIN DIHYDROCHLORIDETABLET;ORAL
KUVAN

>D>	+	BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007	Apr CFTG
>A>	AB	+	100MG	N022181	001	Dec 13, 2007	Apr CFTG
>A>		SAPROPTERIN DIHYDROCHLORIDE					
>A>	AB	PAR PHARM INC	100MG	A207200	001	May 10, 2019	Apr NFTG

SELEGILINE HYDROCHLORIDECAPSULE;ORAL
SELEGILINE HYDROCHLORIDE

>D>	AB	PACK PHARMS LLC	5MG	A206803	001	Apr 02, 2019	Apr CAHN
	AB		5MG	A206803	001	Apr 02, 2019	Mar NEWA
>A>	AB	RISING PHARMS	5MG	A206803	001	Apr 02, 2019	Apr CAHN

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

AB		KENTON	5MG	A074912	001	Apr 30, 1998	Mar CAHN
----	--	--------	-----	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

ZELAPAR

+	BAUSCH	1.25MG	N021479	001	Jun 14, 2006	Mar CAHN
---	--------	--------	---------	-----	--------------	----------

>A> SELENIOS ACID

>A> SOLUTION;INTRAVENOUS

>A> SELENIOS ACID

>A>	+	AM REGENT	EQ 600MCG BASE/10ML (EQ 60MCG BASE/ML)	N209379	001	Apr 30, 2019	Apr NEWA
-----	---	-----------	--	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB		CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007	Feb CAHN
AB			EQ 50MG BASE	A077106	002	Feb 06, 2007	Feb CAHN
AB			EQ 100MG BASE	A077106	003	Feb 06, 2007	Feb CAHN

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

AB	+	GENZYME	400MG	N021179	001	Jul 12, 2000	Feb CFTG
AB	+		800MG	N021179	002	Jul 12, 2000	Feb CFTG

SEVELAMER HYDROCHLORIDE

AB		GLENMARK PHARMS LTD	400MG	A204724	001	Feb 08, 2019	Feb NFTG
AB			800MG	A204724	002	Feb 08, 2019	Feb NFTG

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB		LUPIN LTD	EQ 25MG BASE	A212051	001	Mar 22, 2019	Mar NEWA
AB			EQ 50MG BASE	A212051	002	Mar 22, 2019	Mar NEWA
AB			EQ 100MG BASE	A212051	003	Mar 22, 2019	Mar NEWA
AB		MYLAN	EQ 25MG BASE	A201171	001	Mar 25, 2019	Mar NEWA
AB			EQ 50MG BASE	A201171	002	Mar 25, 2019	Mar NEWA
AB			EQ 100MG BASE	A201171	003	Mar 25, 2019	Mar NEWA

SIMVASTATINTABLET; ORAL
SIMVASTATIN

AB	MICRO LABS	5MG	A090383	001	Sep 16, 2011	Mar	CAHN
AB		10MG	A090383	002	Sep 16, 2011	Mar	CAHN
AB		20MG	A090383	003	Sep 16, 2011	Mar	CAHN
AB		40MG	A090383	004	Sep 16, 2011	Mar	CAHN
AB		80MG	A090383	005	Sep 16, 2011	Mar	CAHN

>D> SIPONIMOD>D> TABLET; ORAL
>D> MAYZENT

>D>	+	NOVARTIS PHARMS CORP	0.25MG	N209884	001	Mar 26, 2019	Apr	CAIN
	+		0.25MG	N209884	001	Mar 26, 2019	Mar	NEWA
>D>	+	!	2MG	N209884	002	Mar 26, 2019	Apr	CAIN
	+	!	2MG	N209884	002	Mar 26, 2019	Mar	NEWA

>A> SIPONIMOD FUMARIC ACID>A> TABLET; ORAL
>A> MAYZENT

>A>	+	NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr	CAIN
>A>	+	!	EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr	CAIN

SIROLIMUSSOLUTION; ORAL
RAPAMUNE

AA	+	PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999	Jan	CFTG
AA		NOVITIUM PHARMA	1MG/ML	A211040	001	Jan 28, 2019	Jan	NFTG

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	3GM/100ML	A209476	001	Mar 13, 2019	Feb	NEWA
----	--	--------------------	-----------	---------	-----	--------------	-----	------

SODIUM CHROMATE CR-51INJECTABLE; INJECTION
SODIUM CHROMATE CR 51
@ CURIUM

			100uCi/ML	N016708	001		Jan	CAHN
--	--	--	-----------	---------	-----	--	-----	------

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

>A>	AP	DECATUR	10-200mCi/ML	A204464	001	Oct 21, 2014	Apr	CAHN
>D>	AP	GLOBAL ISOTOPES LLC	10-200mCi/ML	A204464	001	Oct 21, 2014	Apr	CAHN

SODIUM IODIDE I-131CAPSULE; ORAL
SODIUM IODIDE I 131

@	CURIUM	0.8-100mCi	N016515	002		Jan	CAHN
+	@	0.8-100mCi	N016517	001		Jan	CAHN
@		15-100uCi	N016517	002		Jan	CAHN

SOLUTION; ORAL
SODIUM IODIDE I 131

+	@	CURIUM	3.5-150mCi/VIAL	N016515	001		Jan	CAHN
---	---	--------	-----------------	---------	-----	--	-----	------

SODIUM NITROPRUSSIDEINJECTABLE; INJECTION
SODIUM NITROPRUSSIDE

AP		DR REDDYS LABS LTD	25MG/ML	A210114	001	Apr 10, 2019	Mar	NEWA
----	--	--------------------	---------	---------	-----	--------------	-----	------

SODIUM PHENYL BUTYRATEPOWDER; ORAL
BUPHENYL

AB	+	HORIZON THERAP	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Feb	CAHN
----	---	----------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL
BUPHENYL

AB	+	HORIZON THERAP	500MG	N020572	001	May 13, 1996	Feb	CAHN
----	---	----------------	-------	---------	-----	--------------	-----	------

STAVUDINEFOR SOLUTION;ORAL
ZERIT

+ @ BRISTOL-MYERS SQUIBB 1MG/ML N020413 001 Sep 06, 1996 Mar DISC

STRONTIUM CHLORIDE SR-89INJECTABLE; INJECTION
METASTRON

AP +! Q BIOMED 1mCi/ML N020134 001 Jun 18, 1993 Jan CAHN

SUCCINYLSCHOLINE CHLORIDEINJECTABLE; INJECTION
SUCCINYLSCHOLINE CHLORIDE

AP AMRING PHARMS 20MG/ML A210231 001 Jun 04, 2018 Jan CAHN

SUMATRIPTANSPRAY;NASAL
TOSYMRA

+! DR REDDYS LABS LTD 10MG/SPRAY N210884 001 Jan 25, 2019 Jan NEWA

SUMATRIPTAN SUCCINATEINJECTABLE; SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

>D>	@ INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Apr	CAHN
>D>	AP PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	Apr	DISC
>A>	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	Apr	DISC
>A>	@ ZYDUS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Apr	CAHN

TACROLIMUSOINTMENT; TOPICAL
TACROLIMUS

AB	ACCORD HLTHCARE	0.03%	A211688	001	Jan 31, 2019	Jan	NEWA
AB		0.1%	A211688	002	Jan 31, 2019	Jan	NEWA

TADALAFILTABLET; ORAL
ALYQ

AB2	TEVA PHARMS USA	20MG	A209942	001	Feb 05, 2019	Jan	NEWA
	TADALAFIL						
AB	ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209167	002	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209167	004	Mar 26, 2019	Mar	NEWA
AB	AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209654	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209654	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209654	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210392	001	Feb 05, 2019	Jan	NEWA
AB	ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A204809	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A204809	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A204809	004	Mar 26, 2019	Mar	NEWA
AB	AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209744	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209744	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209744	004	Mar 26, 2019	Mar	NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A206285	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A206285	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A206285	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A206286	001	Feb 05, 2019	Jan	NEWA
AB	CIPLA	2.5MG	A209539	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209539	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209539	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209539	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210255	001	Feb 05, 2019	Jan	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A210069	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A210069	003	Mar 26, 2019	Mar	NEWA

TABLET;ORAL
TADALAFIL

AB1		20MG	A210069	004	Mar 26, 2019	Mar	NEWA	
AB2		20MG	A210145	001	Feb 05, 2019	Jan	NEWA	
AB	HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Mar	NEWA	
AB		5MG	A209908	002	Mar 26, 2019	Mar	NEWA	
AB		10MG	A209908	003	Mar 26, 2019	Mar	NEWA	
AB2		20MG	A209907	001	Feb 05, 2019	Jan	NEWA	
AB1		20MG	A209908	004	Mar 26, 2019	Mar	NEWA	
AB	LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Mar	NEWA	
AB		5MG	A210567	002	Mar 26, 2019	Mar	NEWA	
AB		10MG	A210567	003	Mar 26, 2019	Mar	NEWA	
AB1		20MG	A210567	004	Mar 26, 2019	Mar	NEWA	
AB2		20MG	A210572	001	Feb 05, 2019	Jan	NEWA	
>A>	AB	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Apr	NEWA
>A>	AB		5MG	A206957	001	Apr 29, 2019	Apr	NEWA
>A>	AB		10MG	A206956	002	Apr 29, 2019	Apr	NEWA
>A>	AB1		20MG	A206956	003	Apr 29, 2019	Apr	NEWA
AB	QILU PHARM CO LTD	2.5MG	A210420	001	Mar 26, 2019	Mar	NEWA	
AB		5MG	A210420	002	Mar 26, 2019	Mar	NEWA	
AB		10MG	A210420	003	Mar 26, 2019	Mar	NEWA	
AB1		20MG	A210420	004	Mar 26, 2019	Mar	NEWA	
AB	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Mar	NEWA	
AB		5MG	A208934	002	Mar 26, 2019	Mar	NEWA	
AB		10MG	A208934	003	Mar 26, 2019	Mar	NEWA	
AB1		20MG	A208934	004	Mar 26, 2019	Mar	NEWA	
AB	SUNSHINE LAKE	2.5MG	A211335	001	Mar 26, 2019	Mar	NEWA	
AB		5MG	A211335	002	Mar 26, 2019	Mar	NEWA	
AB		10MG	A211335	003	Mar 26, 2019	Mar	NEWA	
AB1		20MG	A211335	004	Mar 26, 2019	Mar	NEWA	
AB	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Mar	NEWA	
AB		5MG	A211839	002	Mar 26, 2019	Mar	NEWA	
AB		10MG	A211839	003	Mar 26, 2019	Mar	NEWA	
AB1		20MG	A211839	004	Mar 26, 2019	Mar	NEWA	
AB2		20MG	A212062	001	Mar 26, 2019	Mar	NEWA	
AB	UNICHEM LABS LTD	2.5MG	A209250	001	Mar 26, 2019	Mar	NEWA	
AB		5MG	A209250	002	Mar 26, 2019	Mar	NEWA	
AB		10MG	A209250	003	Mar 26, 2019	Mar	NEWA	
AB1		20MG	A209250	004	Mar 26, 2019	Mar	NEWA	
AB	WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019	Mar	NEWA	
AB		5MG	A205885	002	Mar 29, 2019	Mar	NEWA	
AB		10MG	A205885	003	Mar 29, 2019	Mar	NEWA	
AB1		20MG	A205885	004	Mar 29, 2019	Mar	NEWA	
AB	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Mar	NEWA	
AB		5MG	A206693	002	Mar 26, 2019	Mar	NEWA	
AB		10MG	A206693	003	Mar 26, 2019	Mar	NEWA	
AB1		20MG	A206693	004	Mar 26, 2019	Mar	NEWA	

TAZAROTENE

CREAM;TOPICAL
TAZAROTENE

AB	FOUGERA PHARMS INC	1%	A211175	001	Jan 28, 2019	Jan	NEWA
----	--------------------	----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE;INJECTION
TECHNESCAN MAG3

+!	CURIUM	N/A	N019882	001	Jun 15, 1990	Jan	CAHN
----	--------	-----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE;INJECTION
TECHNESCAN

+!	CURIUM	N/A	N018321	001		Jan	CAHN
----	--------	-----	---------	-----	--	-----	------

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE;INJECTION
TECHNESCAN PYP KIT

AP	CURIUM	N/A	N017538	001		Jan	CAHN
----	--------	-----	---------	-----	--	-----	------

TECHNETIUM TC-99M RED BLOOD CELL KITINJECTABLE; INJECTION
ULTRATAG

+! CURIUM N/A N019981 001 Jun 10, 1991 Jan CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INTRAVENOUS
ULTRA-TECHNEKOW FM+! CURIUM 1-19 CI/GENERATOR N017243 003 Feb 18, 2014 Jan CAHN
@ 0.25-3 CI/GENERATOR N017243 002 Jan CAHNSOLUTION; INTRAVENOUS, ORAL
TECHNETIUM TC 99M GENERATOR

+ @ GE HEALTHCARE 68-2703mCi/GENERATOR N017693 002 Dec 13, 2013 Feb DISC

TELMISARTAN

TABLET; ORAL

TELMISARTAN

AB	CIPLA	20MG	A078710	001	Jan 08, 2014	Feb	CAHN
	@	40MG	A078710	002	Jan 08, 2014	Feb	CAHN
	@	80MG	A078710	003	Jan 08, 2014	Feb	CAHN
AB	HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019	Feb	NEWA
AB		40MG	A207843	002	Feb 19, 2019	Feb	NEWA
AB		80MG	A207843	003	Feb 19, 2019	Feb	NEWA
	@ MICRO LABS	20MG	A207016	001	Oct 03, 2017	Mar	DISC
	@	40MG	A207016	002	Oct 03, 2017	Mar	DISC
	@	80MG	A207016	003	Oct 03, 2017	Mar	DISC
	@ WATSON LABS	80MG	A078710	003	Jan 08, 2014	Feb	DISC

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

	@ APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jan	DISC
	@	20MG	A204159	002	Jul 05, 2018	Jan	DISC
	@	100MG	A204159	003	Jul 05, 2018	Jan	DISC
	@	140MG	A204159	004	Jul 05, 2018	Jan	DISC
	@	180MG	A204159	005	Jul 05, 2018	Jan	DISC
	@	250MG	A204159	006	Jul 05, 2018	Jan	DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

@ APOTEX INC 300MG A206481 001 Jul 26, 2018 Jan DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

	@ BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Feb	CAHN
	@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Feb	CAHN
	@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Feb	CAHN
	@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Feb	CAHN
AB	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Mar	CAHN
AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	Mar	CAHN
AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	Mar	CAHN
AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	Mar	CAHN

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

>A>	AB	ALEMBIC PHARMS LTD	7MG	A209572	001	Apr 19, 2019	Apr	NEWA
>A>	AB		14MG	A209572	002	Apr 19, 2019	Apr	NEWA
	@	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb	DISC
	@		14MG	A209613	002	Sep 28, 2018	Feb	DISC
	@	APOTEX INC	7MG	A209601	001	Nov 02, 2018	Jan	DISC
	@		14MG	A209601	002	Nov 02, 2018	Jan	DISC
	@	AUROBINDO PHARMA LTD	7MG	A209638	001	Oct 26, 2018	Feb	DISC
	@		14MG	A209638	002	Oct 26, 2018	Feb	DISC
>A>	AB	MSN LABS PVT LTD	7MG	A209623	001	Apr 24, 2019	Apr	NEWA
>A>	AB		14MG	A209623	002	Apr 24, 2019	Apr	NEWA
	@	TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Mar	DISC
	@		14MG	A209700	002	Sep 04, 2018	Mar	DISC
	@	WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018	Feb	DISC

TABLET;ORAL
TERIFLUNOMIDE
@

14MG

A209549 002 Jul 27, 2018 Feb DISC

TESTOSTERONE

GEL;TRANSDERMAL
TESTOSTERONE

@ PAR PHARM

25MG/2.5GM PACKET

A076744 001 May 23, 2007 Mar DISC

GEL, METERED;TRANSDERMAL
TESTOSTERONE

AB ACTAVIS LABS UT INC 1.62% (20.25MG/1.25GM ACTUATION)
AB AMNEAL PHARMS LLC 1.62% (20.25MG/1.25GM ACTUATION)
AB DR REDDYS LABS INC 1.62% (20.25MG/1.25GM ACTUATION)
AB LUPIN ATLANTIS 1.62% (20.25MG/1.25GM ACTUATION)

A204570 001 Apr 10, 2019 Mar NEWA
A207373 001 Apr 10, 2019 Mar NEWA
A208620 001 Apr 10, 2019 Mar NEWA
A208560 001 Apr 10, 2019 Mar NEWA

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION
TESTOSTERONE CYPIONATE

@ MYLAN INSTITUTIONAL

200MG/ML

A040652 001 Dec 11, 2006 Mar DISC

>A> AO

WILSHIRE PHARMS INC

200MG/ML

A206368 001 Apr 24, 2019 Apr NEWA

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL
JATENZO

+ CLARUS

158MG

N206089 001 Mar 27, 2019 Mar NEWA

+

198MG

N206089 002 Mar 27, 2019 Mar NEWA

+!

237MG

N206089 003 Mar 27, 2019 Mar NEWA

TETRABENAZINE

TABLET;ORAL
TETRABENAZINE

@ LUPIN LTD

12.5MG

A210544 001 Apr 20, 2018 Feb DISC

@

25MG

A210544 002 Apr 20, 2018 Feb DISC

AB WEST-WARD PHARMS INT

12.5MG

A209739 001 Apr 08, 2019 Mar NEWA

AB

25MG

A209739 002 Apr 08, 2019 Mar NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC
TETRACAINE HYDROCHLORIDE

>A> BAUSCH

0.5%

N210821 001 Mar 12, 2019 Apr CAHN

>D>

VALEANT PHARMS

0.5%

N210821 001 Mar 12, 2019 Apr CAHN

0.5%

N210821 001 Mar 12, 2019 Mar NEWA

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION
THALLOUS CHLORIDE TL 201

+! CURIUM

1mCi/ML

N018150 001 Jan CAHN

AP

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

! HERITAGE PHARMA

100MG

A089807 001 Apr 30, 1990 Feb CAHN

!

200MG

A089808 001 Apr 30, 1990 Feb CAHN

AB

300MG

A089763 001 Apr 30, 1990 Feb CAHN

AB

@

450MG

A081236 001 Nov 09, 1992 Feb CAHN

THIOTHIXENE

CAPSULE;ORAL
THIOTHIXENE

AB MYLAN

1MG

A071093 002 Jun 23, 1987 Mar CTEC

AB

2MG

A071093 003 Jun 23, 1987 Mar CTEC

AB

!

5MG

A071093 004 Jun 23, 1987 Mar CTEC

AB

10MG

A071093 001 Jun 23, 1987 Mar CTEC

AB

NOVITIUM PHARMA

1MG

A211642 001 Apr 05, 2019 Mar NEWA

AB

2MG

A211642 002 Apr 05, 2019 Mar NEWA

AB

5MG

A211642 003 Apr 05, 2019 Mar NEWA

AB

10MG

A211642 004 Apr 05, 2019 Mar NEWA

TICAGRELOR

TABLET; ORAL

TICAGRELOR

AB		AMNEAL PHARMS CO	90MG	A208531	001	Jan 23, 2019	Jan	NEWA
AB		HISUN PHARM HANGZHOU	90MG	A208575	001	Jan 23, 2019	Jan	NEWA
	@	WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Feb	DISC
	@		90MG	A208390	002	Sep 04, 2018	Feb	DISC

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

	@	AMNEAL PHARMS LLC	50MG/VIAL	N211158	001	Aug 02, 2018	Feb	DISC
--	---	-------------------	-----------	---------	-----	--------------	-----	------

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOPTIC

AT	+	VALEANT PHARMS INTL	EQ 0.25% BASE	N018086	001		Jan	CAHN
AT1	+		EQ 0.5% BASE	N018086	002		Jan	CAHN
		TIMOPTIC IN OCUDOSE						
	+	VALEANT PHARMS INTL	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Jan	CAHN
	+		EQ 0.5% BASE	N019463	002	Nov 05, 1986	Jan	CAHN

TABLET; ORAL

BLOCADREN

>D>	@	MERCK	5MG	N018017	001		Apr	CRLD
>A>	+	@	5MG	N018017	001		Apr	CRLD
>D>	@		10MG	N018017	002		Apr	CRLD
>A>	+	@	10MG	N018017	002		Apr	CRLD
>D>	@		20MG	N018017	004		Apr	CRLD
>A>	+	@	20MG	N018017	004		Apr	CRLD

TIMOLOL MALEATE

>A>	AB	INVATECH PHARMA	5MG	A207556	001	May 02, 2019	Apr	NEWA
>A>	AB		10MG	A207556	002	May 02, 2019	Apr	NEWA
>A>	AB		20MG	A207556	003	May 02, 2019	Apr	NEWA
>D>		MYLAN	5MG	A072668	002	Jun 08, 1990	Apr	CTEC
>A>	AB		5MG	A072668	002	Jun 08, 1990	Apr	CTEC
>D>			10MG	A072668	003	Jun 08, 1990	Apr	CTEC
>A>	AB		10MG	A072668	003	Jun 08, 1990	Apr	CTEC
>D>		!	20MG	A072668	001	Jun 08, 1990	Apr	CTEC
>A>	AB	!	20MG	A072668	001	Jun 08, 1990	Apr	CTEC

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB		ALKEM LABS LTD	EQ 2MG BASE	A212196	001	Mar 27, 2019	Mar	NEWA
AB			EQ 4MG BASE	A212196	002	Mar 27, 2019	Mar	NEWA
AB			EQ 6MG BASE	A212196	003	Mar 27, 2019	Mar	NEWA
AB		CADILA PHARMS LTD	EQ 2MG BASE	A210021	001	Mar 26, 2019	Mar	NEWA
AB			EQ 4MG BASE	A210021	002	Mar 26, 2019	Mar	NEWA
AB			EQ 6MG BASE	A210021	003	Mar 26, 2019	Mar	NEWA
AB		RICONPHARMA LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb	NEWA
AB			EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb	NEWA
AB			EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb	NEWA

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB		ALKEM LABS LTD	EQ 2MG BASE	A211798	001	Jan 25, 2019	Jan	NEWA
AB			EQ 4MG BASE	A211798	002	Jan 25, 2019	Jan	NEWA
	@	PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Mar	DISC
	@		EQ 4MG BASE	A207170	002	Jan 26, 2017	Mar	DISC

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

AN		DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Mar	CMFD
	@		300MG/5ML	A207080	001	Jul 09, 2018	Jan	DISC

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

>A>	AT	ALEMBIC PHARMS LTD	0.3%	A211847	001	Apr 19, 2019	Apr	NEWA
-----	----	--------------------	------	---------	-----	--------------	-----	------

TOLCAPONETABLET; ORAL
TASMAR

AB	+	BAUSCH	100MG	N020697	001	Jan 29, 1998	Mar	CAHN
		@	200MG	N020697	002	Jan 29, 1998	Mar	CAHN

TOPIRAMATECAPSULE, EXTENDED RELEASE; ORAL
QUDEXY XR

BC	+	UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014	Feb	CTEC
BC	+		50MG	N205122	002	Mar 11, 2014	Feb	CTEC
BC	+		100MG	N205122	003	Mar 11, 2014	Feb	CTEC
BC	+		200MG	N205122	005	Mar 11, 2014	Feb	CTEC
		TROKENDI XR						
>D>	+	SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Apr	CTEC
>A>	BC	+	200MG	N201635	004	Aug 16, 2013	Apr	CTEC

TRANEXAMIC ACIDINJECTABLE; INJECTION
TRANEXAMIC ACID

AP		ACIC PHARMS	100MG/ML	A209326	001	Feb 22, 2019	Feb	NEWA
>A>	+	EXELA PHARMA SCS LLC	10MG/ML	N212020	001	Apr 15, 2019	Apr	NEWA
AP		MICRO LABS	100MG/ML	A206713	001	Jun 27, 2017	Mar	CAHN

TREPROSTINIL DIOLAMINETABLET, EXTENDED RELEASE; ORAL
ORENITRAM

	+	UNITED THERAP	EQ 1MG BASE	N203496	003	Dec 20, 2013	Feb	CHRS
	+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013	Feb	CHRS

TRETINOINCREAM; TOPICAL
TRETINOIN

AB1		TARO PHARMS	0.05%	A211644	001	Jan 25, 2019	Jan	NEWA
AB			0.1%	A211645	001	Jan 22, 2019	Jan	NEWA

TRIAMCINOLONE ACETONIDECREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

AT		STRIDES PHARMA	0.025%	A210346	001	Feb 11, 2019	Jan	NEWA
AT			0.1%	A210346	002	Feb 11, 2019	Jan	NEWA
AT			0.5%	A210346	003	Feb 11, 2019	Jan	NEWA
		INJECTABLE; INJECTION						
>A>		KENALOG-80						
>A>	+	APOTHECON	80MG/ML	N014901	002	Apr 12, 2019	Apr	NEWA
		TRIAMCINOLONE ACETONIDE						
	@	TEVA PHARMS USA	40MG/ML	A209852	001	Oct 05, 2018	Mar	DISC

TRICLABENDAZOLETABLET; ORAL
EGATEN

	+	NOVARTIS PHARMS CORP	250MG	N208711	001	Feb 13, 2019	Feb	NEWA
--	---	----------------------	-------	---------	-----	--------------	-----	------

TRIENTINE HYDROCHLORIDECAPSULE; ORAL
TRIENTINE HYDROCHLORIDE

AB		AMNEAL PHARMS LLC	250MG	A210619	001	Feb 08, 2019	Feb	NEWA
>A>	AB	ZYDUS PHARMS	250MG	A211554	001	Apr 26, 2019	Apr	NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDECAPSULE; ORAL
TRIMETHOBENZAMIDE HYDROCHLORIDE

AB		LUPIN	300MG	A076546	001	Aug 20, 2003	Feb	CAHN
----	--	-------	-------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE
@ LUITPOLD

	@	LUITPOLD	100MG/ML	A091330	001	Mar 08, 2011	Feb	DISC
	@	LUITPOLD	100MG/ML	A091329	001	Mar 08, 2011	Feb	DISC

URSODIOLCAPSULE;ORAL
URSODIOL

>D>	AB	AMNEAL PHARMS CO	300MG	A211301	001	Oct 16, 2018	Apr	DISC
>A>		@	300MG	A211301	001	Oct 16, 2018	Apr	DISC

VALACYCLOVIR HYDROCHLORIDETABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE

>D>	AB	WATSON LABS INC	EQ 500MG BASE	A090370	001	Mar 16, 2011	Apr	DISC
>A>		@	EQ 500MG BASE	A090370	001	Mar 16, 2011	Apr	DISC
>D>	AB		EQ 1GM BASE	A090370	002	Mar 16, 2011	Apr	DISC
>A>		@	EQ 1GM BASE	A090370	002	Mar 16, 2011	Apr	DISC

VALPROATE SODIUMINJECTABLE;INJECTION
DEPACON

>D>	AP	+! ABBVIE	EQ 100MG BASE/ML	N020593	001	Dec 30, 1996	Apr	DISC
>A>		+ @	EQ 100MG BASE/ML	N020593	001	Dec 30, 1996	Apr	DISC
		VALPROATE SODIUM						
>D>	AP	HIKMA FARMACEUTICA	EQ 100MG BASE/ML	A078523	001	Feb 17, 2010	Apr	CHRS
>A>	AP	!	EQ 100MG BASE/ML	A078523	001	Feb 17, 2010	Apr	CHRS

VALRUBICIN

SOLUTION;INTRAVESICAL

>A>	AO	VALRUBICIN						
>A>	AO	CUSTOPHARM INC	40MG/ML	A206430	001	Apr 19, 2019	Apr	NFTG
		VALSTAR PRESERVATIVE FREE						
>D>	AO	+! ENDO PHARM	40MG/ML	N020892	001	Sep 25, 1998	Apr	CFTG
>A>	AO	+!	40MG/ML	N020892	001	Sep 25, 1998	Apr	CFTG

VALSARTANTABLET;ORAL
VALSARTAN

AB	ALKEM LABS LTD	40MG	A205536	001	Mar 12, 2019	Feb	NEWA
AB		80MG	A205536	002	Mar 12, 2019	Feb	NEWA
AB		160MG	A205536	003	Mar 12, 2019	Feb	NEWA
AB		320MG	A205536	004	Mar 12, 2019	Feb	NEWA

VANCOMYCIN HYDROCHLORIDECAPSULE;ORAL
VANCOMYCIN HYDROCHLORIDE

>A>	AB	ORIENT PHARMA CO LTD	EQ 125MG BASE	A210729	001	Apr 29, 2019	Apr	NEWA
>A>	AB		EQ 250MG BASE	A210729	002	Apr 29, 2019	Apr	NEWA

SOLUTION;INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

+!	XELLIA PHARMS APS	EQ 500MG BASE/100ML	N211962	001	Feb 15, 2019	Feb	NEWA
+!		EQ 1GM BASE/200ML	N211962	002	Feb 15, 2019	Feb	NEWA
+!		EQ 1.5GM BASE/300ML	N211962	003	Feb 15, 2019	Feb	NEWA
+!		EQ 2GM BASE/400ML	N211962	004	Feb 15, 2019	Feb	NEWA

VARDENAFIL HYDROCHLORIDETABLET;ORAL
VARDENAFIL HYDROCHLORIDE

>D>	AB	AMNEAL PHARMS CO	5MG	A210738	001	Oct 31, 2018	Apr	DISC
>A>		@	5MG	A210738	001	Oct 31, 2018	Apr	DISC
>D>	AB		10MG	A210738	002	Oct 31, 2018	Apr	DISC
>A>		@	10MG	A210738	002	Oct 31, 2018	Apr	DISC
>D>	AB		20MG	A210738	003	Oct 31, 2018	Apr	DISC
>A>		@	20MG	A210738	003	Oct 31, 2018	Apr	DISC

VASOPRESSINSOLUTION;INTRAVENOUS
VASOSTRICT

+!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Mar	CDFR
+!		200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Mar	CDFR

VIGABATRINFOR SOLUTION;ORAL
VIGADRONE

AA	SHANGHAI	500MG/PACKET	A210196	001	Jun 21, 2018	Mar	CAHN
----	----------	--------------	---------	-----	--------------	-----	------

VINCRIStINE SULFATEINJECTABLE, LIPOSOMAL;INTRAVENOUS
MARQIBO KIT

	+! ACROTECH	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012	Mar	CAHN
--	-------------	------------------	---------	-----	--------------	-----	------

VORICONAZOLEPOWDER;IV (INFUSION)
VORICONAZOLE

AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Feb	CTEC
----	-------------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL
VORICONAZOLE

AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	Feb	CAHN
AB		200MG	A206762	002	May 24, 2016	Feb	CAHN
>A>	AB	CADILA	A206747	001	May 24, 2016	Apr	CAHN
>A>	AB		A206747	002	May 24, 2016	Apr	CAHN
>D>	AB	ZYDUS PHARMS	A206747	001	May 24, 2016	Apr	CAHN
>D>	AB		A206747	002	May 24, 2016	Apr	CAHN

ZIDOVUDINEINJECTABLE;INJECTION
ZIDOVUDINE

	@ LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	DISC
--	------------	---------	---------	-----	--------------	-----	------

ZIPRASIDONE HYDROCHLORIDECAPSULE;ORAL
ZIPRASIDONE HYDROCHLORIDE

AB	CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Feb	CAHN
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Feb	CAHN
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Feb	CAHN
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Feb	CAHN

ZOLEDRONIC ACIDINJECTABLE;INTRAVENOUS
RECLAST

AP	+! NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar	CDFR
	ZOLEDRONIC						
AP	GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Mar	CDFR
	ZOLEDRONIC ACID						
AP	ACCORD HLTHCARE	EQ 4MG BASE/5ML	A205279	001	Nov 28, 2016	Mar	CDFR
AP	ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Mar	CDFR
AP	AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Mar	CDFR
AP	AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	Mar	CDFR
AP	APOTEX INC	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar	CDFR
AP	AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Mar	CDFR
AP		EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Mar	CDFR
AP	BPI LABS LLC	EQ 4MG BASE/5ML	A207341	001	Dec 29, 2017	Mar	CDFR
AP	BRECKENRIDGE PHARM	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Mar	CDFR
AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Mar	CDFR
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Mar	CDFR
AP	CIPLA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Mar	CDFR
AP	DR REDDYS LABS LTD	EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018	Mar	CDFR
AP		EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar	CDFR
AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar	CDFR
AP		EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar	CDFR
AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Mar	CDFR
AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Mar	CDFR
AP		EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Mar	CDFR
AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	Mar	CDFR
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar	CDFR
AP		EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar	CDFR
AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Mar	CDFR
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Mar	CDFR
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Mar	CDFR
AP		EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Mar	CDFR
AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Mar	CDFR
AP	SAGENT PHARMS	EQ 4MG BASE/5ML	A091493	001	Nov 24, 2014	Mar	CDFR

INJECTABLE; INTRAVENOUS								
ZOLEDRONIC ACID								
>A>	AP	SHILPA MEDICARE LTD	EQ 4MG BASE/5ML	A208513	001	May 15, 2019	Apr	NEWA
		@ SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Mar	CDFR
		@	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Mar	CDFR
	AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CDFR
ZOMETA								
		+ @ NOVARTIS	EQ 4MG BASE/VIAL	N021223	001	Aug 20, 2001	Mar	CDFR
	AP	+	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Mar	CDFR
	AP	+	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Mar	CDFR
INJECTABLE; IV (INFUSION)								
ZOLEDRONIC ACID								
	AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Mar	CDFR
SOLUTION; INTRAVENOUS								
ZOLEDRONIC ACID								
		HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Mar	CDFR
<u>ZOLPIDEM TARTRATE</u>								
SPRAY, METERED; ORAL								
ZOLPIMIST								
		+! AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008	Feb	CAHN
TABLET; ORAL								
ZOLPIDEM TARTRATE								
>A>		@ STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007	Apr	CAHN
>A>		@	10MG	A076062	002	Apr 23, 2007	Apr	CAHN
>D>		@ STRIDES VIVIMED	5MG	A076062	001	Apr 23, 2007	Apr	CAHN
>D>		@	10MG	A076062	002	Apr 23, 2007	Apr	CAHN
TABLET; SUBLINGUAL								
INTERMEZZO								
		+ @ PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	Mar	DISC
		+ @	3.5MG	N022328	002	Nov 23, 2011	Mar	DISC
ZOLPIDEM TARTRATE								
	AB	! NOVEL LABS INC	3.5MG	A204299	002	Jun 03, 2015	Mar	CHRS
<u>ZONISAMIDE</u>								
CAPSULE; ORAL								
ZONISAMIDE								
>A>	AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Apr	CAHN
>A>	AB		50MG	A077813	002	Aug 16, 2006	Apr	CAHN
>A>	AB		100MG	A077813	003	Aug 16, 2006	Apr	CAHN
>D>	AB	BLUEPHARMA	25MG	A077813	001	Aug 16, 2006	Apr	CAHN
>D>	AB		50MG	A077813	002	Aug 16, 2006	Apr	CAHN
>D>	AB		100MG	A077813	003	Aug 16, 2006	Apr	CAHN

ACETAMINOPHENSUPPOSITORY;RECTAL
ACEPHEN

ACP NIMBLE	120MG	N018060	001		Feb	CAHN
@	325MG	N018060	003	Dec 18, 1986	Feb	CAHN
@	650MG	N018060	002		Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

>A>	GRANULES INDIA LTD	650MG	A211544	001	Apr 16, 2019	Apr	NEWA
	@ HERITAGE PHARMA	650MG	A207035	001	May 31, 2018	Mar	DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	NEWA
TORRENT	5MG/5ML	A090474	002	Mar 30, 2009	Jan	CAHN
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
TORRENT	5MG/5ML	A090474	001	Mar 30, 2009	Jan	CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

CHLORHEXIDINE GLUCONATE

>A>	BAJAJ	0.75%	N020111	001	Sep 11, 1997	Apr	CTNA
>D>	DYNA-HEX						
>D>	BAJAJ	0.75%	N020111	001	Sep 11, 1997	Apr	CTNA
		0.75%	N020111	001	Sep 11, 1997	Jan	CMFD

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

!	AVANTHI INC	12MG	A040829	001	May 13, 2009	Jan	CHRS
---	-------------	------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A210676	001	Feb 14, 2019	Jan	NEWA
----------------------	--	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

>A>	ACTAVIS ELIZABETH	25MG;220MG	A207597	001	Jan 25, 2019	Jan	NEWA
	PERRIGO R AND D	25MG;220MG	A208499	001	May 10, 2019	Apr	NEWA

ESOMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

>D>	ACTAVIS ELIZABETH	EQ 20MG BASE	A209202	001	Mar 05, 2019	Apr	DISC
>A>	@	EQ 20MG BASE	A209202	001	Mar 05, 2019	Apr	DISC
		EQ 20MG BASE	A209202	001	Mar 05, 2019	Feb	NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

>A>	HI TECH	0.05MG/SPRAY	A208024	001	Apr 17, 2019	Apr	NEWA
-----	---------	--------------	---------	-----	--------------	-----	------

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

@ OHM LABS INC	600MG	A209254	001	Jul 16, 2018	Mar	DISC
@	1.2GM	A209254	002	Jul 16, 2018	Mar	DISC

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

@ GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018	Feb	DISC
-----------------	-----------	---------	-----	--------------	-----	------

KETOCONAZOLESHAMPOO; TOPICAL
NIZORAL A-D

+! KRAMER 1% N020310 001 Oct 10, 1997 Jan CAHN

KETOTIFEN FUMARATESOLUTION/DROPS; OPHTHALMIC
ZADITOR

! ALCON PHARMS LTD EQ 0.025% BASE A077200 001 Sep 02, 2008 Feb CTNA

LEVOCETIRIZINE DIHYDROCHLORIDETABLET; ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE
PERRIGO R AND D 5MG

A211983 001 Mar 26, 2019 Mar NEWA

LEVONORGESTRELTABLET; ORAL
LEVONORGESTREL>A> ACCORD HLTHCARE 1.5MG A207660 001 May 02, 2019 Apr NEWA
& APOTEX INC 1.5MG A205329 001 Sep 18, 2018 Jan DISCLORATADINECAPSULE; ORAL
LORATADINE
& BIONPHARMA INC 10MG

A202538 001 Dec 21, 2018 Mar DISC

TABLET; ORAL
LORATADINE
GUARDIAN DRUG 10MG
NEWGEN PHARMS LLC 10MGA207569 001 Mar 12, 2019 Mar CAHN
A207569 001 Mar 12, 2019 Feb NEWATABLET, CHEWABLE; ORAL
LORATADINE
SUN PHARM 5MG

A210088 001 Apr 16, 2018 Mar CAHN

MINOXIDILAEROSOL, FOAM; TOPICAL
MINOXIDIL (FOR WOMEN)

>A> TARO PHARM 5% A209074 002 Apr 22, 2019 Apr NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
ALEVE-D SINUS & COLD

+! BAYER EQ 200MG BASE; 120MG N021076 001 Nov 29, 1999 Mar CPOT

NICOTINE POLACRILEXTROCHE/LOZENGE; ORAL
NICOTINE POLACRILEXPLD ACQUISITIONS EQ 2MG BASE A207868 001 Feb 07, 2019 Feb NEWA
EQ 4MG BASE A207868 002 Feb 07, 2019 Feb NEWA
& WATSON LABS INC EQ 2MG BASE A209206 001 Jun 26, 2018 Feb DISC
& EQ 4MG BASE A209206 002 Jun 26, 2018 Feb DISC
& WATSON LABS TEVA EQ 2MG BASE A209519 001 Jul 02, 2018 Feb DISC
& EQ 4MG BASE A209519 002 Jul 02, 2018 Feb DISCOMEPRAZOLETABLET, DELAYED RELEASE; ORAL
OMEPRAZOLE

>A> APOTEX INC 20MG A210070 001 Feb 11, 2019 Apr CTEC

RANITIDINE HYDROCHLORIDETABLET; ORAL
RANITIDINE HYDROCHLORIDE>A> STRIDES PHARMA EQ 75MG BASE A209160 001 Mar 05, 2018 Apr CAHN
>A> EQ 150MG BASE A209161 001 Feb 22, 2018 Apr CAHN
>D> STRIDES VIVIMED EQ 75MG BASE A209160 001 Mar 05, 2018 Apr CAHN
>D> EQ 150MG BASE A209161 001 Feb 22, 2018 Apr CAHN

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL

COLGATE TOTAL

+ @ COLGATE PALMOLIVE 0.24%;0.3%

N020231 001 Jul 11, 1997 Mar DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2019

NO APRIL 2019 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2019 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ABIRATERONE ACETATE</u>						
A 208327	001				PC	Apr 29, 2019
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259	001	10167291	Jul 01, 2036	DP U-2145		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	002	8461137	Feb 22, 2031	DS DP		
		8748413	Jul 10, 2030	DS DP		
		8828978	Jul 01, 2030	DP		
		9132125	Jul 01, 2030	DS DP	U-2249	
		9549923	Jul 01, 2030	DS DP		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	003	8461137	Feb 22, 2031	DS DP		
		8748413	Jul 10, 2030	DS DP		
		8828978	Jul 01, 2030	DP		
		9132125	Jul 01, 2030	DS DP	U-2249	
		9549923	Jul 01, 2030	DS DP		
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	>A> 10034867	Jul 07, 2020	DP U-2513		
		>A> 10034867	Jul 07, 2020	DP U-2514		
		>A> 10085974	Mar 13, 2029	DP U-2513		
		>A> 7078412	Jul 07, 2020	DS DP U-2513		
		>A> 9056100	Jul 07, 2020	DP U-2513		
		>A> 9333195	Jul 07, 2020	DP U-2513		
		>A> RE46417	Feb 10, 2025	DS DP U-2513		
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595	001	>A> 10034867	Jul 07, 2020	DP U-2513	NC	Mar 29, 2022
		>A> 10034867	Jul 07, 2020	DP U-2514		
		>A> 10085974	Mar 13, 2029	DP U-2513		
		>A> 6681768	Aug 07, 2022	DP		
		>A> 7078412	Jul 07, 2020	DS DP U-2513		
		>A> 7750023	Jul 07, 2020	DP U-2513		
		>A> 8051851	Apr 22, 2027	DP		
		>A> 8129405	Jul 07, 2020	DP U-2513		
		>A> 9056100	Jul 07, 2020	DP U-2513		
		>A> 9333195	Jul 07, 2020	DP U-2513		
		>A> RE46417	Feb 10, 2025	DS DP U-2513		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	001				ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	002				ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	003				ODE-230	Jan 12, 2025
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001	10124131	May 18, 2031	DP		
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636	002	10022510	May 18, 2031	DP		
		10124131	May 18, 2031	DP		
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	10183012	Nov 26, 2028	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	10183012	Nov 26, 2028	U-2104			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	>A> 10251900	May 15, 2035	U-2414			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	10130580	Apr 19, 2024	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001	>A> 7112592	Feb 24, 2022	DS DP U-2244		
		>A> 7112592	Feb 24, 2022	DS DP U-2508		
		>A> 7112592	Feb 24, 2022	DS DP U-282		
		>A> 8178554	Jul 24, 2021	DS DP U-2245		
		>A> 8178554	Jul 24, 2021	DS DP U-2509		
		>A> 8178554	Jul 24, 2021	DS DP U-282		
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854	001				>A> NCE	Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854	002				>A> NCE	Oct 24, 2023
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247	001	6479535	May 06, 2024	DP U-594		
		6479535	May 06, 2024	DP U-904		
<u>BECLOMETHASONE DIPROPIONATE - ONASL</u>						
N 202813	001	10188811	Oct 21, 2031	DP		
<u>BECLOMETHASONE DIPROPIONATE - ONASL</u>						
N 202813	002	10188811	Oct 21, 2031	DP		
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 205128	001				PC	Aug 18, 2019
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819	001	10220049	Jun 03, 2029	DP U-916		
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819	002	10220049	Jun 03, 2029	DP U-916		
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079	001	10179137	Aug 31, 2030	DP U-1858		
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	003	7417148	Dec 11, 2025	U-1283		
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772	001	9012462	Jul 31, 2030	DS		
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772	002	9012462	Jul 31, 2030	DS		
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772	003	9012462	Jul 31, 2030	DS		
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708	001	10201517	Jun 13, 2031	DP		
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819	001	10198218	Jun 06, 2031	U-2489		
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819	002	10198218	Jun 06, 2031	U-2489		
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063	001	>A> 10231964	Jul 02, 2034	U-1583		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	>A> 8927592	Oct 27, 2030	U-1630			
	>A> 8927592*PED	Apr 27, 2031				
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	10213442	Feb 02, 2027	DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	>A> RE47350	Jul 16, 2029	U-1750			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001					NCE	Apr 29, 2019
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS</u>						
N 021587 001	>A> 10238640	May 25, 2024	DP			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001					>A> NP	Mar 29, 2022
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	>A> 10231961	Feb 07, 2037	DP			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10226423	Dec 20, 2037	DP			
	9907751	Nov 22, 2036	DP			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 210895 001	>A> 7229613	Apr 17, 2022	U-2516			
<u>CROFELEMER - MYTESI</u>						
N 202292 001	>A> 7341744	Jun 02, 2022	DP U-1319			
	>A> 9585868	Oct 31, 2031	U-1319			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10166184	Oct 15, 2032	DP U-2341			
<u>DALFAMPRIDINE - DALFAMPRIDINE</u>						
A 206863 001					PC	Mar 09, 2019
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					M-238	Feb 22, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002					M-238	Feb 22, 2022
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	9889115 9889115*PED	Jun 23, 2019 Dec 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	9889115 9889115*PED	Jun 23, 2019 Dec 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	9889115 9889115*PED	Jun 23, 2019 Dec 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	9889115 9889115*PED	Jun 23, 2019 Dec 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	9889115 9889115*PED	Jun 23, 2019 Dec 23, 2019	U-1305			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	10201542	Oct 18, 2033	DP U-1753			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	10201541 10201584	May 17, 2032 May 17, 2032	DP U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 001					PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 002					PC	Apr 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 003					PC	Apr 05, 2019
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					M-239	Dec 12, 2021
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					M-239	Dec 12, 2021
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU</u>						
N 206910 001					M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU</u>						
N 206910 002					M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU</u>						
N 206910 003					M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001					M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002					M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003					M-239	Dec 12, 2021
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002	7049328	Jun 28, 2021	U-735			
	8703156	Oct 29, 2029	DP U-735			
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Aug 13, 2027	DP U-1412			
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001	8409606	May 14, 2030	DP		NP	Nov 30, 2021
	8563027	Feb 12, 2030	U-2487			
	9254267	Sep 11, 2024	DP			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10159683	May 23, 2034	DP			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	>A> 8129385	Oct 05, 2027	DS DP		>A> NC	Apr 08, 2022
	>A> 9242986	Dec 08, 2029	DS DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10238620	May 18, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10238620	May 18, 2027	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	10058564	Apr 05, 2022	U-1063			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021			U-1306	
	7332481	May 24, 2021			U-2451	
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021			U-1306	
	7790704	May 24, 2021			U-2451	
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023			U-1306	
	7795293	May 21, 2023			U-2451	
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021			U-1306	
	7332481	May 24, 2021			U-2451	
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021			U-1306	
	7790704	May 24, 2021			U-2451	
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023			U-1306	
	7795293	May 21, 2023			U-2451	
	7795293	May 21, 2023			U-930	
	7795293*PED	Nov 21, 2023				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021			U-1306	
	7332481	May 24, 2021			U-2451	
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021			U-1306	
	7790704	May 24, 2021			U-2451	
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023			U-1306	
	7795293	May 21, 2023			U-2451	
	7795293	May 21, 2023			U-930	
	7795293*PED	Nov 21, 2023				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021			U-1306	
	7332481	May 24, 2021			U-2451	
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021			U-1306	
	7790704	May 24, 2021			U-2451	
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023			U-1306	
	7795293	May 21, 2023			U-2451	
	7795293*PED	Nov 21, 2023				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021			U-1306	
	7332481	May 24, 2021			U-1736	
	7332481*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021			U-1306	
	7790704	May 24, 2021			U-1736	
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023			U-1306	
	7795293	May 21, 2023			U-1736	
	7795293*PED	Nov 24, 2023				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1736			
	>A> 7160870*PED	May 20, 2023				
	>A> 7332481	May 24, 2021			U-1306	
	>A> 7332481	May 24, 2021			U-1736	
	>A> 7332481*PED	Nov 24, 2021				
	>A> 7452874	May 24, 2021	DS DP			
	>A> 7452874*PED	Nov 24, 2021				
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1736			
	>A> 7473686*PED	Nov 24, 2021				
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-1736			
	>A> 7547719	Jul 13, 2025	DS DP U-2452			
	>A> 7547719*PED	Jan 13, 2026				
	>A> 7790704	May 24, 2021			U-1306	
	>A> 7790704	May 24, 2021			U-1736	
	>A> 7790704*PED	Nov 24, 2021				
	>A> 7795293	May 21, 2023			U-1306	
	>A> 7795293	May 21, 2023			U-1736	
	>A> 7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS		U-2152	
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS		U-2152	
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	>A> 10258637	Apr 03, 2034			U-2290	
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	>A> 10258637	Apr 03, 2034			U-2290	
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	>A> 10258637	Apr 03, 2034			U-2290	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	>A> 10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	>A> 10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	>A> 10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	>A> 10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	>A> 10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	>A> 10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	>A> 10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	>A> 10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	>A> 10258637	Apr 03, 2034	U-2290			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVAL</u>						
N 211109 001	8796245	Aug 07, 2029	U-2380			
	8906887	Dec 28, 2030	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	>A> 8895601	May 22, 2031	DS DP		>A> NCE	Apr 12, 2024
	>A> 9464071	Apr 28, 2031	U-2518			
	>A> 9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	>A> 8895601	May 22, 2031	DS DP		>A> NCE	Apr 12, 2024
	>A> 9464071	Apr 28, 2031	U-2518			
	>A> 9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	>A> 8895601	May 22, 2031	DS DP		>A> NCE	Apr 12, 2024
	>A> 9464071	Apr 28, 2031	U-2518			
	>A> 9902714	Mar 26, 2035	DP			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	8785500	Jul 09, 2031	U-2502		NCE*	Mar 05, 2024
	9592207	Mar 20, 2027	U-2502			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	>A> 10258630	Dec 20, 2033	U-2316			
	>A> 10258630	Dec 20, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	>A> 10258630	Dec 20, 2033	U-2316			
	>A> 10258630	Dec 20, 2033	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10206932	Nov 21, 2032	U-2439			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2020	DP U-1577		I-790	Nov 06, 2020
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10179216	Jul 08, 2033	DP U-2133			
	>A> 10252010	Feb 07, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10195375	Feb 14, 2031	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10208073	May 23, 2032	U-2301			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-1826			
	6774122	Jan 09, 2021	U-2108			
	6774122	Jan 09, 2021	U-2163			
	6774122	Jan 09, 2021	U-2504			
	6774122	Jan 09, 2021	U-596			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-1826			
	7456160	Jan 09, 2021	U-2108			
	7456160	Jan 09, 2021	U-2163			
	7456160	Jan 09, 2021	U-2504			
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-1826			
	8329680	Jan 09, 2021	U-2108			
	8329680	Jan 09, 2021	U-2163			
	8329680	Jan 09, 2021	U-2504			
	8329680	Jan 09, 2021	U-596			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-1826			
	8466139	Jan 09, 2021	U-2108			
	8466139	Jan 09, 2021	U-2163			
	8466139	Jan 09, 2021	U-2504			
	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001					NCE	Nov 28, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394	001				>A> NPP	Apr 30, 2022
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284	001	10183002	Sep 22, 2030	U-1816		
		10183003	Sep 22, 2030	U-1816		
		10183004	Sep 22, 2030	U-1816		
		10183005	Sep 22, 2030	U-1816		
		10183006	Sep 22, 2030	U-1816		
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355	001	>A> 6517847	Aug 03, 2020	DP		
		>A> 8809307	Nov 02, 2031	DP		
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354	001	>A> 10251895	Jun 06, 2036	DP	>A> NP	Apr 25, 2022
		>A> 6517847	Aug 03, 2020	DP		
		>A> 8809307	Nov 02, 2031	DP		
<u>HYDROCORTISONE VALERATE - HYDROCORTISONE VALERATE</u>						
A 211750	001				CGT	Jul 16, 2019
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001				M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	002				M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	001	10213386	Mar 03, 2036	DP	M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	002	10213386	Mar 03, 2036	DP	M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	003	10213386	Mar 03, 2036	DP	M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	004	10213386	Mar 03, 2036	DP	M-236	Jan 25, 2022
<u>IBUPROFEN - CHILDREN'S ADVIL-FLAVORED</u>						
N 020589	002	>A> 10238640	May 25, 2024	DP		
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	001	>A> 10238644	Dec 11, 2029	U-68		
		>A> 10238645	Aug 18, 2029	U-1455		
		>A> 10238645	Aug 18, 2029	U-172		
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751	002	10220155	Jul 17, 2026	DP		
		7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		
		RE46363	Aug 03, 2026	DP		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172	004	7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986	002	7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	>A> 10220155	Jul 17, 2026	DP			
	>A> 10220155*PED	Jan 17, 2027				
	>A> 6268343	Aug 22, 2022	DS DP			
	>A> 6268343*PED	Feb 22, 2023				
	>A> 6899699	Jan 02, 2022	DP			
	>A> 6899699*PED	Jul 02, 2022				
	>A> 7615532	Jun 28, 2029	DS DP			
	>A> 7615532*PED	Dec 28, 2029				
	>A> 7762994	May 23, 2024	DP			
	>A> 7762994*PED	Nov 23, 2024				
	>A> 8579869	Jun 30, 2023	DP			
	>A> 8579869*PED	Dec 30, 2023				
	>A> 8672898	Jan 02, 2022	DP			
	>A> 8672898*PED	Jul 02, 2022				
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8684969*PED	Apr 20, 2026				
	>A> 8846618	Jun 27, 2022	DS DP			
	>A> 8846618*PED	Dec 27, 2022				
	>A> 8920383	Jul 17, 2026	DP			
	>A> 8920383*PED	Jan 17, 2027				
	>A> 8937042	May 05, 2029	DP			
	>A> 8937042*PED	Nov 05, 2029				
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9108002*PED	Jul 20, 2026				
	>A> 9132239	Feb 01, 2032	DP			
	>A> 9132239*PED	Aug 01, 2032				
	>A> 9457154	Sep 27, 2027	DP			
	>A> 9457154*PED	Mar 27, 2028				
	>A> 9486588	Jan 02, 2022	DP			
	>A> 9486588*PED	Jul 02, 2022				
	>A> 9616180	Jan 20, 2026	DP			
	>A> 9616180*PED	Jul 20, 2026				
	>A> 9687611	Feb 27, 2027	DP			
	>A> 9687611*PED	Aug 27, 2027				
	>A> 9775953	Jul 17, 2026	DP			
	>A> 9775953*PED	Jan 17, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	>A> 9861757	Jan 20, 2026	DP			
	>A> 9861757*PED	Jul 20, 2026				
	>A> RE46363	Aug 03, 2026	DP			
	>A> RE46363*PED	Feb 03, 2027				
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9011391	Mar 26, 2024		U-1923		
	9011391	Mar 26, 2024		U-2496		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	10201672	Aug 02, 2030	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	10201672	Aug 02, 2030	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	10201672	Aug 02, 2030	DP			
<u>IVABRADINE - CORLANOR</u>						
N 209964 001	>A> 7361649	Feb 22, 2026	DS DP U-1694			
	>A> 7361650	Feb 22, 2026	DS DP U-1694			
	>A> 7867996	Feb 22, 2026	DS DP U-1694			
	>A> 7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10206877	Apr 14, 2035	DP U-2498			
	>A> 10239867	Apr 09, 2027	DS DP U-2512			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	10206939	Mar 13, 2034	U-1631			
<u>LAROTRECTINIB - VITRAKVI</u>						
N 210861 001					NCE	Nov 26, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAROTRECTINIB - VITRAKVI</u>						
N 210861	002				NCE	Nov 26, 2023
<u>LAROTRECTINIB - VITRAKVI</u>						
N 211710	001				NCE	Nov 26, 2023
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259	001	10174017	Jan 27, 2030	DS DP U-1524	NC	Mar 12, 2022
		8394826	Nov 10, 2030	DS DP U-1524	NCE	Dec 18, 2022
		8450344	Jul 11, 2026	DS DP U-1524		
		9096569	Jul 11, 2026	DS DP U-1524		
		9415043	Mar 14, 2034	DS		
		9931336	Mar 14, 2034	DS DP U-1524		
		9993470	Mar 14, 2034	DS DP U-1524		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	001	7189740	Apr 11, 2023	U-1982		
		7468363	Oct 07, 2023	U-1983		
		7968569	Oct 07, 2023	U-1984		
		8404717	Apr 11, 2023	U-1982		
		8530498	May 15, 2023	U-1984		
		8648095	May 15, 2023	U-1984		
		8741929	Mar 08, 2028	U-1983		
		9056120	Apr 11, 2023	U-1982		
		9101621	May 15, 2023	U-1985		
		9101622	May 15, 2023	U-1986		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	002	7189740	Apr 11, 2023	U-1982		
		7468363	Oct 07, 2023	U-1983		
		7968569	Oct 07, 2023	U-1984		
		8404717	Apr 11, 2023	U-1982		
		8530498	May 15, 2023	U-1984		
		8648095	May 15, 2023	U-1984		
		8741929	Mar 08, 2028	U-1983		
		9056120	Apr 11, 2023	U-1982		
		9101621	May 15, 2023	U-1985		
		9101622	May 15, 2023	U-1986		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	003	7189740	Apr 11, 2023	U-1982		
		7468363	Oct 07, 2023	U-1983		
		7968569	Oct 07, 2023	U-1984		
		8404717	Apr 11, 2023	U-1982		
		8530498	May 15, 2023	U-1984		
		8648095	May 15, 2023	U-1984		
		8741929	Mar 08, 2028	U-1983		
		9056120	Apr 11, 2023	U-1982		
		9101621	May 15, 2023	U-1985		
		9101622	May 15, 2023	U-1986		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	004	7189740	Apr 11, 2023	U-1982		
		7468363	Oct 07, 2023	U-1983		
		7968569	Oct 07, 2023	U-1984		
		8404717	Apr 11, 2023	U-1982		
		8530498	May 15, 2023	U-1984		
		8648095	May 15, 2023	U-1984		
		8741929	Mar 08, 2028	U-1983		
		9056120	Apr 11, 2023	U-1982		
		9101621	May 15, 2023	U-1985		
		9101622	May 15, 2023	U-1986		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	7189740	Apr 11, 2023	U-1982			
	7468363	Oct 07, 2023	U-1983			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	7189740	Apr 11, 2023	U-1982			
	7468363	Oct 07, 2023	U-1983			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001 >A>	10259791	Aug 26, 2035	DS			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002 >A>	10259791	Aug 26, 2035	DS			
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	10183012	Nov 26, 2028	U-2311			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001 >A>	8962630	Dec 09, 2029	U-2505			
	>A> 9416136	Aug 20, 2029	U-2505			
	>A> 9868739	Nov 09, 2031	U-2505			
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	6514482	Sep 19, 2020	DP U-2484		NP	Dec 21, 2021
	6613308	Sep 19, 2020	U-2484			
	6858199	Nov 04, 2021	U-2485			
	6921528	Jun 19, 2020	U-2485			
	6979437	Sep 19, 2020	U-2484			
	7146978	Apr 16, 2021	U-2486			
	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	7556798	Nov 04, 2021	U-2485			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			
	8628754	Jun 19, 2020	U-2485			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8802628	Oct 30, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8802628	Oct 30, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	>A> 6268343	Aug 22, 2022	DS DP U-968			
	>A> 6268343*PED	Feb 22, 2023				
	>A> 7762994	May 23, 2024	DP			
	>A> 7762994*PED	Nov 23, 2024				
	>A> 8114833	Aug 13, 2025	DS DP			
	>A> 8114833*PED	Feb 13, 2026				
	>A> 8579869	Jun 30, 2023	DP			
	>A> 8579869*PED	Dec 30, 2023				
	>A> 8846618	Jun 27, 2022	DP			
	>A> 8846618*PED	Dec 27, 2022				
	>A> 9265893	Sep 23, 2032	DP			
	>A> 9265893*PED	Mar 23, 2033				
	>A> 9968659	Jan 09, 2037			U-2313	
	>A> 9968659*PED	Jul 09, 2037				
	>A> RE41956	Jan 21, 2021	DP			
	>A> RE41956*PED	Jul 21, 2021				
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	>A> 10220155	Jul 17, 2026	DP			
	>A> 10220155*PED	Jan 17, 2027				
	>A> 6268343	Aug 22, 2022	DS DP U-1255			
	>A> 6268343*PED	Feb 22, 2023				
	>A> 6899699	Jan 01, 2022	DP			
	>A> 6899699*PED	Jul 01, 2022				
	>A> 7762994	May 23, 2024	DP			
	>A> 7762994*PED	Nov 23, 2024				
	>A> 8114833	Aug 13, 2025	DP			
	>A> 8114833*PED	Feb 13, 2026				
	>A> 8579869	Jun 30, 2023	DP			
	>A> 8579869*PED	Dec 30, 2023				
	>A> 8672898	Jan 02, 2022	DP			
	>A> 8672898*PED	Jul 02, 2022				
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8684969*PED	Apr 20, 2026				
	>A> 8846618	Jun 27, 2022	DP			
	>A> 8846618*PED	Dec 27, 2022				
	>A> 8920383	Jul 17, 2026	DP			
	>A> 8920383*PED	Jan 17, 2027				
	>A> 9108002	Jan 26, 2026	DP			
	>A> 9108002*PED	Jul 26, 2026				
	>A> 9132239	Feb 01, 2032	DP			
	>A> 9132239*PED	Aug 01, 2032				
	>A> 9457154	Sep 27, 2027	DP			
	>A> 9457154*PED	Mar 27, 2028				
	>A> 9486588	Jan 02, 2022	DP			
	>A> 9486588*PED	Jul 02, 2022				
	>A> 9616180	Jan 20, 2026	DP			
	>A> 9616180*PED	Jul 20, 2026				
	>A> 9687611	Feb 27, 2027	DP			
	>A> 9687611*PED	Aug 27, 2027				
	>A> 9775953	Jul 17, 2026	DP			
	>A> 9775953*PED	Jan 17, 2027				
	>A> 9861757	Jan 20, 2026	DP			
	>A> 9861757*PED	Jul 20, 2026				
	>A> 9968659	Jan 09, 2037			U-2438	
	>A> 9968659*PED	Jul 09, 2037				
	>A> RE46363	Aug 03, 2026	DP			
	>A> RE46363*PED	Feb 03, 2027				
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	>A> 10265370	Nov 06, 2035	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	10226471	Aug 31, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219	001				NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565	001	10058511	May 03, 2033	DP U-2492		
		9056057	May 03, 2033	DP U-2491		
		9393213	May 03, 2033	DP		
		9532955	May 03, 2033	U-2491		
		9737491	May 03, 2033	U-2492		
		9827191	May 03, 2033	DP U-2493		
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776	001	10172874	Aug 08, 2031	DP		
		10183034	Aug 08, 2031	U-2490		
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591	001	6890957	Aug 07, 2021	DP		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	002	>A> 8628799	Jul 13, 2025	DP		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	003	>A> 8628799	Jul 13, 2025	DP		
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400	001	10231927	Jan 02, 2033	U-1349		
		10231927	Jan 02, 2033	U-1699		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	001	10039719	Dec 16, 2019	U-2357		
		10039719*PED	Jun 16, 2020			
		6419960	Dec 16, 2019	DP		
		6419960*PED	Jun 16, 2020			
		7083808	Dec 16, 2019	DP		
		7083808*PED	Jun 16, 2020			
		7247318	Dec 16, 2019	DP		
		7247318*PED	Jun 16, 2020			
		7438930	Dec 16, 2019	DP	Y	
		7438930*PED	Jun 16, 2020			
		8580310	Dec 16, 2019	DP		
		8580310*PED	Jun 16, 2020			
		9066869	Dec 16, 2019	DP		
		9066869*PED	Jun 16, 2020			
		9801823	Dec 16, 2019	DP		
		9801823*PED	Jun 16, 2020			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	002	10039719	Dec 16, 2019	U-2357		
		10039719*PED	Jun 16, 2020			
		6419960	Dec 16, 2019	DP		
		6419960*PED	Jun 16, 2020			
		7083808	Dec 16, 2019	DP		
		7083808*PED	Jun 16, 2020			
		7247318	Dec 16, 2019	DP		
		7247318*PED	Jun 16, 2020			
		7438930	Dec 16, 2019	DP	Y	
		7438930*PED	Jun 16, 2020			
		8580310	Dec 16, 2019	DP		
		8580310*PED	Jun 16, 2020			
		9066869	Dec 16, 2019	DP		
		9066869*PED	Jun 16, 2020			
		9801823	Dec 16, 2019	DP		
		9801823*PED	Jun 16, 2020			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	10039719	Dec 16, 2019			U-2357	
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035		U-2357	NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10111839	Oct 30, 2035		U-2357	NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10111839	Oct 30, 2035		U-2357	NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035		U-2357	NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035		U-2357	NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001 >A>	10238634	Jun 28, 2032	DP			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10195214	Jun 19, 2037	U-1643			
	10231983	Aug 22, 2038	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001 >A>	10251873	May 30, 2038	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCYCLINE HYDROCHLORIDE</u>						
A 091424 002					PC	Aug 21, 2019
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001 >A>	10166205	Jan 31, 2033	DP			
	>A> 10166206	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10220158	Mar 20, 2035	DP U-2500			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10143792	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	10174017	Jan 27, 2030	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10233154	Sep 25, 2035	DS			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370		I-793	Jan 25, 2022
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			
	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10188644	Sep 02, 2036	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10188644	Sep 02, 2036	DP U-1556			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	>A> 6335447	Apr 06, 2020	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	>A> 7456168	Jan 16, 2023	U-1998			
	>A> 7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	>A> 7456168	Jan 16, 2023	U-1998			
	>A> 7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	>A> 7456168	Jan 16, 2023	U-1998			
	>A> 7456168	Jan 16, 2023	U-2515			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	10188637	Mar 28, 2037	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS U-998			
	5856336*PED	Jun 25, 2021				
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS U-998			
	5856336*PED	Jun 25, 2021				
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS U-998			
	5856336*PED	Jun 25, 2021				
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8987262	Oct 16, 2028	U-1988			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
A 211694 001					CGT	Sep 04, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 001					PC	May 27, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046	002				PC	May 27, 2019
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001	RE47301	Feb 02, 2027	DP		
	>A>	RE47351	Jun 22, 2019	DS DP	U-869	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	001	10220155	Jul 17, 2026	DP		
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884	001	>A> 7939519	May 19, 2024	DS DP	>A> NCE	Mar 26, 2024
	>A>	8492441	Nov 30, 2030	U-2511		
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884	002	>A> 7939519	May 19, 2024	DS DP	>A> NCE	Mar 26, 2024
	>A>	8492441	Nov 30, 2030	U-2511		
<u>SODIUM OXYBATE - XYREM</u>						
N 021196	001	10213400	Mar 15, 2033	U-2499	>A> ODE-231	Oct 26, 2025
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078	001	9913860	Oct 22, 2033	DS	U-2312	
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078	002	9913860	Oct 22, 2033	DS	U-2312	
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	008	10220155	Jul 17, 2026	DP		
		7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	009	10220155	Jul 17, 2026	DP		
		7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	010	10220155	Jul 17, 2026	DP		
		7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	011	10220155	Jul 17, 2026	DP		
		7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108	001	10206895	Apr 01, 2034	DP	U-2096	
		10206895	Apr 01, 2034	DP	U-2494	
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128	001	>A> 10245228	Jan 05, 2027	DP	U-1351	
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684	001	10232061	Jul 06, 2038	DP		
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884	001	8268791	May 09, 2026	DP		
		8440631	May 09, 2026	DP	U-1719	
		9211282	Jul 19, 2031	DP	U-1719	
		9283280	Jul 01, 2025	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	10166190	May 30, 2028	DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 003	>A> 7182958	Apr 26, 2020	DP U-155	Y		
	>A> 7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	>A> 7182958	Apr 26, 2020	DP U-155	Y		
	>A> 7182958*PED	Oct 26, 2020				
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10189837	Oct 20, 2031	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002	10189837	Oct 20, 2031	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAVABOROLE - KERYDIN</u>						
N 204427	001				>A> NCE >A> PED	Jul 07, 2019 Jan 07, 2020
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435	001	>A> 10065947	Feb 03, 2030	DP		
		>A> 9624250	Feb 03, 2030	DS DP U-2507		
		>A> 9988406	Feb 03, 2030	DP		
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436	001	>A> 10065947	Feb 03, 2030	DP		
		>A> 9624250	Feb 03, 2030	DS DP U-2507		
		>A> 9988406	Feb 03, 2030	DP		
<u>TEDUGLUTIDE RECOMBINANT - GATEX KIT</u>						
N 203441	001	5789379	Apr 14, 2020	DS DP U-1320	ODE-37	Dec 21, 2019
		5789379*PED	Oct 14, 2020		PED	Jun 21, 2020
		7056886	Sep 18, 2022	DP U-1320		
		7056886*PED	Mar 18, 2023			
		7847061	Nov 01, 2025	U-1320		
		7847061*PED	May 01, 2026			
		9060992	Nov 01, 2025	U-1320		
		9060992*PED	May 01, 2026			
		9539310	Nov 01, 2025	U-1320		
		9539310*PED	May 01, 2026			
		9545434	Nov 01, 2025	U-1320		
		9545434*PED	May 01, 2026			
		9545435	Nov 01, 2025	U-1320		
		9545435*PED	May 01, 2026			
		9555079	Nov 01, 2025	U-1320		
		9555079*PED	May 01, 2026			
		9572867	Nov 01, 2025	U-1320		
		9572867*PED	May 01, 2026			
		9592273	Nov 01, 2025	U-1320		
		9592273*PED	May 01, 2026			
		9592274	Nov 01, 2025	U-1320		
		9592274*PED	May 01, 2026			
		9968655	Nov 01, 2025	U-2308		
		9968655*PED	May 01, 2026			
		9968656	Nov 01, 2025	U-2308		
		9968656*PED	May 01, 2026			
		9968658	Nov 01, 2025	U-1320		
		9968658*PED	May 01, 2026			
		9974835	Nov 01, 2025	U-1320		
		9974835*PED	May 01, 2026			
		9974837	Nov 01, 2025	U-1320		
		9974837*PED	May 01, 2026			
		9981014	Nov 01, 2025	U-1320		
		9981014*PED	May 01, 2026			
		9981016	Nov 01, 2025	U-1320		
		9981016*PED	May 01, 2026			
		9987334	Nov 01, 2025	U-1320		
		9987334*PED	May 01, 2026			
		9987335	Nov 01, 2025	U-1320		
		9987335*PED	May 01, 2026			
		9993528	Nov 01, 2025	U-1320		
		9993528*PED	May 01, 2026			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089	001	8241664	Mar 29, 2029	DP U-2506		
		8492369	Dec 20, 2030	DP U-2506		
		8778916	Apr 12, 2030	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 001					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 002					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 003					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 004					CGT	Oct 02, 2019
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	RE46284	Dec 16, 2026	U-1751		I-794	Feb 24, 2022
	RE46284	Dec 16, 2026	U-2503		ODE-229	Feb 22, 2026
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	RE46284	Dec 16, 2026	U-1751		I-794	Feb 24, 2022
	RE46284	Dec 16, 2026	U-2503		ODE-229	Feb 22, 2026
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	>A> 8703781	Oct 15, 2030	DS DP U-1712			
	>A> 8703781	Oct 15, 2030	DS DP U-2020			
	>A> 8703781	Oct 15, 2030	DS DP U-2037			
	>A> 8703781	Oct 15, 2030	DS DP U-2302			
	>A> 8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	>A> 8703781	Oct 15, 2030	DS DP U-1712			
	>A> 8703781	Oct 15, 2030	DS DP U-2020			
	>A> 8703781	Oct 15, 2030	DS DP U-2037			
	>A> 8703781	Oct 15, 2030	DS DP U-2302			
	>A> 8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	>A> 8703781	Oct 15, 2030	DS DP U-1712			
	>A> 8703781	Oct 15, 2030	DS DP U-2020			
	>A> 8703781	Oct 15, 2030	DS DP U-2037			
	>A> 8703781	Oct 15, 2030	DS DP U-2302			
	>A> 8703781	Oct 15, 2030	DS DP U-2305			
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711 001					NCE ODE-228	Feb 13, 2024 Feb 13, 2026
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Feb 10, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Feb 10, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	>A> 10159681	Apr 13, 2030	U-2510			
	>A> 9844510	Dec 08, 2028	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2023	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2023	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-237 PED	Feb 22, 2022 Aug 22, 2022

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 39th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm